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CD69 is early expressed upon leukocyte activation and controls lymphocyte trafficking and cytokine 
secretion. In this thesis, the function of CD69 was studied in hematopoietic progenitor cells and in 
Vaccinia virus infection. 
During the host response to viral infection, the transmembrane CD69 protein is highly upregulated in 
all immune cells. We have studied the role of CD69 in the murine immune response to Vaccinia virus 
(VACV) infection, and we report that the absence of CD69 enhances protection against VACV at both 
short and long times postinfection in immunocompetent and immunodeficient mice. Natural killer 
(NK) cells were implicated in the increased infection control, since the differences were greatly 
diminished when NK cells were depleted. This role of NK cells was not based on an altered NK cell 
reactivity, since CD69 did not affect the NK cell activation threshold in response to major 
histocompatibility complex class I NK cell targets or protein kinase C activation. Instead, NK cell 
numbers were increased in the spleen and peritoneum of CD69-deficient infected mice. That was not 
just secondary to better infection control in CD69-deficient mice, since NK cell numbers in the spleens 
and the blood of uninfected CD69-/- mice were already augmented. CD69-deficient NK cells from 
infected mice did not have an altered proliferation capacity. However, a lower spontaneous cell death 
rate was observed for CD69-/- lymphocytes. Thus, our results suggest that CD69 limits the innate 
immune response to VACV infection at least in part through cell homeostatic survival. 
As we have just shown above, total splenic cell counts were found increased in CD69-/- mice at steady 
state and after infection, and these results are in agreement with previous results of our laboratory 
[1]. As well, CD69 interacts with S1P1 which mediates leukocytes trafficking. Thus, we studied the 
possible role of CD69 targeting in leukocyte mobilization. As result, we described for the first time the 
capacity of anti-CD69 monoclonal antibodies (mAbs) to induce a rapid and massive egress of mature 
leukocytes as well as hematopoietic stem and progenitor stem cells (HSPC) from bone marrow, both 
in wild type mice treated with anti-mCD69 mAb and in transgenic huCD69 mice in CD69-/- background 
treated with anti-huCD69 mAb.  A single dose of anti-human CD69 mAb induced a decrease in total 
leukocytes number in bone marrow and an increase in spleen and blood. These effects on cell 
distribution were already apparent at 4 hours after treatment and could be observed for at least 6 
days. The coadministration of FTY720 and anti-CD69 mAbs impaired the decrease in bone marrow 
cellularity observed by anti-CD69 treatment, demonstrating the role of S1P1 in mobilization of bone 
marrow leukocytes. The treatment also upregulated S1P1 and CXCR4 surface levels and induced mTOR 
signaling. Importantly, the treatment led to the proliferation and expansion of HSPC. CD69 targeting 
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and AMD3100 (inhibitor of CXCR4), induced similar mobilization, but anti-CD69 produced increased 
proliferation and the quantity of HSPC were higher in anti-CD69 than in AMD3100-treated mice both 
in BM and spleen. The combined treatment with CD69 targeting and AMD3100 do not have neither a 
synergic effect nor a clear additive effect on BM mobilization. We propose the use of anti-human CD69 
as a new mobilizer of hematopoietic stem cell (HSCs). The mobilization of HSC is used for treatment 
for people who have reduced cell counts as a result of diseases or due to chemotherapeutic agents. 
Since CD69 targeting increased mobilization of bone marrow cells to periphery, resembling CD69-/- 
mice and due to that the absence of CD69 improved the immune response to Vaccinia virus infection, 
we analyzed the influence of human and mouse CD69 targeting on Vaccinia virus infection. We 
reported that the increase of leukocyte number in SLO (secondary lymphoid organs) previously 
described for human and mouse CD69 targeted mice both in immunocompetent and immunodeficient 
mice (Chapter II) remained augmented during the infection and provided an improved capacity to 
clear the viral infection. CD69 targeting increased NK cells reactivity and augmented number and 
percentage of IFNγ-producing NK cells. In human CD69 targeted mice was examined the humoral 
mediators and found increased IL17a, IL17b, IL17f, IL-1α, IL-1β, Lymphotoxin α (LTα), Lymphotoxin β 
(LTβ), IFNγ, CCL2 and CCL12. Together these results suggested the possibility of using CD69 targeting 
as a treatment for enhancing anti-Vaccinia response, opening the possibility to use this treatment to 
increase vaccination responses. 
When analyzing CD69 overexpression, it was found an increased numbers of single positive T cells in 
thymus and a higher increase in T regulatory cells, leading to a high reduction in T lymphocytes and 
even higher reduction of Treg cells in SLO. Likewise, B cells were moderately reduced in SLO, although 
an unexpected augment in NK cell number were found in bone marrow, thymus and spleen. In 
addition, a huge increase of IL17a, IL17b, IL17f, IL21, IL-1α, IL-1β, IL7, CCL2, CCL12, CCL7 and CCL8 was 
found together with a moderated increase of TNF and IFNγ in CD69 overexpressing mice. Thus, these 
results are in agreement with a major function of CD69 in controlling humoral mediators production, 
in addition to retention of B lymphocytes in bone marrow, T lymphocytes in thymus and T and B cells 
in lymph nodes. Overall, the overexpression of CD69 reinforces the role of CD69 influencing in NK, B 
and T cell development and its influence in lymphocyte homeostasis and trafficking. During VACV 
infection, SLO cell expansion occurred in WT mice whereas was impaired in the overexpressing mice. 
Thus, the difference in the number of cells between WT and CD69 overexpressing mice is even higher. 
CD69 overexpressing mice showed a better control of VACV infection in spite of the strong reduction 
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of T and B cells and the vast reduction of number of IFNγ-producing NK and T cells in SLO.  However, 
no differences in the number of infiltrating cells were observed in non-lymphoid organs. Besides, we 
found a better response to Vaccinia virus infection both analyzed in ovaries after intraperitoneal 
infection, in lung after intranasal infection and in spleen, lymph nodes, kidney, lung and liver after 24 
hours of intravenously infection. Overall, we hypothesize that innate cells of CD69 overexpressing mice 
must have an augmented activity producing high humoral mediators levels such as IL17 and other 
cytokines found in this mice. More works are needed to know the mechanism implicated in this 
response.
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CD69 se expresa de manera temprana tras la activación leucocitaria y controla la migración linfocitaria 
y la secreción de citoquinas. En esta tesis, se ha estudiado la función de CD69 en la células 
hematopoyéticas progenitoras y en la infección por el virus Vaccinia.  
Durante la respuesta inmune frente a la infección viral, la proteína transmembrana CD69 es expresada 
en todas las células inmunitarias. En este trabajo, se ha estudiado el papel de CD69 en la respuesta 
inmune frente a la infección por el virus Vaccinia (VACV) en ratones, y se ha observado que la ausencia 
de CD69 mejora la protección contra VACV tanto a corto como a largo plazo en ratones 
inmunocompetentes e inmunodeficientes. Las células Natural Killer (NK) han sido involucradas a lo 
largo del tiempo con una mejor respuesta frente a la infección y en nuestro trabajo vemos que el 
aumento de células NK en ausencia de CD69 está relacionado con un aumento del control de la 
infección, ya que en estudios de eliminación de células NK, las diferencias no solo fueron abolidas sino 
que en este caso los ratones CD69-/- controlaban peor la infección. Este papel de las células NK no se 
basó en una reactividad alterada de las células NK, ya que CD69 no afectó al umbral de activación de 
las células NK en respuesta a MHC tipo I o a la activación de la proteína quinasa C. En cambio, el 
número de células NK aumentó en el bazo y peritoneo de ratones infectados deficientes para CD69. 
Esto no fue sólo secundario a un mejor control de la infección en ratones deficientes para CD69, ya 
que el número de células NK en bazo y sangre de ratones CD69-/- no infectados ya estaban 
aumentados. Las células NK deficientes en CD69 de ratones infectados no tenían una capacidad de 
proliferación alterada. Sin embargo, se observó una menor tasa de muerte celular espontánea para 
los linfocitos de ratones CD69-/-. Por lo tanto, nuestros resultados sugieren que CD69 controla la 
respuesta inmune innata a la infección por VACV, al menos en parte a través de una mayor 
supervivencia celular. 
Como acabamos de mencionar, los recuentos totales de células esplénicas se encontraron 
aumentados en ratones CD69-/- en estado basal y tras infección, y estos resultados están de acuerdo 
con los resultados anteriores de nuestro laboratorio  [1] y podrían estar relacionados con la interacción 
de CD69 con S1P1. Además, hemos descrito que el tratamiento anti-CD69 simula en múltiples modelos 
la ausencia de CD69. Por lo tanto, se estudió el posible papel del tratamiento anti-CD69 en la  
movilización de leucocitos. Como resultado, describimos por primera vez la capacidad de los mAb anti-
CD69 para inducir una salida rápida y masiva de leucocitos maduros, así como de HSPC de la médula 
ósea, tanto en ratones normales tratados con anti-mCD69 como en ratones que contienen el transgén 
de CD69 humano  en fondo genético  CD69-/-  (huCD69), tratados con anti-huCD69 MAb. Una única 
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dosis de anti-CD69 humano disminuyó el número total de leucocitos de la médula ósea y aumentó los 
del bazo y la sangre en más del 20%. Estos efectos ya eran evidentes a las 4 horas después del 
tratamiento y pudieron observarse durante al menos 6 días. El hecho de que la disminución de la 
celularidad de médula ósea no se observase cuando los anticuerpos  anti-CD69 se coadministraron 
con  FTY720,  indica que la redistribución observada, se debe a la movilización de leucocitos desde la 
médula ósea y que esto depende de la función de S1PR. El tratamiento, también aumentó  la  expresión 
en superficie de S1P1 y CXCR4 e indujo la señalización de mTOR. Es importante destacar que el 
tratamiento llevó a la proliferación y expansión de HSCP. CD69 y AMD3100 (inhibidor de CXCR4), 
indujeron una movilización similar, pero anti-CD69 produjo una proliferación incrementada y la 
cantidad de HSPC fue más alta en tratamientos con anticuerpos anti-CD69 que  con AMD3100, tanto 
en médula ósea como en bazo. El tratamiento combinado con anti-CD69 y AMD3100 no tienen ni  
efecto sinérgico ni un claro efecto aditivo sobre la movilización de células en la médula ósea. 
Proponemos el tratamiento con anticuerpos anti-CD69 humano como un nuevo movilizador de HSCs. 
La movilización de HSC se utiliza para el tratamiento de personas que tienen reducidos los recuentos 
celulares como resultado de enfermedades o debido a agentes quimioterápicos.  
Debido a que el tratamiento con anticuerpos anti-CD69 aumentó la movilización de células de médula 
ósea hacia la periferia y debido a que la ausencia de CD69 mejoró la respuesta inmune frente a la 
infección por el virus Vaccinia, se analizó la influencia de los tratamientos anti-CD69 humano y de 
ratón en la infección por el virus Vaccinia. El aumento del número de leucocitos en SLO previamente 
descritos para ratones tratados con anti-CD69 humano y de ratón tanto en ratones 
inmunocompetentes como inmunodeficientes (Capítulo I y II) permanecieron aumentados durante la 
infección y proporcionaron una capacidad mejorada para eliminar la infección viral. El tratamiento con 
anti-CD69 indujo una mayor reactividad de las células NK y un número aumentado de células NK 
productoras de IFN. En ratones tratados con anti-CD69 humano se analizaron los mediadores 
humorales y se encontraron aumentados IL17a, IL17b, IL17f, IL-1α, IL-1β, Lymphotoxin α (LTα), 
Lymphotoxin β (LTβ), IFN, CCL2 y CCL12. Juntos, estos resultados sugieren la posibilidad de utilizar 
anticuerpos anti-CD69 como tratamiento para mejorar la respuesta anti-Vaccinia, abriendo la 
posibilidad de utilizar este tratamiento para aumentar las respuestas de vacunación. 
Cuando se analizó la sobreexpresión de CD69, se encontró un aumento del número de células T 
maduras en timo y un mayor aumento de células T reguladoras, lo que condujo a una alta reducción 
de los linfocitos T y una mayor reducción de las células Treg en los órganos linfoides secundarios. Del 
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mismo modo, las células B se redujeron moderadamente en SLO, aunque un aumento inesperado en 
el número de células NK se encontró en médula ósea, timo y bazo. Además, se ha encontrado un 
elevado incremento de la expresión de IL17a, IL17b, IL17f, IL21, IL-1α, IL-1β, IL7, CCL2, CCL12, CCL7 y 
CCL8 junto con un moderado incremento de TNF e IFNγ en ratones que sobreexpresan CD69. Por 
tanto, estos resultados están de acuerdo con una función de CD69 en el control de la producción de 
mediadores humorales y en la retención de linfocitos B en la médula ósea, linfocitos T en el timo y 
células T y B en nódulos linfáticos, además de un papel de CD69 en el control de IL17 y otras citoquinas. 
Durante la infección con Vaccinia, en el ratón WT ocurre una gran expansión del bazo aumentando 
mucho su número de células y esta capacidad esta anulada en el ratón que sobreexpresa CD69. De 
esta forma, la diferencia en el número de células es incluso mayor entre estos ratones. Sin embargo, 
la sobreexpresión de CD69 mostró un mejor control frente a la infección por el virus Vaccinia a pesar 
de la fuerte reducción de células T y B y la reducción del número de células NK y T en SLO productoras 
de IFN.  A pesar de esto, las células infiltrantes en los órganos no linfoides fueron similares entre el 
ratón WT y el que sobreexpresa CD69. Se encontró una mejor respuesta a la infección por el virus 
Vaccinia tanto en ovarios después de la infección intraperitoneal, en pulmón después de la infección 
intranasal y en bazo, ganglios linfáticos, riñón,  pulmón el hígado después de 24 horas de infección 
intravenosa.  En conjunto, en este ratón, las células inmunes deben tener muy aumentada su actividad 
dada la gran cantidad de citoquinas producidas. Se necesita un mayor trabajo para conocer los 
mecanismos involucrados. 
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1. HEMATOPOIETIC SYSTEM 
 
The hematopoietic system is originated in bone marrow during adult life, where stem cells will give 
rise to the progenitors responsible for development of the different hematopoietic lineages that 
subsequently will originate all mature blood cells and will migrate to the lymph, secondary lymphoid 
organs and tissues. In Figure 1 is schematized how this pluripotent hematopoietic stem cells will give 
rise to the hematopoietic cells. A common myeloid progenitor produces the progenitor of 
megakaryocytes and erythrocytes and the progenitor of macrophages and granulocytes. The 
progenitor of megakaryocytes and erythrocytes will originate megakaryocytes that in blood will appear 
as platelets and erythroblasts that will mature to erythrocytes. The progenitor of macrophages and 
granulocytes will give rise to polymorphonuclear leukocytes such as neutrophils, eosinophils, 
basophils, monocytes and dendritic cells. Monocytes will reach tissues where they will mature to mast 
cells, macrophages and 
dendritic cells. On the other 
hand, the pluripotent 
hematopoietic stem cells will 
also generate a common 
lymphoid progenitor, which 
will give rise to the NK, T and 
B lymphocytes which after 
maturation process will be 
developed in activated NK 
cells, T lymphocytes and 
plasma cells respectively. 
While B lymphocytes 
differentiate into bone 
marrow, T lymphocytes do so 
in thymus. Both, from these 
locations, they will migrate 
through the bloodstream to the secondary lymphoid organs and lymph where they will mature. After 
encountering an antigen, they will be able to develop an effective immune response through 
Figure 1. Development of hematopoietic system. All blood cells of the hematopoietic 
system come from a common progenitor, named hematopoietic stem cell, which 
will originate all the lymphoid and myeloid cells of the immune system.   
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
36 
differentiation into effector cells capable of combating the infection. Preserving homeostasis in 
hematopoiesis is essential for the proper development of the immune system that will ensure the 
maintenance of the substantial numbers of the different types of blood cells.  
 
1.1 Hematopoietic progenitor and stem cells and their niche 
 
The study of stem cells has been a breakthrough thanks to the studies that have been carried out for 
approximately 20 years, when they began the first trials. The importance of these cells led to the 
development of new effective tools that can induce a rapid mobilization of HSC into the circulation 
and later they can be collected through non-invasive techniques such as blood extraction. HSC therapy 
represents one of the most successful advances in cell-based therapies applied in hematological 
disorders. However, new advances must be performed to ensure a greater number of HSC cells. 
Hematopoietic stem cells (HSC) are developed in bone marrow microenvironment throughout adult 
life where they differentiate. Hematopoietic stem cells are defined by their ability to self-renew to 
differentiate, giving rise to the rest of the cells of the hematopoietic system and letting reconstitution 
in animals that have been irradiated [2]. Bone marrow offers the suitable environment for the long-
term survival, functionality and cell integrity of these cells. The stem cell niche sends signals that 
support HSC properties, including self-renewal capacity and long-term multilineage repopulation 
ability. HSC are responsible for the development of the different blood cells during the process of 
haematopoiesis  while some undifferentiated stem cells are retained at basal levels within bone 
marrow [3]. The number of these cells increases during processes of cellular damage and signals of 
stress [4]. This fact allows preserving hematopoietic stem cell homeostatic conditions capable of 
inducing maturation of hematopoietic cells if was necessary due to pathogen attack.  
Stem cells represent a very small percentage of the entire bone marrow and are contained within Lin- 
(negative lineage) HSC compartment (Fig.2). Lin- cells are constituted by hematopoietic cells that do 
not express markers of mature hematopoietic lineages such as T and B lymphocytes, NK cells, dendritic 
cells and myeloid cells and within Lin- cells we can distinguish two subpopulations according to Sca-1 
and c-kit expression which do not express markers for mature hematopoietic lineages. Sca-1 is defined 
as the common biological marker used to identify HSC along with other markers and c-kit is also known 
as stem cell factor receptor and is expressed on HSC including multipotent hematopoietic stem cells, 
progenitors committed to myeloid and/or erythroid lineages, and T and B cell precursors and the 
interaction with its ligand is critical for the development of hematopoietic stem cells. Two 
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subpopulations can be distinguished according to Sca-1 and c-kit expression: KSL cells (c-Kithi Sca+ Lin-
) and CLP cells (Common lymphoid progenitors) as shown in figure 2. The image displays the different 
markers that can be used to differentiate the different stages of maturation of HSC cells of human and 
mouse. KSL cells are an early form of hematopoietic stem cells whereas CLP cells are descendants of 
the pluripotential hematopoietic stem cell (pHSC) which are capable of generating all of the cell types 
of the complete blood cell system.  
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Figure 2. Different hematopoietic stem cell development between mice and humans. HSC are characterized by self-renewal 
capacity. Throughout differentiation, stem cells from mice and humans express different surface markers and define the 
different subsets of HSC hierarchy. 
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Besides, three functionally HSC subpopulations can be identified within KSL cells according to CD34 
and FLT3 expression: LT-HSC o long term HSC (KSL CD34neg FLT3neg), ST-HSC o short term HSC (KSL 
CD34+ FLT3neg) o MPP or multipotent progenitors (KSL CD34+ FLT3+) [5] [6-8]. LT-HSCs have life-long 
and  self-renewing potential through a process of asymmetric cell division [9], and give rise to ST-HSCs 
and MPP with more restricted self-renewing capacity. ST-HSCs are lineage-restricted progenitors and 
undergo extensive proliferation and differentiation to produce differentiated and functional 
hematopoietic cells. MPP or multipotent progenitor cells are less primitive cells and have low or no 
self-renew capability. ST-HSCs or multipotent progenitors (MPPs) are only able to sustain 
hematopoiesis in the short term, while LT-HSCs must persist for the lifespan of the organism to 
perpetually replenish the hematopoietic system.  HSC transplants will be performed by the transfer of 
LT-HSCs in irradiated animals, which as we have described have greater capacity for engraftment and 
self-renewal. Suitable antibody combinations of these markers may allow the analysis of all these cell 
populations and their isolation by sorting technique. Purification method starts with isolation of bone 
marrow or blood cells where these cells can be found. Once extracted, HSCs can be collected by 
magnetic cell separation (MACS) or single-cell sorting based on cell surface markers expression 
described above [10]. The previously mentioned markers can be used to differentiate HSC 
subpopulations in mice, however, in humans there are other markers that allow us to differentiate 
stem cells and purify them. The main cell surface marker of HSC in humans is CD34+ cells which is 
down-regulated when cells are differentiated into more abundant mature cell [11] and, unlike mice, 
they do not express Sca-1 and other markers described in mouse hematopoietic progenitors.   
The vast majority of HSC resides in bone marrow though HSC can be also found in different tissues 
including spleen, liver and blood. Most HSCs appear to be located in an area proximal to the bone 
called endosteal niche [12], where osteoblasts provide an environment that supports maintenance 
and survival of the HSCs [13]. A second progenitor niche in bone marrow is proximal to sinusoidal 
endothelium named perivascular niche [14]; which has been suggested to contain higher fraction of 
cycling HSCs and thus comprising more differentiated population of stem cells.  
The output of progenitor cells from bone marrow is dependent on mechanisms that influence cell 
adhesion and migration to mediate the egress of these cells into the bloodstream (Fig.3). 
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CXCL12 (SDF-1, stromal cell-derived factor-1) is the principal chemoatracttant of HSC and is expressed 
by bone marrow osteoblasts, endothelial cells and stromal cells [15]. The interaction of CXCL12 with 
its receptor CXCR4, is the key to regulate the retention or egress of HSC. CXCL12 also plays an active 
chemotactic role in mobilization, and an increase of CXCL12 levels in plasma is sufficient to induce 
bone marrow cell mobilization [16]. The balance between CXCL12 and CXCR4 plays a crucial role in the 
retention and release of HSC within bone marrow [17, 18]. The migration of HSC also depends on 
Sphingosine-1-phosphate (S1P)/Sphingosine-1-phosphate receptor 1 (S1P1) axis. Cells expressing 
S1P1 respond to an increase of S1P concentration; S1P is low expressed in bone marrow and high in 
plasma. HSCs also express S1P receptors allowing the mobilization from non-lymphoid peripheral 
tissues to draining lymphatics [19] through interaction with S1P1.  Increase plasma S1P levels and S1P1 
expression in bone marrow progenitor cells generate a gradient from bone marrow to blood, so that 
the increase of S1P levels in plasma enhances HSC egress from bone marrow [20] The up-regulation 
of S1P1 in HSC and the increase of S1P will result in the mobilization of HSC. S1P signaling is essential 
for stem cell mobilization and these levels are transiently elevated in the plasma and BM during 
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Figure 3. Different mechanism of stem cell mobilization. 
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AMD3100 treatment, as well as G-CSF-induced mobilization [4]. Although the increase of S1P could be 
related with the increase of CXCL12, an evidence direct not has been demonstrated [21]. It has been 
described that under homeostatic conditions, there is a balance between CXCL12 and S1P, while 
CXCL12 is held elevated to keep stem cells in a quiescent state in bone marrow, S1P is expressed in 
small amounts to reduce the output of bone marrow cells. By the other hand, in stress situations, the 
expression of S1P in blood and bone marrow increases, while CXL12 decreases to facilitate the outflow 
of progenitor cells [22]. The use of S1P/S1P1 axis disruptors, such as FTY720, or S1P1-deficient mice 
had reduced HSC output from bone marrow, demonstrating the contribution of S1P/S1P1 axis to the 
egress of HSCs/HPCs [4]. The binding of Stem cell factor (SCF) and its ligand c-Kit also influences in 
precursors and stem cells mobilization[23]. SCF has been shown to increase the survival of HSCs in 
vitro and contributes to the self-renewal and maintenance of HSCs in-vivo. SCF promotes cell survival, 
proliferation, differentiation, adhesion and functional activation [24]. SCF has been shown to increase 
adhesion and thus may play a large role in ensuring that HSCs remain in the niche [23]. C-kit is 
expressed by HSC cells and is considered as a potent chemoatracttant. C-Kit downregulation leads to 
a lower binding of SCF to c-Kit and to a stem cell mobilization. Finally, the vascular cell adhesion 
molecule 1(VCAM1)/ vascular leukocyte antigen 4 (VLA4) axis have been also described as major 
factors of HSC cell mobilization. VLA-4 is a receptor for vascular cell adhesion molecule-1 and 
fibronectin [25]. It has a crutial role in lymphopoiesis, inflammatory recruitment of leukocytes, and 
other situations that require cell adhesion to the vascular endothelium due to mediate cell–cell and 
cell–matrix interactions in a wide range of biological contexts [26, 27]. The expression of VLA-4 and 
VCAM-1 are related to cell adhesion, whereas VLA-4 is expressed on hematopoietic precursor cells 
and most of leukocytes including monocytes, lymphocytes, eosinophils and basophils, VCAM-1 is 
expressed on mesenchymal stem cells (MSC). 
Originally, HSC were extracted from the bone marrow of big bones [21] but currently the use of 
mobilizers that act on any of the mechanisms mentioned above are the treatment of choice to achieve 
a high number of these cells from blood to be transplanted in individuals who present leucopoenia as 
a consequence of the course of some diseases or as a result of chemotherapeutic treatments [28-30]. 
Some of these agents with mobilization effects are presented below:  
 
Granulocyte colony stimulating factor (G-CSF): G-CSF is induced by infection and other stress stimuli to 
be produced by osteoblasts and induces the differentiation and maturation of HSC cells [30]. The 
mechanism of action by which induces this increase in output of stem cells is produced by: (1) 
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secretion of proteases (MMP-9, NE and CG), (2) depletion of osteoblasts, (3) inhibition macrophage 
stimulation of MSCs, resulting in reduced production and expression of CXCL12, (4) increase of the 
sympathetic tone in the BM microenvironment, (5) alteration of chemotactic gradients of S1P and 
CXCL12 [31] and (6) upregulation of S1P1 [4].The mobilization induced by G-CSF is mainly mediated by 
CXCL12, inducing a transient increase of CXCL12 followed by a decrease [4]. Treatment with G-CSF is 
based on a daily treatment for 5 days at doses of 10 μg/kg/day administered by subcutaneous injection 
and apheresis starts to be performed at the end of this schedule. The number of apheresis that should 
be carried out in patients depends on the efficiency of mobilization. G-CSF is the most widely used 
mobilizer agent and currently in clinical procedures only G-CSF alone or the combination with one of 
the mobilizers mentioned below (AMD3100) are used. 
 
Granulocyte-macrophage colony stimulating factor (GM-CSF): Although GM-CSF can also be used as a 
mobilizer of bone marrow HSC cells, its effect is more reduced than that induced by G-CSF even with 
higher doses [30]. GM-CSF has side effects of toxicity, such as fever, hypoxemia, and first-dose effect 
[32]. 
 
AMD3100: (Mozobil, Plerixafor) is a peptide that blocks the CXCL12 interaction with CXCR4 in bone 
marrow. CXCR4 is expressed by mesenchymal stem cells. AMD3100 was initially developed for the 
treatment of HIV infection, since CXCR4 is a coreceptor for virus entry in CD4 T cells and its role in 
stem cell mobilization was later discovered [33]. AMD3100 is extremely specific in its affinity and acts 
as antagonist for the CXCR4 receptor. The inhibition of CXCR4 by AMD3100 produces a rapid increase 
in circulation of hematopoietic progenitors and HSC [34]. Treatments with AMD3100 increase white 
blood cell (WBC) counts which reach a peak approximately 6 hours after injection of AMD3100 in 
human and after 1 hour in mice. AMD3100 is administered subcutaneously at 160–240 μg/kg on day 
4 or 5 after G-CSF, 6 h prior to apheresis. The use of AMD3100 is only employed in patients with a 
serious risk for mobilization failure and it is approved to be used in combination with G-CSF for stem 
cell mobilization in patients with myeloma and lymphoma [35, 36]. AMD3100 is able to induce a faster 
mobilization than G-CSF, however, the ability to mobilize HSC is more limited than G-CSF, while the 
joint treatment increases the output of HSC higher than the treatment of each one separately. The 
combination regimen mobilized up to 50% more CD34+ cells and reduced the number of apheresis 
procedures, however, AMD3100 has a high cost. 
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Stem cell factor is also known as SCF, KIT-ligand, KL, or steel factor. Stem cell factor is a hematopoietic 
growth factor produced by endothelial cells and perivascular stromal cells in the bone marrow niche 
[30]. It has particular importance in the mast cell and erythroid lineages, but also acts on multipotential 
stem and progenitor cells, megakaryocytes, and a subset of lymphoid progenitors. SCF-induced 
mobilization of stem cells and progenitor cells from the bone marrow into the blood may be mediated 
by binding to c-Kit or alterations in the interactions of hematopoietic cell integrins with VCAM-1 or 
fibronectin [37]. A recombinant human SCF used in combination with G-CSF has been showed to 
increase stem cell yield in poor mobilizers [38-41]. Clinical studies showed that treatment with SCF 
increases the numbers of progenitor cells of many types [42].  
 
Sphingosine-1-phosphate (S1P) agonists. S1P is a bioactive phospholipid produced by peripheral blood 
mainly by erythrocytes [43, 44], activated platelets [45] as well as by endothelial cells [46-48]. The 
administration of S1P agonist one hour prior to AMD3100 treatment induced dose-dependent HSC 
mobilization and this mobilization was increased adding G-CSF to the treatment [49]. Therefore, we 
can conclude that the treatment with agonist of S1P agonists will improve HSC mobilization. 
 
VCAM1/VLA4 inhibitors: VLA-4 regulates HSC adhesion to vascular cell adhesion molecule-1 (VCAM-1) 
within bone marrow stroma [50]. VCAM1/VLA4 axes are the major factors of HSC retention together 
with CXCL12/CXCR4. In preclinical studies, blockade of VLA4 expressed on HSCs resulted in 
mobilization of HSC progenitors into the bloodstream [51] through preventing interaction with its 
ligand, VCAM1 [52, 53]. One of these treatments is Natalizumab, a monoclonal VLA4 antibody which 
is used for the treatment of multiple sclerosis and Crohn's disease and was found to induce a modest 
increase in peripheral CD34+ cell count that was found higher in combination with AMD3100 or with 
AMD3100 plus G-CSF [54, 55]. Combination of the three drugs caused a 17-fold increase in HSC 
number compared with G-CSF alone [56]. These data are promising and further studies are needed to 
explore the role of VLA4 inhibition in stem cell mobilization. 
 
Parathyroid hormone (PTH): is a hormone secreted by the parathyroid gland involved in the regulation 
of calcium and phosphorus metabolism and besides presents regulatory effects on bone formation 
and bone resorption [25]. Activation of the receptor for PTH and PTH-related protein (PTHrP) (PPR) in 
osteoblasts have been associated to a significant expansion of the pool of HSC in the adult bone 
marrow and to their increased mobilization into the bloodstream [57]. PTH accelerates differentiation 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
43 
and activation of osteoclasts at least in part by upregulation of macrophage-colony stimulating factor 
(M-CSF). PTH treatment induced an increase in plasma HSC similar to that produced by G-CSF 
treatment [58-60]. It is necessary to carry out more studies to know the role of PTH in the mobilization 
of HSC.  
 
Proteasome inhibitors. Bortezomib has been shown to be capable of inducing mobilization of HSC [61]. 
Bortezomib blocks the activation of nuclear factor-κB by preventing proteasomal degradation of IκBα 
[62]. However, these results were found when the treatment was performed in mice deficient for VLA-
4. Therefore, it means that both pathways must be involved so that the mobilization can be developed. 
On the other hand, studies were also conducted on treatments combined with Bortezomib with G-CSF 
or AMD3100, and the result was a greater induction of stem cell mobilization.  
 
Growth-regulated protein β (Groβ): also called CXCL2, belong to CXC chemokine family which binds to 
the CXCR2 receptor that is expressed in bone marrow microenvironment [63]. CXCL2 is expressed by 
HSCs and lymphoid progenitors of bone marrow and regulates the mobilization of these cells including 
short-term and long-term progenitor cells. Studies in monkeys revealed that the mobilization peak 
occurred within one hour to the 4 hours whereas in mice it take place within the first 15 minutes to 
30 minutes and persists for 90 minutes. Transplantation with HSCs in Groβ treatment resulted in faster 
neutrophil and platelet recovery in mice, with enhanced engraftment and repopulation activity [64]. 
Besides, mobilization included all classes of short term progenitor cells. Combined treatment with a 
single dose of G-CSF and Groβ obtained the same results as the 5-day treatment with G-CSF [65, 66]. 
Therefore, Groβ treatment is postulated as a good mobilizer alone or with G-CSF whose rapid 
mobilization enhances homing and engraftment properties. 
 
Stabilization of hypoxia-inducible factor (HIF):  HIF has a significant role in BM HSC quiescence and self-
renewal. In HSCs niche, HSC proliferation and function is plainly affected by oxygen since HSCs with 
long-term reconstitution ability reside in hypoxic areas of the bone marrow [67, 68]. HIFs are being 
described as crucial regulators of the stem cell phenotype [69]. Also, in vitro studies culturing human 
bone marrow HSCs under hypoxic conditions (1.5% O2) promoted their ability to engraft and 
repopulate the hematopoietic compartment of immunodeficient NOD/SCID mice[70]. HIF induce 
CXCL12 promoting homing to tissues and HIF-1α influence in VEGF-A in the BM sinusoids, leading to 
vasodilation and enhancement of HSC mobilization [71]. Besides, it has been demonstrated that the 
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treatment combined with G-CSF and AMD3100 led to an increase in mobilization of HSCs in mice when 
compared with a combination of G-CSF and AMD3100 alone [72]. 
 
Therefore, there are described different treatments that can induce the mobilization of stem cells 
from bone marrow to bloodstream and the combination of two or more of these treatments is 
important to significantly increase the output of HSC from bone marrow. However, it is necessary to 
develop more drugs that have more advantages than the previous ones, reducing significantly the 
number of apheresis that must be performed with a greater capacity of mobilization. In this thesis, 
there will be presented results in a new treatment that mobilize HSC based in CD69 as target.  
 
2. IMMUNE SYSTEM 
 
The immune system exists to protect the host from infection induced by viruses, bacteria, fungi and 
parasites. The development of an effective immune response is mediated by the cells and soluble 
factors of the immune system which are mobilized through the blood and lymphatic system to the 
different organs to block the spread of pathogens. The immune system is composed of several 
biological processes that let to establish a response against external aggressions and sort out the 
reaction against the own. The immune response occurs in two phases: innate immune response and 
adaptive immune response. The first line of defense against infection comprises the epithelia formed 
by internal and external surfaces of the body and phagocytes that lie beneath all epithelial surfaces 
and engulf and digest invading microorganisms. The innate immune response is constituted by innate 
mechanisms that act immediately with performed elements and are followed by an “early induced 
response” that induces inflammation trigger by local infection captured by phagocytes which recruit 
and activate other effector cells.  The innate immunity depends on germline-encoded receptors to 
recognize features that are common to many pathogens. With these receptors, the cells of the innate 
immune response can detect in the pathogens a variety of danger signals called molecular patterns 
associated with danger (DAMP) or the presence of pathogen-associated molecular patterns (PAMP). 
These receptors are used by the innate immunity to discriminate very efficiently between host cell and 
pathogen and identify broad classes of pathogen. The soluble mediators of the innate immunity such 
as cytokines are different to distinct pathogens and in this way the innate response contributes to the 
induction of an appropriate adaptive immune response.  
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Epithelia is protected by many kinds of chemical defenses, including antimicrobial peptides and 
enzymes. The phagocytes residing beneath the epithelia, act both in the direct killing of 
microorganisms and in producing in cytokines and chemokines that induce an inflammatory response 
and recruit new phagocytic cells and circulating effector cells to the site of infection. The humoral 
innate immunity is composed, in addition, by cytokines, chemokines and soluble circulating defensive 
proteins named complement system, constituted by plasma proteins that are activated by 
microorganisms promoting their removal by phagocytic cells. Cytokines produced by macrophages 
such as TNF-α, IL-l, and IL-6, in addition to the important local effects, have long range effects being 
the most important the initiation of the acute-phase response. Within a day or two, the acute-phase 
response provides to the host of several proteins with functional properties of antibodies capable to 
recognize a broad range of pathogens. However, unlike antibodies, acute-phase proteins have not 
structural diversity. The interferons produced by viral infected cells also contribute to host defenses 
in several ways. Induced resistance to viral replication in all cells, increases antigen presentation and 
activate NK cells to kill virus infected cells.  
This early induced response is also constituted by NK lymphocytes which are activated by interferons 
and macrophage-derived cytokines to serve as an early defence against virus and other intracellular 
infections. NK cells differentiate and mature in bone marrow, circulate into the blood and lymph and 
can be found in lymph nodes, spleen, tonsils, and thymus. They present cytotoxic granules and through 
their expression of a range of germ line-encoded receptors, they are able to recognize virus-infected 
cells either by direct recognition of viral proteins or by sensing of infection-induced reductions in major 
histocompatibility complex class I (MHC-I) levels and expression of stress molecules. The NK cells also 
eliminate tumour cells as they downmodulate MHC molecules. Upon this recognition, NK cells become 
activated, proliferate, and use a range of effector mechanisms to eliminate target cells. These include 
the production of cytokines, such as the expression of death-inducing ligands of the tumor necrosis 
factor (TNF) superfamily of receptors [73] and gamma interferon (IFN-γ) [74, 75], which represent a 
key player in antiviral defense; the secretion of granzyme B (GrzB) and perforin-containing cytotoxic 
granules in the immune synapse with the infected cells. NK cells can be also stimulated to secrete IFN-
y by IL-12 produced by dendritic cells and macrophages or by IL-18 produced by activated 
macrophages acting in synergy with IL-12 [76, 77]. Finally, the innate immune system is also 
constituted by a subset of immune cells named innate lymphoid cells (ILCs) whose functions are 
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related to resistance to pathogens, regulation of autoimmune inflammation, tissue remodeling, cancer 
and metabolic homeostasis [78].  
 
Only if an infectious organism can breach the innate defence, the adaptive immune response have to 
arise. This immune response is characterized by the generation of antigen specific effector cells, that 
target the specific pathogen, and memory cells which prevent reinfection with the same organism. 
Relevant players in the adaptive immune response are B cells with a B cell antigen receptor (BCR) and 
T cells with a T cell antigen receptor (TCR) which are produced along life in bone marrow and thymus 
respectively. During T and B cell development in each lymphocyte is generated one unique antigen by 
a sophisticated gene rearrangement process. At any time, one person has approximately 1010 
lymphocytes between T and B cells subset and each lymphocyte has a different receptor that 
recognizes a distinct epitope (Fig.4). Thus, the adaptive immune system uses a large repertoire of 
receptors that recognize a huge variety of antigens. The adaptive immune response is activated when 
mature dendritic cells process the pathogen and migrate to SLO to present the antigen to T lymphocyte 
(Fig. 4). B and T lymphocytes that circulate by SLO are characterized for their high variety of receptors. 
The recognition of soluble antigens by B cells is performed by the BCR. When a T cell that recognize 
part of the pathogen encounter the migrated DC, stop the migration and proliferate and mature to 
Figure 4. Activation of immune response.  Left, Activation of inflammatory response. Macrophages are triggered after 
encountering pathogen and cytokines and chemokines are released to increase the permeability of blood vessels. Neutrophils 
and monocytes migrate to the site of infection. Right, adaptive immune response is imitated by dendritic cells that after pathogen 
recognition migrate to lymph nodes and induce clonal expansion of antigen-specific lymphocytes. Adapted from 
“Immunobiology” by Janeway. 
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arm effector T cells. If they are CD8 T cells would be cytotoxic cells which destroy host cells infected 
with the invading pathogen. If they are CD4 T cell could differentiate to T helper cells Th1, Th2, Th17 
and regulatory T cells (Treg) which perform different effector functions through different cytokines 
production. Th1 cells, through the production of IFNγ, activate macrophages to respond more 
efficiently to destroy engulf pathogens. The function of Th2 cells is the activation and differentiation 
of B cells to recognize specifically the pathogen through the production of IL4 and IL5 cytokines. Once 
differentiated, B cells mature to improve the fighting of its receptor in pathogen recognition and later 
will end differentiated in plasma cells that secrete its BCR as Igs. These Igs disseminate through the 
body and once bound to the pathogen activate effector mechanism such as the complement system 
that makes holes in the pathogen. Also, the Igs, once bound to the antigen, link to phagocytes by Fc 
of the Igs to engulf the pathogen. However, the humoral immune response will be effective through 
the contribution of cytokines which will allow the clonal expansion of B lymphocytes in response to a 
specific antigen. In addition to Th1 and Th2, a third population of T lymphocytes, Th17, has been seen 
to mediate in immune and inflammatory processes. Th17 has been characterized by the secretion of 
IL17. The signaling pathway used by the vast majority of cytokines is mediated by JAKs and STATs [79]. 
Treg cells also contribute to adaptative immune response regulating the proliferation of effector cells 
to modulate immune response and to avoid exacerbated reactions. Treg function is performed by the 
production of anti-inflammatory cytokines such as TGF-β and IL10 [80, 81]. Of all lymphocytes 
activated in response to an antigen, the majority of effector cells die, however 10% remain as long-
living memory cells constituting the main reservoir of pathogen specific-T cells and are named memory 
T cells [82]. These cells constitute a cellular subpopulation crucial to improve the immune response 
against a pathogen presented for a second time. We can differentiate three types of memory T cells 
according to their circulation pattern and resident tissues and according to surface markers expression 
and cytokines production [83] and they are: central memory T cell (TCM), effector memory T cells 
(TEM) and tissue resident memory T cells (TRM). TRM cells express CD69 and CD103 and are retained 
on tissues.  
 
3. CD69 
 
3.1 Structure 
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CD69 is also named AIM (activation inducer molecule), EA-1 (early activation antigen), MLR-3 or Leu-
23. CD69 is a disulfide-linked homodimeric membrane type II C-type lectin. CD69 is formed by a 
polypeptide of 199 aa (225Kb) containing a single N-linked glycosylation site in its extracellular domain 
and differences in glycosylation results in differences in size ranging from 28 to 32 kD [84-89]. CD69 is 
constitutively phosphorylated at the serine residues (Ser18 and Ser30) and non-glycosylated dimers 
can be also found [90, 91].  
 
 
3.2 Gene structure and regulation 
 
CD69 gene is clustered in the NK gene complex located on distal mouse chromosome 6 and human 
chromosome 12 [92-94]. CD69 mRNA gene contains 5 exons with a short 5'UTR (untranslated region) 
end and a long 3'UTR ends [92]. The 3'UTR presents sequences involves in post transcriptional 
degradation of CD69 mRNA [95]. The expression of CD69 is strongly regulated by transcriptional 
mechanisms [96]. In human and mouse CD69 promoters, it has been described the existence of a TATA 
element 30 base pairs upstream to the transcription start site (TSS) which guides transcription in 
resting and stimulated cells. Proximal to promoter region, it has been detected cis-elements that 
interact with transcription factors such as Erg-1, Erg-3, ATF-3/CREB and Ap-1 upon stimulation [97, 
98]. A -78 to +16 region of human CD69 gene has been reported to be responsible of basal CD69 
Figure 5. CD69 gene structure.  
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transcription. In this region, it has been also showed the binding of Sp1 at position -56 and NFΚB motif 
at position -223 of the human CD69 promoter required for induction of CD69 in response to TNFα 
[92]. 
Comparison between different species of CD69 gene showed the existence of a promoter and four 
conserved noncoding sequences (CNS), CNS1, CNS2, CNS3 and CNS4 located 5'upstream of the 
promoter [96]. 
 
In addition, a non-conserved hypersensitivity site (HS) has been located within the first intron of the 
CD69 gene that binds a huge number of transcription factors and polymerase II [99]. CNS2 and CNS4 
have been described as potent enhancers of CD69 activity whereas CNS1 and CNS3 do not seem to 
influence in this activity. In a transgenic model, it was analyzed CD69 expression in combinations of 
the different CNSs with the promoter using hCD2 as reporter [96]. The addition of CNS1 and CNS2 
caused suppression of CD69 expression whereas further addition of CNS3 and CNS4 supported 
development-stage and lineage-specific regulation in T cells but not in B cells.   
 
3.3 Expression 
 
CD69 is broadly expressed in bone marrow-derived cells. CD69 is expressed in all leukocytes upon 
activation in inflammatory, infectious or stressful processes and is constitutively expressed in platelets 
and not expressed in erythrocytes [91, 100-103]. In non-infected and healthy mice, the expression of 
CD69 is detected in small proportions in the main leukocytes subsets of SLO [104]. CD69 is slightly 
expressed in bone marrow B cell precursors [105]. Also, CD69 is low expressed in immature 
thymocytes and highly expressed in mature thymocytes [1]. Tissue resident NK cells in liver and NKT 
cells in thymus, spleen and liver, also known as type I innate lymphoid cells (ILC1), express CD69[106]. 
In addition, CD69 is expressed in all infiltrating leukocytes in non-lymphoid organs such as tissue 
Promoter CNS1 CNS2 CNS3 CNS4 
Figure 6. Vista Genome Browser of CD69 gene. CD69 is constituted by a promoter and four conserved non-
coding sequences (CNS1-CNS4). VISTA plot of conservation human (base) to mouse sequences, where curve 
shows percentage of conservation; red zones are conserved non-coding sequences (CNSs). 
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resident memory T cells and epidermal Langerhans cells. CD69 is early expressed in lymphocytes 2-3 
h after treatment with anti-CD3 and anti-CD28 [87] but is expressed at later times in myeloid cells. In 
myeloid populations, CD69 expression reaches its maximum in about 24 h after treatment with PMA 
[107]. In bone marrow derived murine macrophages, lipopolysaccharide (LPS) is a potent inducer of 
CD69 [107]. CD69 is expressed as response to cytokines such as IL-2, TNFα and IFNα/β cytokines [91, 
108]. Induction of CD69 can be produced upon antigen-specific TCR and BCR stimulation with anti-
CD3/CD28, anti-CD2/CD28, anti-IgM and anti-CD16 mAb [109]. Human peripheral eosinophils acquire 
CD69 expression after GM-CSF or IL-13 stimulation [110]. CD69 has been detected within T cells at 
high levels in synovial fluid and synovial membrane from chronic rheumatoid arthritis patients [111]. 
Studies in patients with chronic active viral hepatitis, CD69 expression has been identified in liver-
infiltrating CD69+ lymphoid cells both in portal tracts and in periportal areas [112]. Also, it has been 
described CD69 expression in NK cells and T lymphocytes in tumour infiltrates [113]. Bronchoalveolar 
eosinophils from patients with asthma and eosinophilic pneumonia [110] patients with B-cell 
lymphocytic leukaemia also express CD69 [114]. 
 
3.4 CD69 signaling  
 
The need of PMA, in addition of anti-CD69, to produce IL-2 induction, suggests that CD69 is not capable 
of activating protein kinase C (PKC) signaling alone [94, 115]. CD69 activation involves calcium-
dependent signaling pathways through activation of PKC [116].The role of GTP binding proteins as 
transducer molecules during T cell activation [117, 118] and the association of CD69 to GTP binding 
protein such as Ras, Raf and Vav have also been described [115, 119]. Other studies reported that 
CD69 induces AP-1 activity which has been involved in early T-cell activation processes [120]. AP-1 
activation is related to the activation of ERK which can also influence in cytokine production, cell 
proliferation and activation of phospholipase A2 [121-123]. The relation between CD69 and ERK 
members of MAPK family has been described. CD69 induces activation of ERK, which promotes 
granulocyte exocytosis in different cell types [122, 124, 125]. CD69 leads to ERK phosphorylation and 
stabilizes TGF-β on cell surface of CD69+ CD4+ CD25- T cells [126]. Other studies have described the 
ability of CD69 to initiate the PTK-dependent signaling pathway in activated NK cells mediated by PCL-
2 and VAV-1 [127]. CD69 also induces the activation of Syk. In the association of CD69 cytoplasmic tail 
with Jak2, Jak3, Stat1 and Stat5, it has been demonstrated the importance of Jak3 and Stat5 in Th17 
differentiation [128].  It has been showed that CD69 regulates through STAT5 and ERK signaling 
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pathways the suppression activity of CD4+FOXP3+ CD69+ Treg cells [129]. Thus, in CD69-/- Tregs, Stat5 
phosphorylation was inhibited whereas phospho-erk was enhanced. CD69 deficiency inhibits Stat5 
phosphorylation, BIC/mRNA155 transcription and increase suppressor of cytokine signaling 1 (SOCS1) 
expression [130]. Also, in thymic CD4+ FOXP3+ Treg cells, CD69 has been showed to be associated with 
the transporter complex LAT1-CD98 together with an enhanced L-Trp uptake and promoting IL22 
secretion [131].  
 
3.5 Function 
 
The in vivo role of CD69 has been studied in CD69 knockout mice model and in targeting of CD69 with 
anti-CD69 mAbs using different animal models of human diseases [100]. The vast majority of these 
works have demonstrated the role of CD69 as negative regulator of immune response through the 
production of a variety of cytokines and leukocyte trafficking [132]. In contrast, early in vitro studies 
pointed to role of CD69 as an activation molecule [91]. 
   
a. In vitro 
 
MAb CD69 induced the activation of intracellular signals in different cell types. A co-culture with CD69 
crosslinking and phorbol esters induced the expression of IL-2, IFNγ, CD25, TNFα synthesis [133] and 
an increased proliferation [101]. MAb CD69 stimulates glycolysis, synthesis of diacylglycerol and an 
increase of intracellular Ca2+ levels [134]. In platelets, CD69 crosslinking generates Ca2+ influx, 
degranulation, and platelet aggregation [103] while in monocytes induced the production of NO [101]. 
Cross-linking of CD69 mediates extracellular Ca2+ influx [109, 135, 136]. In a different setting, anti-
CD69 seemed to block the ability of T cells to activate macrophages by cell contact [137]. On the other 
hand, anti-CD69 induces apoptosis of monocytes or eosinophils [138, 139]. Also, anti-CD69 mediates 
inhibitory signals on IL-1 receptor (IL-1R) or CD3-mediated T-cell proliferation [88]. All these data 
indicate that CD69 behaves in vitro as a co-stimulatory receptor although it could vary depending on 
the cellular context. 
 
b. In vivo:  
 
CD69 knockout mouse model was generated and described for the first time by Lauzurica et al in the 
year 2000 [105] and in this part of this thesis is named KO1, whereas other CD69 knockout mouse 
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model was published by Nakayama et al. two years later and here will be named KO2 [140]. Whereas 
exon II and III was deleted in the KO1, promoter and exon I was eliminated in the KO2.  
 
CD69 deficient mice (KO1) showed greater antitumor activity against NK-sensitive tumors (RMA-S 
lymphoma and RM-1 prostate carcinoma) [1]. This higher response was found to be dependent on NK 
cells and T lymphocytes and associated with an increased production of MCP-1 and IL-1β and a 
reduced secretion of TGFβ.  Importantly, an increase of lymphocytes in basal and anti-tumor 
conditions was found in peritoneum and spleen. It was found a reduced apoptosis in T lymphocytes 
and NK cells. In addition, increased recruitment of NK cells and T lymphocytes to the tumour site was 
observed. The absence of CD69 favoured an increase of the cellularity in spleen and peritoneum. These 
data demonstrated for the first time the role of CD69 as negative regulator of the immune response 
and show the possibility for immune therapy using CD69 as target.  
 
The role of CD69 in infection has been studied in CD69-/- (KO1) mice model in Listeria monocytogenes 
model [141]. In Listeria monocytogenes infection, the immune response in the absence of T and B 
lymphocytes in CD69-/- RAG2-/- mice was augmented accompanied by an increased Lm elimination. 
However, CD69-/- mice showed an increased IFNα, β and γ expression without differences in TGF-β 
expression whereas an increased liver and spleen damage and an increased susceptibility to Lm 
infection were found compared to WT mice. CD69-/- mice shortly die after Lm challenge in spite of the 
improved control observed in CD69-/- RAG2-/- mice.  Since, it was reported that Lm Listeriolysin induces 
apoptosis of activated lymphocytes as evasion mechanism and that CD69-/-mice have an increased 
activation, the increased activated number of lymphocytes in CD69-/- mice led to an enhanced 
lymphocytes elimination and a lesser control of Lm burden.      
 
The role of CD69 has been studied in collagen induced arthritis type II (CIA) in CD69-/- mice which is 
mediated by a T-cell response and the production of antibodies against collagen type II [142]. CD69 
knockout mice (KO1) had exacerbated the T and B cell immune response to type II collagen and 
therefore the disease. In addition, there was a greater production of IgG2c and IgG2b isotypes and the 
IgG3 isotype and a locally increased T-cell proliferation. TGF-β levels were reduced and an 
enhancement of local cytokine production such as IL-1β, RANTES, MIP-1α and MIP-1β was detected. 
Collagen-induced arthritis model showed that CD69 decreases the autoimmune reactivity and 
inflammation response.  
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Collagen II (CII)-antibody induce arthritis (CAIA) has been developed with the two different CD69 
knockout mice model with opposite results. In this model, the arthritis is induced with a mixture of 
anti-CII monoclonal antibody followed by Lipopolysaccharides (LPS). In CD69-/- (KO1) mice model [143], 
this arthritis was not grossly reduced but the increase in local proinflammatory cytokines and a 
decrease in joint of TGF-β level were also observed. Whereas using CD69-/- (KO2) mice [144], it was 
reported a markedly reduced inflammatory response, suggesting that CD69 plays an activating role in 
neutrophil function. 
 
The atherosclerosis development in ApoE-/- and double deficient ApoE-/- CD69-/- were studied in CD69-
/- (KO1) mice [145]. In the absence of CD69, the production of IFN and IL10 were elevated in activated 
T cells. These mice were fed with control or a high-fat diet to explore the role of CD69 on both 
spontaneous and diet-induced atherosclerosis and it was observed no differences in size and 
composition of atheromas between presence and absence of CD69. Therefore, though the production 
of cytokines are elevated in atherosclerotic ApoE-/- CD69-/- mice, the absence of CD69 does not 
influence in the formation of atheromas.    
 
Using OT-II TCR transgenic mice with CD4 T cells OVA-specific CD69-/- (KO1) mice, it has been studied 
the role of CD69 in differentiation of CD4 T cells to Th17 cells [128, 146]. It has been demonstrated in 
vitro that CD69 deficient CD4 T cells activated with anti-CD3 and anti-CD28 had an increase of IL-17 
and IFNγ production whereas IL17 but not IFNγ expression was augmented after OVA challenge. When 
CD4T cells were differentiated under specific in vitro conditions to Th1, Th2 and Th17 linages, IL17 was 
found increased in all of them and CD69 deficient mice immunized with type II collagen showed a 
higher proportion of antigen-specific Th17 subpopulation in the draining lymph nodes than WT mice. 
In vitro experiments showed that CD69 is associated with Jak3/Sta5 in regulating Th17 differentiation. 
For all this, CD69 reduces IL17 production and T-cell differentiation to Th17.  
 
The influence of CD69 has also been studied in an albumin-induced asthmatic model in both two 
models of CD69 knockout mice, KO1 and KO2. KO1 mice showed an exacerbated allergic airway 
inflammation [147] and this response was associated with an increase of Th2 and Th17 cytokines. In 
the lungs was found a higher expression of VCAM-1 and the bronchoalveolar lavage showed a greater 
number of macrophages and eosinophils together with an increase in IL-4, IL-5, IL-13, IL-17, Eotaxin 
and IgE. In addition, an increase of oxazolone-induced skin contact hypersensitivity accompanied by 
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the increase of TNFα, IFNγ, IL-1β, IL-6 and IL-17 was showed. On the contrary, KO2 mice developed 
allergic asthma but in attenuated form compared to WT mice and the observed pattern of cytokines 
was different to that found in the CD69-/- (KO1) mice [148].    
 
Experimental autoimmune myocarditis was also developed in CD69-/- mice (KO1) by immunizing 
animals with β-myosin [149]. This disease is associated with an increased infiltration of inflammatory 
cells into the heart myocardium followed by a cascade of physical and chemical changes leading to 
heart failure. These mice developed an exacerbated Th17 and IFNγ response in lymph nodes and 
spleen accompanied by an increased leukocyte infiltration in cardiac tissue, a higher increase in heart 
size in relation to the body and a developed necrosis of cardiac muscle. Thus, newly an increased 
autoimmune response to myosin challenge was showed in this autoimmune model. 
 
In vivo skin contact sensitization model showed an increased inflammatory response in the absence of 
CD69 associated with an increase of DC in skin. Dendritic cells of CD69 deficient mice are more efficient 
in migrating to draining lymph nodes and this effect is S1P/S1P1 axis-dependent [150]. This increased 
recruitment leads to an enhanced immune response. 
 
In a model of peritoneal fibrosis induced by dialysis fluid exposure, in normal or uremic status, it was 
found that the absence of CD69 (KO1) exhibited an enhanced inflammation and fibrosis [151]. The 
effluents showed an induction of proinflammatory and profibrotic cytokine production such as IL17, 
IL6, TGFβ and IL1β and chemokines such as GM-CSF, MIP1α, MIP1β and MCP-3 at 20 days after PDF 
exposure whereas at 40 days was induced a higher recruitment of T CD4 and T CD8 lymphocytes and 
an augmented Th17 and a smaller increase of FOXP3 CD4 T cells in the absence of CD69. This ratio of 
Th17 and Treg was increased in CD69 knockout mice. In addition, mix bone barrow from CD69-/- and 
RAG2-/-γc-/- transplanted in WT mice had a similar response than the observed in CD69-/- mice.  
 
Recently, a role of CD69 in an autoimmune model of psoriasis induced by IL-23 injection has been 
described in KO1 mice [131]. The absence of CD69 leads to a reduced expression of IL-22 and STAT-3 
and a lower inflammatory response in the psoriasis model. CD69 did not affect to IL17 secretion by γδ-
T cells. However, CD69 controls the secretion of IL22 produced by γδ-T cells and this control is 
dependent on the aryl hydrocarbon receptor (AhR). In this work was reported that CD69 is associated 
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with the transporter complex LAT1-CD98 and enhances L-Trp uptake. L-Trp is a metabolic precursor 
of AhR ligand that promotes IL22 secretion.  
 
CD69 regulates the homing of CD4 T cells to the intestinal tissues in vivo. Using an in vivo competitive 
homing assay with CD4 T cells of CD69-/- (KO2) mice [153], it was found that their migration to intestinal 
tissue was increased compared with WT CD4T cells. CD4 T cells of CD69-/- mice had increased 
chemokines expression such as CCL1, CXCL10 and CCL19 and chemokines receptors.  
 
Crohn’s colitis model has been performed by two groups using KO2 mice. Mice were treated with 
dextran sodium sulphate (DSS) in both groups. Radulovic. et al. found local increased cell accumulation 
and expression of chemokines and sever intestinal inflammation. Hassegawa et al. using the same 
CD69-/- (KO2) mice and the same DSS induced colitis model [152], found intestinal inflammation 
attenuated. Overall, the results in cytokines and chemokines expression are different in both studies, 
indicating the complex analysis of the mucosa inflammatory response.  
 
Several regulatory T cell subsets have been studied based on the expression of CD69 molecule (review 
below). 
 
In the mucosal inflammatory response, the effect of CD69 in Treg differentiation was studied using 
KO2 mice model in an antigen-specific transfer colitis model. Colitis was induced by adoptive transfer 
of T CD4 CD69+/+ and T CD4 CD69-/- cells in Rag-/- mice [153]. This cell transfer showed an increased 
induction of colitis and impaired oral tolerance in cell adoptive transferring from CD69-/- mice. In this 
model, T CD4 CD69-/- cells had reduced potential to differentiate into FOXP3 regulatory T cell in vivo 
and in vitro [153]. The absence of CD69 in TCD4 lymphocytes increased the production of 
proinflammatory cytokines such as IFN-γ, TNF-α, and IL-21 and decreased production of TGF-β1. This 
work showed for the first time that the absence of CD69 impaired differentiation and suppressor 
function of Treg cells [129].   
 
Also, Cortes et al showed that Treg expressing CD69+FOXP3+ have higher suppressor activity than the 
classical FOXP3+CD25+ Treg cell population by adoptive transfer experiments. WT CD4+FOXP3+ CD69+ 
Treg cells reduced more efficiently OVA-induced immune response and the inflammatory response 
in CD69-/- (KO1) mice. The characterization of this peripheral FOXP3+CD69+ Treg subset compared 
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with WT CD4+FOXP3+ CD69- subset, showed a higher expression of FasL, IFNγ, IL2, IL4 and ICOS and 
chemokines such as CXCL5 and CXCL10 Treg but similar high levels of CTLA-4,  CD38 and GITR 
molecules and secretion of TGFβ. In this work, it was demonstrated that the suppression activity of 
CD4+FOXP3+ CD69+ Treg cells is regulated by STAT5 and ERK signaling pathways. In CD69-/- Tregs, 
Stat5 phosphorylation was inhibited whereas phospho-erk was enhanced.  
 
On the other hand, in thymic FOXP3+ Tregs cells, CD69 deficiency (KO1) inhibits Stat5 phosphorylation 
and BIC/mRNA155 transcription and increases suppressor of cytokine signaling 1 (SOCS1) expression. 
Also, CD69 deficiency, in FTOC cultures impairs thymic Tregs development in embryos, adults and also, 
severely inhibits development of thymus Tregs in Rag2-/- γc-/- hematopoietic chimeras reconstituted 
with CD69-/- stem cells. These results point to CD69 as regulator of Treg development. 
 
Other studies about the influence of CD69 in regulatory T cells were described in tumor infiltrating 
leukocytes. A new subset of regulatory T cells that supress T cell proliferation through membrane 
bound TGF-β1 was described as CD69+ CD4+ CD25- T cells infiltrating tumors [126]. They do not 
express FOXP3, secrete IL10, TGFβ, IL2 and IFNγ. Importantly, these tumor derived CD69+ regulatory 
T cells induced in tumor macrophages the ability to produce high amount of IDO protein [154]. CD69+ 
T cells induce considerable amounts of indoleamine 2, 3-dioxigenase (IDO) in tumor associated 
macrophages leading to downregulation of inflammatory immune response. 
 
The role of CD69 was revealed in leukocyte migration and retention in the study of CD69 knockout mice.  
CD69 was described as decisive in regulation of T cell trafficking through S1P1 expression which can 
physically interacts with CD69. S1P1 is a G-coupled receptor which binds sphingosine 1-
phosphate (S1P) and belongs to a sphingosine-1-phosphate receptor subfamily comprising five 
members (S1PR1-5). Each one of these receptors is predominantly expressed in a cell type. The role 
of S1P1 has been performed in vivo models with S1P1 conditional and knockout mice model and with 
agonist or antagonist of S1P1 receptor which can deregulate the S1P receptor inducing lymphocyte 
retention in lymph nodes [155]. At steady state, when CD69 has not been expressed, lymphocytes are 
continually recirculating to preserve normal concentrations of leucocytes in lymphoid organs and 
bloodstream, necessary for immune surveillance [156]. The cells expressing S1PR are attracted by 
increased gradients of its ligand, S1P, which is highly expressed in plasma. The expression of CD69 
leads to S1P1 downregulation and retention of lymphocytes in lymph nodes, so that in the course of 
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the immune response can be developed effector functions at the site of inflammation (Fig.7). In innate 
and B and T lymphocytes resident in non-lymphoid tissues, CD69 acts retaining these cells preventing 
its egress to circulation. CD69 forms a complex with S1P1 which is negatively regulated and this 
interaction has been deeply characterized [157, 158]. Works of Cyster lab demonstrated that S1P1 
controls lymphocyte egress from thymus, spleen and lymph nodes and that CD69 modulates 
trafficking S1P1-dependent [158-160].  
 
It was showed that CD69-/- T and B cells were poorly retained in lymph nodes after treatment with 
poly: IC or infection with lymphocytic choriomeningitis (LCMV). In LCMV infection, in the adoptive 
transfer of CD69-/- and CD69+/+ T and B cells, CD69 deficient cells were less efficiently retained in lymph 
nodes and were found higher increased in lymph 18 hours after infection [108].  Correspondingly, mice 
overexpressing CD69 in thymus had increased proportion of single positive T CD4 and T CD8 cells 
compared to WT [140, 161]. Furthermore, S1P1 has been considered to contribute in immature B-cell 
egress from bone marrow to lymphoid secondary organs [162, 163] and in homing of plasma cells to 
bone marrow or in retaining in secondary lymphoid organs [164]. Thus, forced expression of CD69 in 
bone marrow immature B cells also reduces the number of immature B cells in the blood. The influence 
of S1P1 in regulatory T cells is established in development, differentiation and function of this 
subpopulation both in thymus and periphery [130, 165]. However, the control of NK migration 
depends essentially on S1P5, although at least in part it also depends on S1P1 [166]. As well, it has 
Figure 7. CD69 and S1P1 are mutually downregulated. Adapted of Shiow et al. Nature. 
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been demonstrated that CD69 modulates skin dendritic cells migration through S1P1 [150] in a model 
of skin sensitization. 
Furthermore, the function of CD69 in promoting the retention of effector and resident memory T cells 
(TEM and TRM) has been defined.  
 
The role of CD69 has been analyzed in Tissue-resident memory CD8 T cells (TRM) using a combination 
of infection of herpes simplex virus infection (HSV) along with adoptive transfer of CD8 T cell specific 
for this pathogen [167]. It was found that CD69 and CD103 are necessary for the optimal formation 
and survival of CD8 TRM cells in the skin using CD69 deficient (KO1) antigen specific T cells, it was 
shown a reduction in TRM cell numbers and this reduction occurs shortly after the entry of T cells into 
the skin.  
Also, in an infection model of Influenza virus using CD69-/- (KO2) mice [168], memory specific CD8 T 
cells (TRM) and effector memory CD8 T cells (TEM) response were measured in the lung. The 
accumulation of T cells in lung were found reduced using CD69-/- mice. Although specific niches for 
lung-resident memory CD8 T cells allow CD69-independent maintenance. These cells that express 
CD69 and persist in bone marrow are characterized by being associated with IL-7 of stromal cells. In 
addition, CD69 regulates the formation of CD4 T-helper memory cells. The absence of CD69 (KO2) 
induces fewer effective memory immune response and as a consequence produces deficiency of the 
memory Th cell to produce high-affinity antibodies. Accordingly with these studies, CD69+ thymic 
memory CD8 T cells contain two subsets with distinctive recirculation potential. CD69 is required for 
optimal formation of CD103+ TRM cells but CD69 expression alone did not identify permanently 
resident T cells [169].  In addition, CD69 expression was associated with a subset of virus-specific 
memory CD8 T cells in SLO with phenotype markers associated with TRM that express CD69 [170].  
Mackay et al also showed that CD69 regulates effector T cell egress from peripheral tissues and 
prolongs T cell retention and favors memory formation. In CD8 T cells, the signaling pathways leading 
to activation coincides with the transcriptional downregulation of S1P1. Therefore, CD69 expression 
interferes with S1P1 function [171].   
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c. In vivo CD69 targeting  
  
Anti-mouse CD69 2.2 and 2.3 and anti-human CD69 2.8 antibodies only recognize mouse CD69 and 
human CD69 respectively and were produced in CD69 knockout mice injecting cells expressing both 
molecules. These antibodies were generated in our lab and were used in most of the above described 
models. Anti-mouse CD69 2.2 (IgG1) induced an internalization of CD69 and not the elimination of 
CD69 positive cells [172] and thus not activate complement or bind Fc receptors. Anti-CD69 2.3 (IgG2a) 
activates complement and binds FC receptor and therefore depletes CD69+ cells. Anti-CD69 2.8 (IgG1) 
actuates as control of anti-CD69 2.2. Other laboratories use the anti-mouse CD69 generated in 
hamster distributed commercially. 
 
In NK cell dependent tumor model, the targeting of CD69 showed reduced tumor growth, increased 
NK cells cytotoxicity and a reduction in the production of TGF-β, similar to the result obtained in CD69 
deficient mice. However, CD69 targeting increased production of IFNγ unlike CD69 deficient mice. 
Also, therapeutic administration in healthy animals generated NK cell cytotoxicity activity in the 
absence of tumor priming. In addition, in vitro, anti-CD69 triggers NK cell function on resting NK cell 
and a reduction of TGF-β, and an increase of IFNγ production [1].  
 
Also, it was studied the targeting of CD69 in collagen-induced arthritis (CIA) through two different types 
of antibodies: anti-CD69 2.2 and anti-CD69 2.3. The difference between both treatments is that anti-
CD69 2.2 induces the internalization of CD69 and the second depletes CD69 positive cells. The first 
antibody led to an exacerbated response of the disease, reproducing the phenotype found in CD69 
knockout mice whereas the treatment with anti-CD69 2.3 was able to reduce the disease due to a 
reduction in the proinflammatory cytokine production, lymphocyte proliferation and frequency of CII-
specific T cells producing IFN-γ [173].  
 
In atherosclerosis mice model, similar to the results obtained in CD69-/- (KO1) mice, CD69 targeting 
with anti-mouse CD69 2.3 did not display different atheroma development compared to non-treated 
mice in fat-fed ApoE-/- mice [145]. 
 
In an ovoalbumin-induced allergic asthmatic model, in vivo treatment with the anti-CD69 2.2 antibody 
produced similar results to CD69 knockout mice. Martin et al. described a greater inflammatory 
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response in the treated mice along with an increase in number of eosinophils [147]. Wang et al. 
showed that CD69 targeting using commercial antibody prevented the development of airway hyper-
responsiveness while the analysis of bronchoalveolar fluid revealed an increase in eosinophil 
infiltration, mucus production, and a significant reduction of IL-5 [174].  
 
Peritoneal fibrosis, induced by dialysis fluid exposure, it was found that the CD69 targeting exhibited 
an enhanced inflammation and fibrosis similar to that found in the absence of CD69 [151]. 
 
In psoriasis, the treatment with anti-CD69 2.2 similarly to the absence of CD69 reduced the uptake of 
aminoacid through Lat-1 [131]. 
 
Colitis: The anti-CD69 treatment also inhibited the induction of DSS induced colitis. IL10 expression 
was found increased in the colon DSS CD69 treated mice [152]. 
 
Tregs, CD69+ FOXP3+ Tregs secrete higher amounts of TGF-β and have a potent suppressor activity 
which is impaired by treatment with anti-CD69 2.2 [129]. The use of anti-mouse CD69 2.2 inhibited 
tTreg development in FOCT cultures of embryonic thymuses [130].  
 
Ligand, Anti-CD69 2.2 binding to CD69 blocked interaction with Galectin-1 that was carbohydrate 
dependent [175]. 
 
3.6 Ligands  
 
Currently, it has been described Galectin-1 as a ligand for CD69 that is expressed mainly by tolerogenic 
dendritic cells and activated T and B cells but not resting, and significantly upregulated in activated 
macrophages and T regulatory lymphocytes [176]. Selective binding of CD69 to Galectin-1 in DCs 
modulates differentiation of T lymphocytes to Th17, confirming that CD69 acts as a negative control 
of pro-inflammatory responses [177]. Galectins have a carbohydrate recognition domain with affinity 
for beta-galactosides [178] and it has been described that galectin-1 but no other galectins binds to 
extracellular domain of CD69 through sites of N-glycosylation present in CD69 [179]. Galectin-1 
promotes cell apoptosis which may contribute to the immunosuppressive effects of CD69 protein 
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[180].  Functional assays of both mouse and human T cells demonstrated the role of CD69 in the 
negative effect of Galectin-1 on Th17 differentiation. Galectin-1 has not been the only ligand 
associated with CD69. Also, it has been described S100A8/S100A9 as an endogenous ligand expressed 
in myeloid cells. The interaction between CD69 and S100A8/S100A9 is carbohydrate dependent 
leading to Treg differentiation, regulating TGF-β and IL-4 and inhibiting STAT3 pathway [181]. S1P1 
interacts with CD69 and this interaction occurs between proximal regions of CD69 membrane and 
transmembrane helix 4 of S1P1 [157] promoting a high affinity binding. CD69 binds to S1P1 on surface 
of lymphocytes mediating its internalization, preventing the outflow of lymphocytes [108, 182], 
whereas the absence of CD69 promotes S1P1 expression on the surface and lymphocyte outflow at 
the circulation. So, we can say that CD69 and S1P1 are downregulated mutually. In addition, early 
biochemical studies showed glucidic ligands for CD69 [183]. Immunoprecipitation and sequencing 
identified calreticulin as a CD69 interacting protein at surface of lymphocytes [184]. The implication of 
these potential ligands, however, has not been deeply explored. CD69 cytoplasmic tail interacts with 
Jak3/Stat5 and this interaction impairs Th17 differentiation [128]. 
 
4. VACCINIA VIRUS 
 
4.1 Description 
 
Vaccinia virus (VACV) is a member of the Poxviridae family belonging to Orthopoxvirus genus and was 
used as a vaccine to eradicate the Variola virus from the same family. Other orthopoxviruses include 
Variola virus (VAR), cowpox virus (CPV), monkeypox virus (MPV), ectromelia virus (ECT), camelpox virus 
(CMPV), raccoonpox virus and tatera poxvirus. The use of Vaccinia virus has continued over time 
because it is an exceptional model for studying the interactions that are established between virus and 
host and because it can be used as a vector for the expression of foreign genes. It is a large DNA virus 
with a linear double-stranded DNA genome that encodes many of their own enzymes for transcription 
[185] and DNA replication [186]. It is considered unique within DNA viruses because they only 
reproduce in the cytoplasm of the host cell, outside of the nucleus [187].It has a broad cellular tropism 
and infects almost all cell lines in culture. The virus codifies in its genome several proteins that give 
resistance against the action of interferons. Members of this virus family do not usually establish 
persistent or latent infections and have a low mutation rate [188]. VACV infection is initially controlled 
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by the innate immune response, but can only be eradicated by adaptive immunity being B and T cells 
important since Rag-/- mice will finally succumb to the infection [189].  
The viral particle is a structure surrounded by a lipoprotein envelope. The replication cycle of Vaccinia 
virus begins with the entry of virus and ends with the assembly of complex macromolecular structures 
to form an infectious particle that induces cellular infection with secretion of early mRNAs and proteins 
(Fig. 8).  
 
DNA replication begins a few hours later from infection. Vaccinia virus induces the formation of 4 
different types of virions: intracellular mature virus (IMV), intracellular enveloped virus (IEV), cell-
associated enveloped virus (CEV) and extracellular enveloped virus (EEV). These virions differ 
according to their abundance, structure, location and the role that they play in the viral replication 
Figure 8. Vaccinia virus replication. Adapted from Harrison SC et al. PNAS. 
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cycle. IMV is the most abundant form of virus and is responsible for transmitting infection between 
hosts [190, 191]. IEV is formed by wrapping of IMV with intracellular membranes, and allows viral 
dissemination to the cell surface on microtubules. CEV is important for cell-to-cell spread. Lastly, EEV 
mediates the long-range dissemination of virus in cell culture and, probably, in vivo [192, 193]. Vaccinia 
virus is the only one that produces two infectious virus forms: IV and EV being EV related to promoting 
virus spread and to supporting mechanisms of immune virus evasion of antibody [194, 195] and 
complement [191].  
 
4.2 Use of Vaccinia virus as vector expression 
 
The technology of using recombinant viruses as live vaccines by introducing a heterologous gene of 
another microorganism began to be used more than 10 years ago [196, 197] and are also potent tools 
for gene therapy. They are effective vaccines to induce both humoral immunity by the production of 
specific antibodies, and cellular immunity, without the risk of exposure in the recipient animals [198-
201]. Currently, Vaccinia virus vectors are being evaluated in many clinical trials although viral 
attenuation is necessary to reduce the adverse effects. Vaccinia virus is used to construct directed 
targets for vaccines candidates against various diseases, such as HIV-1 [202], hepatitis [203] influenza 
[204], malaria [205], tuberculosis (TB) [206], and even in oncogenic diseases of both human and 
domestic animals [207] and display high immunity.   
 
4.3 Immune response to Vaccinia virus infection 
 
In immune response to Vaccinia virus infection, both innate and adaptive immune response are 
involved. Next, we will detail the immune cells that have been described as important in this response. 
The innate immune response in Vaccinia virus infection include macrophages, dendritic cells, NK cells 
and production of cytokines, chemokines, complement and TLR. An increased severity infection was 
found in ectromelia virus infection in components of the complement system deficient mice [208].  
 
The importance of macrophages has been also described in Vaccinia virus infection. It was observed 
that the depletion of the alveolar macrophages induced a higher viral replication and an exacerbation 
of the disease [209]. In addition, as a consequence of the lack of alveolar macrophages, a recruitment 
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of inflammatory cells into the lungs is induced, which produces a worse control of the infection [210] 
and links with a decrease in the weight of mice and an increase in temperature corporal. 
  
Myeloid derived suppressor cells (MDSC) are a population of immature myeloid cells that regulate the 
immune system [211] and include myeloid progenitor cells, immature macrophages, immature 
dendritic cells (DCs), and immature granulocytes. Following to Vaccinia virus infection, these cells 
accumulate at the site of infection and regulate the activity of NK cells. The depletion of these cells 
induced a reduction in viral titre but an increase in mortality associated with an increased IFN 
production and therefore a poor control of infection by Vaccinia virus [212].   
 
Dendritic cells are important in generating an immune response against poxvirus in vivo. The infectivity 
of Vaccinia virus is superior in immature than in mature cells. It has been found that Vaccinia prevents 
the maturation of dendritic cells and induces their apoptosis. In order to be able to carry out an 
immune response against Vaccinia, it is necessary that some DCs survive to the infection and initiate 
T-cell response or that may have matured before infection since they are less susceptible. Cross-
presentation is another mechanism to induce a T cell response to Vaccinia virus [213]. Poxvirus 
infections can induce rapid and systemic release of IL-1β, IFN-α, GM-CSF and TNF-α [214, 215], all of 
which could affect DC maturation from precursors [216-218].  
 
NK cells are crucial players in the first line of defense in innate immune response with a critical role in 
antiviral responses. NK cells were also critical for clearance in NK cell depleted mice in Vaccinia virus 
showing a higher viral titre [219]. They represent an essential tool in the fight against poxviruses like 
Vaccinia virus. VACV-infected cells have increased sensitivity to NK cell lysis. NK cells are activated by 
IFNα and β, IL-12 and IL-18 and its function is regulated by activator and inhibitory receptors [220]. 
Inhibitory receptors recognize MHC I and impede the response against self-antigens whereas the 
activators are related to NK cells activation [220] such as NKG2D which has been shown to be 
necessary for the function of NK cells [219, 221, 222] The production of type I IFN facilitates viral 
clearance. Another strategy for activation of NK cells is mediated via TLR-2 stimulation by Vaccinia 
virus in NK cells through PI3K-ERK pathway [221]. STAT1 is also involved in the activation of NK cells 
which was critical for the elimination of infection and whose signaling in dendritic cells promotes the 
expression of NKG2D ligands [223]. In NK cell depletion assays, Stat1-/- mice resulted in an increase in 
host susceptibility and a lower survival to VACV infection [224].  
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Also, the immune response against Vaccinia virus infection is mediated by IFNs which are a potent 
antiviral tool in Vaccinia virus removal [225-227]. IFNs are a group of glycoproteins that are classified 
into: Type I including IFN-alpha (IFNα) and IFN-beta (IFNβ) and others such as IFN-kappa, IFN-delta, 
IFN-omega and their activity is mediated by Type I IFN receptor which are ubiquitously expressed, Type 
II which includes IFNγ and is majorly secreted by activated T cells and NKs cells that induce macrophage 
activation and promote a Th1 response [228, 229] and Type III that includes IFN lambda which also 
acts in viral response but has a more limited distribution.  
 
To test the importance of IFNγ, an IFNγ-deficient model has been used, which has demonstrated a 
significant increase in mortality after ECTV infection and an increase in viral titers compared to control 
mice suggesting a role for IFNγ in controlling early virus replication and recovery from ECTV infection 
[224]. In the same mouse model, it has been observed that IFNγ also contributes to the best anti-
Vaccinia immune response in a respiratory VACV infection by restricting viral dissemination and 
promoting survival [230]. The influence of type I IFNs has also been demonstrated by the development 
of IFNαβR-/- mice. IFNαβR−/− NK cells failed to produce effector molecules indicating that type I IFN was 
critical for NK cell activation in response to Vaccinia virus infection. IFNαβR−/− mice displayed higher 
levels of viral titre compared to WT mice. Therefore, type I IFN control immune response to Vaccinia 
virus infection [219]. 
 
Figure 9. IFN signaling and mechanisms of immune evasion of Vaccinia virus against IFN production. “Vaccinia  virus 
immune evasion: mechanisms, virulence and immunogenicity” by Smith et al. Journal of general virology. 
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In addition to IFN, there are other cytokines that influence in anti-Vaccinia immune response to be 
effective and regulated. Fundamentally we are talking about TNF, IL-18, IL23 and IL17, which influence 
in the innate and adaptive immune response. TNF mediates protection against Vaccinia virus by 
inducing apoptosis of infected cells. The major cells expressing TNF are macrophages and activated T 
cells. The anti-Vaccinia effect of TNF was studied in TNF-/- mice, which significantly had more weight 
loss than WT and a significantly higher VACV titer compared to WT controls. TNF, like IFN, plays a 
protective role in controlling Vaccinia virus infection [231].  IL-18; also called IFN-inducing factor, is a 
proinflammatory cytokine [232] that regulates the innate and adaptive immune response. IL-18 is 
expressed by activated monocytes and macrophages and its activation begins with binding to its 
receptor which induces IFN synthesis and activation of NK and CTL cells [232, 233] as well as 
proliferation and cytotoxicity of these cells [234-237]. Administration of recombinant IL18 in mice has 
demonstrated its antiviral activity [77, 233] whereas IL18 deficient mice exhibited less ability to control 
VACV infection. IL18 can act synergistically with IL12 to promote Th1 responses, which has an essential 
role in defense against pathogens through IFN production [76]. Therefore, the joint action of both 
cytokines is essential for viral clearance and the generation of both specific and non-specific anti-
Vaccinia responses. IL2, in spite of its importance in the development of a correct cytotoxic anti-viral 
immune response, the absence in mice of IL2 had a similar or slightly reduced anti-Vaccinia response 
to WT mice [238, 239]. The Th2 immune response is characterized by IL4 production that suppresses 
T CD8 response. In the immune response to Vaccinia virus, the absence of IL4 may increase the 
cytotoxic capacity of CD8 T cells and may improve viral clearance, but since CD8 is not the only cell 
capable of removal Vaccinia virus, the response in mice deficient for IL4 was similar to control mice 
[240]. IL12 e IL23 have been also described to regulate Th1-mediated immune responses. Whereas 
IL12 promotes the differentiation of IFN-γ-producing Th1 cells and generates an important antiviral 
response, IL23 stimulates production of IFN-γ increasing the cytotoxic capacity of CTLs. The study of 
anti-Vaccinia immune response indicates that IL-23, but not IL-12, is essential for controlling Vaccinia 
virus infection and for enhancing host defense [241]. IL17 has also been implicated in the response to 
Vaccinia virus infection. It is produced by Th17 cells and induces the production of proinflammatory 
cytokines, chemokines, and adhesion molecules in some cell types. IL-17-deficient mice were less 
resistant to infection than WT mice [241]. In addition, treatment with an anti-IL-17 mAb in VV-IL-23-
infected IFN-gamma-deficient mice resulted in a significant increase in viral titers compared to non-
treated mice.  
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The recruitment of activated leukocytes to the site of infection is mediated by chemokines [242, 243], 
which play an important role in the response to pathogens [244]. They are expressed on cell surface 
and bind to their ligand by establishing gradients that allow the induction of cell attraction to the 
needed sites. One of the chemokines that has been described its role in immune response to Vaccinia 
virus infection is CCL2, which recruits monocytes, NK cells and T lymphocytes at the site of infection. 
In addition, CCL2 expression is mediated by type I Interferon. CCL2 deficient mice showed a failure to 
recruit NK cells and T lymphocytes to the lung after intranasal Vaccinia virus infection [245].  
 
Together, all mechanism of the innate response initiate a powerful adaptive immune response 
essential for proper elimination of Vaccinia virus infection. All mechanisms previously described and 
the adaptive immune response are summarized in Figure 10. 
In adaptive immune response, TCD4 cells have been described as important in the anti-viral response 
[246]. They are the cells responsible for the differentiation of B cells giving rise to production of specific 
antibodies against Vaccinia virus and for inducing specific T CD8 virus responses. Activated T CD4 cells 
Figure 10. Immune response in Vaccinia virus infection. Adapted of “The immunology of smallpox vaccines”. Curr Opin Immunol. 
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are able to produce IFN, express CD127 and IL2 and proliferate [247, 248]. They have two effective 
mechanisms, the first is mediated by Fas/FasL to induce apoptosis of infected cells [249] and second 
is the transfer of cytotoxic granules, which contain perforins and granzymes, to the host cell. Mice 
deficient for CD4 lymphocytes in Vaccinia virus infection exhibited less effective protection against 
Vaccinia virus infection and an increased mortality [250, 251] and showed a reduced number of CTLs. 
 
VACV infection, similar to other viruses, results in the generation of an adaptive immune response 
with the development of virus-specific CD8 T cells that reduce virus dissemination and complete 
clearance of virus. CD8 T cells contribute to this protective immunity via the release of interferon 
gamma (IFN-γ) and thanks to members of the Tumor Necrosis Factor (TNF) [252]. Spriggs et al. [253] 
demonstrated that CD8 deficient mice had similar survival to control mice when they had been 
infected with high doses of the virus and their rate of virus clearance was similar.  
 
The protection induced by humoral immunity has been shown to have a great importance in the 
resolution of Vaccinia virus infection since a large number of viral proteins are recognized by 
immunoglobulins [254, 255]. In response to a viral infection, the antibodies bind directly to the virus, 
inducing aggregation and preventing infection of the host cell. In addition, they induce phagocytosis 
by complement activation. And finally, they can act activating cytotoxic cells once bound to the 
infected cell. Therefore, VACV-specific B cells are crucial in Vaccinia virus protection but CD4 and CD8 
T cells can help to avoid the mortality in B cell deficient mice in VACV infection [255]. 
 
Finally, the formation of a memory immune response is important for proper protection in reinfection. 
Levels of Vaccinia-specific memory B cells are maintained over a long time being able to develop an 
efficient immune response upon re-infection [256]. CD4 deficient mice showed an impaired ability to 
form CD8 memory cells in Vaccinia virus infection, and thus preventing the control of Vaccinia infection 
compared to WT mice [257].  
 
In spite of all the cellular mechanisms existing in the body to fight against Vaccinia virus infection, 
Vaccinia is able to develop multiple mechanisms of immune evasion to prevent its removal. Some of 
these mechanisms are summarized in the following table (Fig.11) [258]. 
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Figure 11. Signaling pathways and patterns recognition receptors in Vaccinia virus infection. Adapted from “The interferon system and 
Vaccinia virus evasion mechanisms” by Mariano Esteban. Journal of interferon and cytokine research. 
  
 
 
 
 
 
 
 
 
 
 
OBJECTIVES
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OBJECTIVES 
 
The study of the role of CD69 in bone marrow leukocyte egress and on the course of VACV infection 
has been approached.    
 
1. Analysis of CD69 absence and targeting in bone marrow leukocytes and HSC mobilization and 
its contribution in the increased number of peripheral leukocytes.  
 
2. CD69 is rapidly expressed in viral infections; its role in the immune response to these infections 
has never been studied to date. We aimed at analyzing the effect of CD69 on the course of 
VACV infection. 
 
a. Analysis of CD69 deficiency in the immune response against Vaccinia virus infection. 
b. Examine the role of CD69 targeting in the immune response to Vaccinia virus infection. 
c. Analysis of the effect of CD69 overexpression in the immune response to Vaccinia virus 
infection.
  
 
  
 
 
 
 
 
 
 
 
 
MATERIALS AND 
METHODS
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MATERIALS AND METHODS 
 
Mice 
 
C57BL/6, Balb/c, Rag2−/− Balb/c mice, all CD69+/+ or CD69−/−, HuCD69 C57BL/6, CD69.BAC GFP C57BL/6 
mice were bred and housed under specific pathogen free conditions in the animal facilities of the 
Instituto de Salud Carlos III (ISCIII), Madrid. HuCD69 mice were obtained by transgenesis of human 
CD69 BAC containing 100kb of CD69 gene by Bristol Meyers and were kindly provided by Dr. Robert 
Graziano. HuCD69 mice have three copies of human CD69 BAC in a mouse CD69 knockout background. 
CD69.BAC GFP mouse lines were generated by Dra. Teresa Laguna by a pronuclear injection of mouse 
CD69 BAC containing 100kb of CD69 gene in mouse oocytes by the Animal Facility of CNB (National 
biotechnology center, Madrid, Spain) in C57bl/6 mice. These mice were crossed in heterozygosis with 
wild type mice. GFP positive mice were used as mice that had incorporated CD69 BAC and GFP 
negative mice were employed as control mice. All mice used in this study were between 6 and 12 
weeks of age, males and females. CD69−/− mice had been backcrossed on the C57BL/6 and the Balb/c 
backgrounds at least nine times. All procedures involving animals and their care were approved by the 
ISCIII Ethics Committees and were conducted according to institutional guidelines. The following image 
shows used mice and procedures. 
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In vivo treatments 
 
HuCD69 mice were treated with anti-human CD69 2.8 and controls were treated with PBS or Isotype 
control anti-mouse CD69 2.2 intravenously whereas C57BL/6, Rag2−/− Balb/c mice were treated with 
anti-mouse CD69 2.2 and anti-human CD69 2.8 or PBS were used as control . Two treatments were 
especially used, 500 µg of anti- CD69 24 hours  before sacrificing or 200 µg of anti-CD69 in two doses 
separated for one week. The anti-mouse CD69 2.2 mAb and anti-human CD69 2.8 mAb (IgG1 isotype) 
were generated in our laboratory [172] by the fusion of NS-1 myeloma cells with spleen cells from a 
CD69−/− mouse previously immunized three times with mouse 300–19 pre-B cells. The Ab were purified 
from concentrated hybridoma supernatants using protein G columns (GE Healhtcare, Piscataway, NJ, 
USA), dialyzed extensively against PBS, further purified by Zeba Spin desalting columns (Thermo 
Scientific) and stored at −80°C. The IgG1 isotype control andbody was likewise produced and purified. 
The resulting antibody preparations were tested on CD69−/− bone marrow-derived DC (BMDC) cultures 
at 10 μg/ml and were unable to upregulate CD80 or CD86 expression levels on these cells. In 
vitro cultures were performed in complete DMEM supplemented with 10% FCS, 50 μM 2-
mercaptoethanol, and 2 mM L-glutamine at 37°C. 
In AMD3100 assays, mice were mobilized with AMD3100 (CXCR4 Antagonist I - CAS 155148-31-5 – 
Calbiochem) dissolved in distilled water with 5mg/kg intraperitoneally and one hour after in 
experiment comparing with anti-human CD69 or 24 hours after treatment in BrdU proliferation assay 
comparing with anti-human CD69. 
In experiments of internalization of S1P1, the inhibitor of S1P receptors, FTY720 (Fingolimod 
hydrochloride purchased from Sigma-Aldrich) has been used at dose of 1mg/kg for mouse 
intraperitoneally 24 hours before sacrificing dissolved in PBS1x.  
In BrdU assays, all mice were injected intraperitoneally with 1 mg of BrdU intraperitoneally. Three hours 
after, mice were sacrificed, and splenocytes and bone marrow cells were collected and stained with 
fluorescent antibodies for cell surface markers.  
NK cells were ablated by a single intravenous (i.v.) injection of 100 µg of anti-Asialo GM1 (eBiociences, 
San Diego, CA) or 50 µg of anti-Asialo GM1 (Wako, Chemicals USA, Richmond, VA) in 200 µl one day 
before infection. Control mice received the same dose of rabbit IgG (Sigma-Aldrich) by the same 
schedule.  Two days after infection mice were sacrificed and analyzed. Completeness of NK depletion 
was determined by the absence of NKp46+ cells in the spleen and blood. 
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For neutralization of IFN-γ, mice were administrated with a single injection i.p. of 250 µg of anti- IFN-
γ (clone xmg 1.2) in 400 µl PBS 1x. The same day, mice were infected i.p. with 1x106 pfu or 1x107 pfu 
of VV in Rag2-/- and Rag2+/+ mice respectively and sacrificed 48 hours after infection for analysis.  
Peritoneal macrophages were elicited by intraperitoneal injection of 2.5 mL of 3% thyoglycolate in 
distilled water. Cells were seeded at 1 x 106/cm2 in RPMI medium containing 10% FBS. Non-adherent 
cells were removed 6 h after seeding by extensive washing with medium. Macrophages were 
stimulated with LPS (Ultrapure 0111:B4 lipopolysaccharide from Escherichia coli purchased from 
InvivoGen) or without stimulation. 6 hours after stimulations, cells were collected for real time PCR 
and 24 hours later for western blot. 
 
Cell Isolation 
 
Cells were collected from Bone marrow (two femurs of each mouse), Blood collected (in 2 mM EDTA 
PBS to avoid coagulation), Spleen, Thymus and Lymph nodes (inguinal, maxillary, mandibular, brachial 
and axillary). Cells from tissues were released by mechanical disaggregation, washed twice with 1x PBS 
and pelleted. Bone marrow cells were extracted by flushed with 1 ml of PBS 1x from femurs of both 
legs. White blood cells (WBC) counts were determined after red blood lysis with ACK solution (0.15 M 
NH4Cl, 1mM KHCO3, 1mM Na2-EDTA, pH 7.4). Blood cells number shown are white blood cell counts 
per 1 ml of blood. Thymus and spleen tissues were disaggregated, and cells were washed in PBS. 
Leukocytes were labeled and analyzed by flow cytometry. 
 
Abs and flow cytometry 
 
Bone Marrow, Blood, Spleen, Thymus and Lymph nodes cells were incubated with anti-CD16/32 (Fc-
block 2.4G2; BD Biosciences, Franklin Lakes, NJ, USA). The following antibodies used against mouse 
intracellular and surface antigens were purchased from eBioscience (San Diego, CA):  anti-CD4 (clone 
RM4-5), anti-CD8 (clone 53-6.7 or clone Ly-2), anti-CD11b (clone M1/70), anti-CD11c (clone N418 or 
clone HL3), anti-CD19 (clone eBio1D3), CD49b (clone DX5), anti-CD25 (clone 3C7), anti-CD69 (clone 
H1.2F3), anti-human CD69 (clone FN50), anti-CD107a (clone eBio4A3), anti-CD117 (clone 2B8), anti-
CD122 (clone TM-b1), anti-F480 (clone BM8), anti-GR1 (clone RB6-8C5), anti- CD43 (clone R2/60), anti-
IgM (clone RMM1), anti-IgD (clone 1126c), anti-CD21 (clone R4E3), anti-CD23 (clone B3B4), anti-B220 
(clone RA3-6B2), anti-CXCR4 (clone 2B11), anti-CD3 (clone 17A2), anti-CD34 (clone RAM34), anti-FLT3 
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(clone A2F10), anti-Sca (clone D7), anti- 117 (clone 2B8) and anti-mouse VLA-4 (clone R1-2), anti-IFN 
(clone XMG 1.2), anti-NKp46 (clone 29A1.4), and anti-TNF (clone MP6-XT22).  Expression of S1P1 on 
BM, blood and spleen cells was detected using polyclonal rabbit anti–mouse S1P1 Ab (Anti-EDG1 
antibody (ab11424) purchased from Abcam) followed by donkey anti–rabbit-PE Ab (Jackson 
ImmunoResearch Laboratories). To assess intracellular production of IFN-γ and TNF-α, 2x106 spleen 
cells were incubated in the presence of brefeldin A (BFA) (5 µg/ml) for 4 h at 37ºC and washed. 
Alternatively, cells were restimulated with 10 ng/ml PMA (Phorbol 12-myristate 13-acetate) and 1 
µg/ml ionomycin or RPMI only in the presence of BFA (5 µg/ml) for 4 hours at 37ºC. Following 
incubation, cells were stained for surface molecules, fixed with 4% paraformaldehyde, washed, and 
incubated with anti-IFNγ mAb, anti-TNF and Granzyme B mAb in the presence of 0,75% saponin in 
PBS1x and 3% of FBS for 20 min at 4°C. The values shown are derived from subtracting the values of 
unstimulated wells (media alone) from the restimulated ones. To assess intracellular production of 4E-
BP1 (clone V3NTY24) and IL-2 (clone JES6-5H4), cells were fixed with paraformaldehyde 4% (Electron 
Microscopy Sciences) for 12 minutes at room temperature in darkness and permeabilized with 1% of 
Saponin (Sigma-Aldrich) for 20 min at 4°C.  For intranuclear staining with anti-mouse T-bet (clone 
eBio4B10) and FOXP3 (clone NRRF30), cells were fixed and permeabilized with the FoxP3/ 
Transcription Factor Buffer Set (BD). BrdU staining was performed using a BrdU Flow kit (Beckton 
Dikinson) and anti-mouse BrdU (clone B44) according to the manufacturer's instructions. Cells were 
analyzed with a FACScanto (Becton Dickinson, Franklin Lakes, NJ, USA), using BD FacsDiva software 
(Becton Dickinson), and data were analyzed with FlowJo (Tree Star Inc., Ashland, OR, USA).  
 
B cells development. 
 
Bone Marrow cells and spleen cells were analyzed to evaluate the different stages of development in 
B cells. Bone Marrow cells were gated according to B220, CD43, IgM and IgD staining as it's shown in 
the following image (left) and by the other hand, spleen cells were classified as described by M. 
Manuela Rosado et al. (right) according to B220, IgM, CD21 and CD23 staining [259]. 
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Vaccinia virus and titers assays 
 
The Western Reserve strain of VACV (kindly provided by Dr. Daniel Lopez) was grown in CV1 cells 
cultured in D-MEM supplemented with 10% FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL 
streptomycin and 5 μM β-mercaptoethanol. The titer was determined by plaque assay on CV1 cells, 
and the viral stock was stored at −80°C in PBS undl use. 1× 106 pfu were injected into Rag2-/- mice, and 
1 × 107 were injected into immunocompetent mice intraperitoneally in 0.2 ml PBS. For survival studies, 
Balb/c mice were inoculated with 1× 105 pfu intranasally and were weighed over time. CD69 BAC mice 
were injected with 1 × 107 pfu and the route of administration was different depending on the organ 
analyzed. Analysis of the viral titre in ovaries was performed by intraperitoneal infection while viral 
titration in spleen, lung, kidney, lymph nodes and liver was assayed at 24 hours after infection by 
intravenous injection.  Experiment of survival was realized through weight measures over time and 
mice were infected with 1× 105 pfu of VACV-WR by intranasal inoculation. 
Viral load was measured by plaque-forming assay. In brief, female mice were sacrificed at the indicated 
times and ovaries and spleen were harvested and stored at −80°C in 0.5 ml of PBS undl use. Ovaries 
and spleen from individual mice were first homogenized and freeze-thawed three times. Serial 
dilutions were plated on confluent CV1 cells. After one day of culture at 37ºC, plates were stained with 
crystal violet and the plaques were counted.  
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Gene expression analysis  
 
Total RNA was isolated from cells with RNeasy Mini Kit (Qiagen) according to the manufacturer´s 
protocol. Quantitative RT-PCR was performed using the ABI 7500 (Applied Biosystems) with SYBR 
Green PCR Master Mix. All samples were analyzed comparing with the expression of the housekeeping 
gene B2m (Beta 2-microglobulin), used as an endogenous control for normalization of the expression 
level of target genes. Primer used for quantitative PCR sequences were as follows:   
ACTB_F: AGCCATGTACGTAGCCATCC 
ACTB_R: CTCTCAGCTGTGGTGGTGAA 
S1P1_F: GTGTCCACTAGCATCCCGGAGGTTAAAGCTCTCCGCAGCTCA 
S1P1_R: CCCAACAGGGGTAGCAGGAAGACCCC 
TGFb_F:  GGTGTVAGAGCCTCACCGCG 
TGFb_R: AGAGCGGGAACCCYCGGCAA  
 
For peritoneal assays, each sample was run in duplicate, and all samples were analyzed in parallel for 
the expression of the housekeeping gene 36B4 (acidic ribosomal phosphoprotein P0), which was used 
as an endogenous control for normalization of the expression level of target genes. Fold induction was 
determined from mean replicate values. Primer sequences are available on request. 
NOS2_F: TGGAGCCAAGGCCAAACACAG  
NOS2_R: TCCACCAGGAGATGTTGAAC 
COX-2_F: CAAGGGAGTCTGGAACATTG 
COX-2_R: ACCCAGGTCCTCGCTTATGA 
TNFα_F: GCCTCTTCTCATTCCTGCTTG 
TNFα_R: CTGATGAGAGGGAGGCCATT 
IFNγ_F: TCAAGTGGCATAGATGTGGAAGAA 
IFNγ_R: TGGCTCTGCAGGATTTTCATG 
 
Expression of inflammatory genes was evaluated with the mouse RT2Profiler PCR Inflammatory 
Cytokines and Receptors Array (SABiosciences) and expression of apoptosis genes was evaluated with 
the mouse RT2Profiler PCR apoptosis (SABiosciences). RNA was obtained from bone marrow and spleen 
in mice treated vs. not treated through RNeasy Mini Kit and for cDNA synthesis First Standard kit 
(SABiosciences) was used. The RT2Profiler array was probed according to the manufacturer’s protocol, 
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using the Profiler PCR Array System and SYBR Green/Fluorescein qPCR master mix (SABiosciences) in 
an ABI 7500 Fast sequence analyzer (Applied Biosystems). Gene expression was measured with 
(http://www.superarray.com/pcr/arrayanalysis.php) web-based software package for the PCR Array 
System, which automatically performs all ΔΔCt based fold-change calculations from the specific 
uploaded raw threshold cycle data. 
                                                                          
mRNA flow cytometry 
 
Cells from bone marrow, spleen and blood were isolated and blood cells were lysed. CXCL12 in blood 
was analyzed by flow cytometry using FlowRNA II Assay kit (Affymetrix eBioscience) according to 
manufacturer’s protocols. Samples were fixed for 30 min at 2-8 °C with PrimeFlow RNA Fixation 
Buffer I (Affymetrix), permeabilized with PrimeFlow RNA Permeabilization Buffer with RNAse 
inhibitors (Affymetrix), fixed again with PrimeFlow RNA Fixation Buffer II for 60 min at room 
temperature. For target probe hybridization for CXCL12, samples were incubated for 2 h at 40 °C. 
Next, samples were treated to signal amplification with PrimeFlow RNA PreAmp mix 1.5 hours at 
40ºC, PrimeFlow RNA Amp mix 1.5 hours at 40ºC and last, samples were incubated with 1 hour at 
40ºC with PrimeFlow RNA Label Probes. Finally, they were resuspended in Storage Buffer and 
acquired on a FACS Canto II (BD Biosciences).  
 
Bone Marrow Chimeras 
 
C57BL/6 recipient mice (CD45.1) were lethally irradiated with a dose of 1050 rads. CD69+/+ (CD45.1/.2) 
and CD69-/- (CD45.2) donor mice were sacrificed, and bone marrow from femurs, tibiae and 
humeri was collected. Cells were passed through a 70-mm nitex mesh. A mixture of 5x106 cells of each 
donor bone marrow was injected intravenously through the tail vein into irradiated recipient mice. 
After 6-8 weeks, BM (tibiae and femurs) and spleen cells were harvested and NK cell numbers (NKp46+) 
and macrophages (F4/80+) were analyzed.  
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Cell Death Assay 
 
Splenocytes from non-infected mice were cultured in 24-well plates (1x106 cells/ml), and cell death 
was assayed at different times after culture by staining with propidium iodide (PI) followed by flow 
cytometric analysis. 
 
CXCL12 ELISA 
 
Plates coated with CXCL12 were purchased to R&D systems.  CXCL12 levels were determined in plasma 
and supernatants of bone marrow, spleen and lymph nodes. Plasma was extracted in EDTA 2M-PBS. 
Supernatants of bone marrow (femurs), spleen and lymph nodes were collected in 500 ul of PBS1x. 
After centrifugation, the supernatant was kept and frozen. Samples were used undiluted and the 
protocol was realized according to manufacturer’s protocols. Optical density was determined with a 
microplate reader set at 450 nm and wavelength correction at 570nm and the analysis reveal the 
CXCL12 expression calculated according to the amount of protein.  
 
Western Blot 
 
For Western Blot. cells were lysed at 4°C with 0.2 mL buffer A (0.5% Chaps, 10mM Tris pH 7.5, 1mM 
Cl2Mg, 1mM EGTA, 10% Glycerol, 5 mM β) and protease inhibitor cocktail (Sigma). Protein content 
was assayed with the Bio-Rad protein reagent. All cell fractionation steps were performed at 4°C. 
Protein extracts were subjected to SDS-PAGE (10–15% gels) and blotted onto polyvinylidene difluoride 
membranes, which were incubated antibodies specific for NOS-2, COX-2 and β-actin. After incubation 
with HRP-conjugated secondary antibody, protein bands were revealed with an enhanced 
chemiluminescence kit (GE Healthcare). β-actin was used as a loading control. After treatment with 
100 mM β-mercaptoethanol, 2% SDS in TBS and heating at 60°C for 30 min, blots were sequentially 
probed with other antibodies. 
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Immunohistochemistry 
 
Immunohistochemistry was carried out on 10 µm-thick serial spleen sections of uninfected Rag2-/- 
CD69-/- and WT mice or mice at 2 days after infection with 105 pfu of VACV. Sections were first stained 
with anti-CD45 or anti-Ki67 and were subsequently stained with haematoxylin. 
 
 
Statistical analysis 
 
All data were plotted and statistically analyzed using Graphpad Prism software. Graphs show the 
means and standard errors of the mean (SEM). Statistical significance was performed using an 
unpaired two-tailed t-test. * p<0.05, ** p<0.01, *** p<0.005. A p<0.05 was considered significant.
  
 
 
 
 
 
 
 
 
 
RESULTS AND 
DISCUSSION
  
 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER I: 
IMMUNE RESPONSE TO 
VACCINIA VIRUS INFECTION IN 
CD69 KNOCKOUT MICE.
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RESULTS 
 
Enhanced in vivo anti-VACV Activity in CD69−/− Mice mediated by NK cells. 
 
During viral infection expression of CD69 is induced in all leukocytes. To evaluate the role of CD69 in 
the host response to Vaccinia virus CD69+/+ and CD69-/- mice were intranasally infected with 105 pfu of 
VACV and their weight and appearance were monitored over time. CD69-/- mice showed reduced 
weight loss relative to their WT counterparts (Fig. 1A). Moreover, we observed that at 10 days post-
infection all CD69+/+mice developed lumbar pustules, whereas CD69-/- mice did not (Fig. 1B).  CD69 WT 
and CD69-/- mice were also infected intraperitoneally and viral titers were analyzed in the ovary. At 7 
dpi, CD69-/- mice had significantly lower titers than did WT mice (Fig. 1C). The difference was already 
significant 1 day after infection (Fig. 1C), which suggested that CD69 is involved in the early anti-viral 
immune response. Indeed, CD69-/- Rag2-/- mice also had lower viral titers than did CD69 WT Rag2-/- at 
2 and 6 dpi (Fig. 1D), and this trend was already observable at 1 dpi (Fig. 1D). No significant differences 
were observed in viral load in spleen at 1 dpi when compared either CD69+/+ with CD69-/- mice or Rag2-
/- CD69+/+ with Rag2-/- CD69-/- mice (Fig. 1E). Therefore, increased control of viral infection was 
observed in CD69-/- mice, also in the absence of adaptive immunity.  
Previous studies showed that NK cells are crucial in VACV clearance in vivo in WT mice [260]. To 
investigate a possible contribution of NK cells to the enhanced anti-viral response observed in CD69-/- 
mice, CD69-/- and WT mice were treated with the NK cell-depleting anti-Asialo MAb one day before 
being infected with VACV, and virus titers were analyzed 1 dpi.  
The anti-Asialo treatment eliminated the significance of the differences in viral load between CD69-/- 
and WT mice (Fig. 2A). In the  Rag2-/- background the depletion of NK cells not only eliminated the 
advantage of CD69-/- mice but rendered them more susceptible to the infection than CD69+/+ mice 
(Fig. 2B) pointing to a differential effect of CD69 deficiency on NK cells and other leukocytes present 
in Rag2-/- mice. Altogether these results show that the increased early control of viral infection 
observed in CD69-/- mice is majorly mediated by NK cells. 
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Figure 1. CD69-/- and Rag2-/- CD69-/- mice are more resistant to VACV infection than their CD69+/+ counterparts. A, CD69+/+ or 
CD69−/− immunocompetent mice were infected intranasally with 105 pfu of VACV-WR. Weight loss was evaluated over 10 
days.  B, At 10 days after intranasal infection, CD69 mice had developed pustular lesions in the lumbar region whereas 
CD69-/- mice were free of them. C, CD69+/+ and CD69-/- mice were infected with 107 pfu of VACV-WR intraperitoneally. 
Ovaries were collected and analyzed for viral load at 24 hours and 7 days after infection. D, Rag2-/- CD69+/+ and Rag2-/-CD69-
/-  mice were infected with 105 pfu of VACV WR and ovaries were collected at 24 hours, 2 days and 6 days after infection. 
E, CD69+/+ and CD69-/- mice (left) and Rag2-/- CD69+/+ and Rag2-/-CD69-/- mice (right) were infected with 106 pfu of VACV-
WR intraperitoneally and splenic viral titers were measured one day post infection. Data shown are representative of one 
experiment (A and B) or a pool of two independent experiments (C-E).  
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Figure 2. NK cells mediate the increased resistance to VACV-WR in CD69-/- mice and Rag2-/- Cd69-/- mice. CD69+/+ and CD69-/- 
mice (A) and Rag2-/- CD69+/+ and Rag2-/-CD69-/- mice (B) were treated with 50 µg of NK cell-depleting anti-Asialo GM1 or of 
rabbit serum control IgG i.v. one day before infection. Mice were then infected with 1×106 pfu of VACV-WR i.p.  Ovaries 
were harvested and assayed for viral load one day post-infection. A, Data shown are pool from two independent 
experiments and representative of four independent experiments. B, Data shown are from one experiment and 
representative of three independent experiments.  
 
Similar NK cell reactivity but increased NK cell numbers in VACV infected mice CD69-/- 
mice 
 
We proceeded to analyze NK cell function in CD69-/- mice. For this, we analyzed cytokine and GrzB 
production and degranulation of NK cells (NKp46+ cells) from infected mice. At early times of infection 
and in uninfected mice, percentages of IFNγ+ and TNFα+ cells within NK cells were equivalent in CD69-
/- and WT splenocytes after PMA restimulation (Fig 3A) as well as in Rag2-/- CD69-/- and Rag2-/-CD69+/+ 
splenocytes after PMA or RMA-S restimulation (Fig 3B and data not shown), pointing to that CD69 
does not affect the cytokine production capacity nor the activation threshold of NK cells. Thus, the NK-
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IFN and TNF producing NK cells (Fig. 3C), and a tendency to increased NK cell numbers in general 
(Fig.3D). Percentages of IFNγ+ and TNFα+ cells within CD4+ and CD8+ T cells were also unaffected by 
CD69 deficiency (Fig. 4A), but increased numbers of IFNγ+ and TNFα+ CD4+ and CD8+ T were present in 
the spleens of CD69-/- mice 24 hours post-infection (fig. 4B). Thus, similarly to NK cells, the reactivity 
of non-cognate, innately-responding T cells is unaltered in CD69-/- mice, but they are increased in 
number.       
The increased NK cell numbers were due not to an augmented proportion of NK cells in the spleens of 
CD69-/- mice but to increased total cell counts (Fig. 3D and data not shown). At 24 hours post-infection, 
CD69-deficient mice had higher numbers of total spleen, blood and peritoneum cells (Fig. 3D, 4C).  All 
the splenic and peritoneal main leukocyte subtypes, (CD4+ and CD8+ T cells, B cells (CD19+), dendritic 
cells (DC) (CD11c hi) macrophages (CD11b hi, F480+, CD11c-), monocytes (CD11b hi, F480-, CD11c-, Gr1 
int, SSC low), neutrophils (CD11b hi, F480-, CD11c-, Gr1 hi, SSC int) and eosinophils (CD11b hi, F480-, CD11c-
, Gr1 low, SSC hi), were increased in number (Fig. 4D, E), but no major differences were found in their 
percentages (data not shown). At 7 days after infection, CD69-/- mice had approximately 40% more 
leucocyte splenic cells than did WT mice (Fig. 3D), and numbers of all the main lymphocyte subsets 
were also increased to the same extent (Fig. 4F).  
Likewise, at 2 and 6 dpi, Rag2-/- CD69-/- mice also had increased spleen leukocyte numbers relative to 
Rag2-/- CD69+/+ mice (Fig. 5A), which was translated to an increased splenic leukocyte density, as seen 
by immunohystochemical staining with anti-CD45 MAb  (Fig. 5B). Numbers of NK cells were also 
significantly higher in CD69-/- Rag2-/- mice (Fig. 5A) but their percentage was unaltered (data not 
shown). Upon ex vivo restimulation the number of IFNγ+, CD107+ and GrzB+ NK cells was also higher in 
CD69-/- Rag2-/- spleen cells (Fig. 5C, D). We also detected a tendency to increase the numbers of NK 
cells producing TNFα, even though this was not statistically significant (Fig. 5C). The numbers of other 
main leukocyte subtypes found in Rag2-/- were also increased in the spleens of CD69-/- Rag2-/- mice 
(Fig. 5E). These data reveal a positive correlation between viral infection control and effector NK cell 
numbers in CD69-/- mice.  
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Figure 3. Unaltered NK cell activation in CD69-/- and Rag2-/-CD69-/- mice infected with VACV. A, CD69-/- and WT mice were 
infected with 1 × 107 pfu i.p of VACV-WR or left uninfected and were sacrificed 24 hours after infection. Spleen cells were 
cultured with PMA/ionomycin and BFA for 4 hours and stained for cell surface markers and intracellular cytokines. 
Percentages of NK cells producing IFNγ or TNFα are shown. B, Rag2-/- CD69+/+ and Rag2-/- CD69-/- were infected with 1 × 105 
pfu i.p of VACV-WR. Spleen cells were collected at 2 and 6 days after infection and re-stimulated with RMA-S cells over 4 
hours; intracellular IFN-γ and TNFα were measured in NK cells and percentages of cytokine-producing cells are plotted. C, 
Number of IFNγ and TNFα-producing NK cells in CD69-/- and CD69+/+  mice 24 hours after infection were measured as in A. 
D, Total cell and NK cell number in spleen of CD69+/+ and CD69-/- mice 24 hours and seven days after infection. A-D, Data 
are a pool of two independent experiments. 
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peritoneum and blood 24 hours after infection. D-E, Numbers of the indicated splenic (D, F) and peritoneal (E) lymphoid 
and myeloid subpopulations at 24 hours (D, E) and 7 days (F) after infection. A-F, Pool of two independent experiments. 
 
Figure 4. CD69-/- mice show increased numbers of activated T cells 
and total leukocytes in the early response to VACV-WR. WT and 
CD69-/- mice were not infected or infected with 107 pfu of VACV-
WR i.p., and were sacrificed at 24 hours or 7 days post-infection 
as indicated. A-B, Spleen cells were stimulated with 
PMA/ionomycin and BFA over 4 hours. Percentages (A) and 
numbers (B) of IFNγ and TNFα CD8+ and CD4+ lymphocytes were 
measured in uninfected mice (A, left panel) and in 24 hours-
infected mice (A, right panel; B). C, Total cell numbers in  
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Figure 5. VACV-infected Rag2-/- CD69-/- mice show increased accumulation of splenocytes and reactive NK cell numbers. A-D. 
Rag2-/- CD69+/+ and Rag2-/- CD69-/- mice were infected with 1 × 105 pfu of VACV i.p. and were sacrificed at days as indicated 
postinfection. A, Graph representing the splenic total cell and NK cell (DX5+) numbers at 2 and 6 days postinfection. B, 
(Top) Immunohistochemical analysis of spleen by staining with anti-CD45 mAb and (bottom) representative plots of NK cell 
stainings (DX5+) 1 day after infection. C, Spleen cells were collected at 2 and 6 days after infection and restimulated with 
RMA-S cells over 4 hours; numbers of IFN-γ and TNFα-positive NK cells are shown. D, Spleen cells were collected at 24 h 
post-infection and cultured with PMA/ionomycin and BFA over 4 hours. Numbers of IFN-γ, GrzB and CD107a-positive NK 
cells are shown. E, Graph representing the numbers of different splenic myeloid subpopulations. A, C, D and E, Pool of two 
independent experiments. B, One staining representative of seven mice. 
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Similar NK cell proliferation rate in CD69-/- Rag2-/- and CD69 WT Rag2-/- mice 
 
The observation that Rag2-/- CD69-/- mice presents an increased accumulation of NK cells in the spleen 
led us to assess whether CD69 is associated with control of NK proliferation in anti-viral immunity. The 
proliferation activity of splenic NK cells of uninfected and VACV infected Rag2-/- CD69-/- and Rag2-/- 
CD69+/+ mice was determined based on their capacity to incorporate BrdU after 2 days of infection. 
Similar BrdU+ percentages were found in  splenic NK cells (Fig. 6A), although the number of  BrdU+ NK 
cells was increased in the spleens of Rag2-/- CD69-/- mice (Fig. 6B). Equivalent results were obtained 
when proliferation of splenic NK cells from infected mice was analyzed with an ex vivo pulse of BrdU 
(data not shown). Furthermore, histological spleen sections two days after infection were stained by 
immunohistochemistry for Ki67, a nuclear protein associated with ribosomal RNA transcription, and a 
slight increase in Ki67 staining in mouse CD69-/-compared to WT was observed, consistent with 
increased numbers of cycling cells (Fig. 6C). NK cells were analyzed for the expression of CD122 (IL-
2Rβ) and CD25 (IL-2Rα) in spleen (Fig. 6D) and in bone marrow (Fig. 6E), but no differences were found 
in the percentages of NK cells expressing these components of the IL-2 receptor. These results show 
that CD69-/- NK cells proliferate at a similar rate as CD69+/+ NK cells but that increased numbers of 
proliferating NK cells are found in CD69-/- mice.  
 
Increased NK cell numbers in uninfected CD69-/- mice 
 
The differences in cellularity between CD69-/- and CD69 WT mice at such early time points of infection 
may be indicative that the cellularity is already altered before the infection. Therefore, we analyzed 
uninfected mice and we observed that total cell and NK cell numbers in spleen were already increased 
in both CD69-/- and CD69-/- Rag2-/- mice (Fig. 7A). Moreover, spleens of CD69 WT and CD69-/- mixed 
bone marrow chimeras at steady state  had higher proportions of CD69-/- NK cells than CD69+/+  NK 
cells within total donors-derived NK cells, pointing that increased NK cell numbers in CD69-/- mice are 
due to an NK cell intrinsic effect. An equivalent observation was not done for other cell types, since, 
for example, the proportions of CD69/- F4/80+ cells were even lower than those of CD69+/+ F4/80+ 
within total donors-derived F4/80+ cells (Fig.7B). An NK cell-intrinsic effect of CD69 deficiency is 
substantiated by the fact that CD69 is expressed on all NK cells of all the organs analyzed, even in the 
earliest maturation stages (Fig. 7C, D). 
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Figure 6. Unaltered NK cell proliferation rate but increased numbers of proliferating NK cells in VACV-infected Rag2-/- CD69-/- 
mice. A and B, Rag2-/- CD69+/+ and Rag2-/- CD69-/- mice were infected with 1x106 pfu of VACV-WR i.p or not infected. Two 
days after infection, mice were injected i.p with 1mg of BrdU for 3 hours and then they were sacrificed. Spleen was 
collected and stained. Percentages (A) and numbers (B) of BrdU+ cells within NK cells (NKp46+) in spleen. C, After 2 days of 
infection, histologic sections of spleen were stained for anti-mouse Ki67 by immunohistochemistry. D and E, Percentages 
of splenic (D) or bone marrow (E) NK cells positive for alpha and beta chain of IL-2 receptor were determined in infected 
and non-infected mice. A and B, Uninfected mice, pool of two independent experiments and infected, one experiment. C, 
One staining representative of seven mice. D and E, Pool of two independent experiments.  
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Steady state NK cell numbers can be affected by NK cell recirculation. S1P5 is a member of the 
sphingosine phosphate receptors family and T-bet-dependent S1P5 expression has been reported to 
control NK cell recirculation through mediating egress from lymphoid organs, finally affecting splenic 
NK cell counts [166]. We reasoned that CD69 could have an effect on NK recirculation through altered 
T-bet expression, and we characterized T-bet expression in bone marrow and spleen NK cells. 
However, we did not observe differences in the expression of T-bet in either site at 1 day after infection 
(Fig. 7E). Thus, CD69 deficiency does not alter NK cell number through altered T-bet expression.  
 
Spontaneous cell death rate is reduced in CD69-/- NK lymphocytes 
 
We also tested whether an increased immune cell survival was contributing to the observed greater 
number of NK cells in CD69-/- mice. Cell death is difficult to test in vivo because dead cells are rapidly 
eliminated. Thus, we cultured Rag2-/- CD69-/- and Rag2-/- CD69 WT splenocytes in vitro and analyzed 
the spontaneous cell death in NK cells by PI staining at different times of culture. No significant 
differences were found at early time points. However, we observed significantly reduced percentages 
of dead cells in Rag2-/- CD69-/- after 60 hours of culture (Fig.8A). These data suggests that the 
lymphocyte accumulation observed in the spleen is contributed by a lower spontaneous cell death 
rate in the CD69-/- mouse and that CD69 has a role in regulating NK cell survival. 
 
 
 
 
 
 
 
 
 
 
 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
101 
Figure 7. NK cell distribution and CD69 expression in NK cells. A, Total cell and NK cell numbers in spleens of unmanipulated 
Rag2+/+ and Rag2-/- mice. B, C57BL/6 recipient mice (CD45.1) were reconstituted with a mixture of wild-type (CD45.1/.2) 
and CD69-/- (CD45.2) bone marrow cells. The values represent percentage of CD69+/+ and CD69-/- NK cells or macrophages 
mice within total donors-derived NK cells or macrophages, respectively. C and D, Spleen, BM, thymus and blood cells from 
unmanipulated Rag2-/- CD69+/+ and CD69−/− were collected and stained for NKp46, CD27, CD11b  and CD69. Overlays of 
CD69 profiles gated on total NK cells (C) or NK cells in the different maturation stages (D) from Rag2-/- CD69+/+ (solid line) 
and Rag2-/- CD69−/− (grey-filled, background control) mice. E, Rag2+/+ and Rag2-/- Mice were infected with 1x106 pfu of VACV-
WR ip. One day after infection, spleen and bone marrow cells were analyzed for T-bet expression on NK cells (NKp46+). The 
graphs show the MFI (Mean Fluorescence Intensity) of intranuclear T-bet staining in spleen and BM NK cells. A, B and E, 
Pool of two experiment. C and D, One experiment representative of two experiments. 
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Figure 8. Attenuation of spontaneous cell death in Rag2-/-CD69-/-. Cell survival was assessed by PI staining of unfractionated 
splenic cells of uninfected Rag2-/-CD69-/- and Rag2-/-CD69+/+ mice at different times of culture. One experiment 
representative of two experiments.  
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DISCUSSION 
 
In this work, we show an early NK cell-mediated increased VACV infection control in CD69-/- mice 
consistent with increased NK cell numbers in peripheral sites in these mice. Two observations point to 
that the increased activated NK cell numbers in the CD69-/- spleens are not secondary to a differential 
infection evolution. On one hand, increased numbers of splenic NK cells were already present in 
uninfected mice, and this was translated to higher numbers of cytokine-producing cells upon in vitro 
restimulation. On the other hand, spleen viremia is not significantly different between CD69+/+ and 
CD69-/- mice. However, it has been suggested that lymphoid organs are not sites of VACV replication 
but rather of viral particles drainage. Unlike spleen, ovaries are the organs that sustain the highest 
virus replication rate in systemic VACV infection [261]. The infection induces recruitment of NK cells 
into the ovary, among other leukocyte types [261]. 
The higher NK cell counts in CD69-/- mice do not seem to be due to increased NK cell proliferation 
capacity but rather by, at least in part, a lower rate of spontaneous cell death.  
CD69 has a negative regulatory role in a number of autoimmune diseases and in anti-tumor immune 
response. In the first report of its role in the immune response to infection, we showed that CD69’s-
mediated immune-regulation was beneficial in the course of Listeria monocytogenes (Lm) bacterial 
infection, CD69 deficiency led to an impaired control of Lm infection, starting at early time points, and 
this was related to an enhanced production of type I and II IFNs and increased leukocyte apoptosis 
[141]. In contrast, we show here that negative immune modulation by CD69 is detrimental in the case 
of the viral infection with VACV in different mouse strains. This differential effect may be due to the 
different interaction of the pathogen with the augmented immune response given in the CD69-/- 
mouse. On one hand, Lm exploits the immune activation to induce massive lymphocyte apoptosis. 
Through the secretion of listeriolysin toxin, it induces apoptosis of lymphocytes sensitized by type I 
IFN. Upon phagocytosis of large amounts of apoptotic lymphocytes, the macrophages secrete IL-10, 
inducing immune-suppression and favoring bacterial outgrowth. In contrast to Lm, VACV virus employs 
large part of its genome to avoid immune recognition and activation [258]. Thus, the enhanced 
immune response of the CD69-/- may be detrimental in one case and beneficial in the other.  
We have previously shown that CD69-/- mice had NK-cell mediated augmented anti-tumor immune 
response [1]. Similarly to the present results, NK cell reactivity was also unaltered in the absence of 
CD69, but the enhanced anti-tumor response was mediated by increased NK cell accumulation. Higher 
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numbers not only of NK cells but also of total leukocytes were reported already at steady state. Thus, 
it is likely that CD69 is also involved in the homeostatic regulation of NK cells as well as of other 
leukocyte subsets. The fact that the early effect of CD69 deficiency on viral control depends on NK 
cells is likely due to that these cells are of chief importance in the early control of this type of infection 
[260]. An effect of CD69 deficiency on the role of other cell types is not excluded, especially at later 
time points of infection.  
Previous results of our group showed that CD69 deficiency did not affect the percentage of VACV-
specific CD8+ T cells at 7 days post-infection, implicating that CD69 affects neither the priming nor the 
expansion rate of virus-specific cells [104]. However, total cell numbers were not recorded then, and, 
considering that steady state T cell numbers are increased in the CD69-/- mouse, it is expectable that 
this will be translated to increased VACV-specific CD8+ T cell numbers during the primary adaptive 
immune response, which will likely contribute to the lower viral titers observed at day 7. 
We have not observed any differences in the percentages of IFN and TNF producing NK cells upon 
ex vivo restimulation with PMA or the MHC-I deficient cell line RMA-S. The strong activation with PMA 
overrides NK cell activation thresholds set by the process of NK cell tuning [262] and thus the results 
with PMA may just reflect an equivalent capacity of CD69 WT and CD69-/- NK cells to produce 
cytokines. Instead, stimulation with MHC-I deficient targets does not override those thresholds [262]. 
Therefore, the equivalent cytokine production upon RMA-S restimulation reflects that, even if CD69 is 
expressed constitutively on NK cells at different maturation stages as well as in infection, it does not 
participate in NK cell tuning [263]. 
Altogether, this work points to a role for CD69 in the resolution of viral infection through a role in 
homeostatic control of NK cells.
  
 
 
 
 
 
 
 
 
 
CHAPTER II: 
INFLUENCE OF HUMAN CD69 
TARGETING IN MOBILIZATION 
OF PROGENITOR CELLS.
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RESULTS 
 
CD69-/- mice show decreased bone marrow cellularity and increased leukocyte counts in 
the periphery. 
 
In the previous work, we have shown that CD69-/- mice (in Rag2-/- background) infected with Vaccinia 
Virus have increased splenic cell numbers of all the main leukocyte subtypes. Total splenic cell counts 
were actually also found increased in these mice at steady state [1] and this was related with a 
decreased cell death rate upon ex vivo culture. Nevertheless, given the role of CD69 in regulating the 
S1P1-mediated egress of T and B cells from lymph nodes and of T cells from the thymus, and the fact 
that S1P1 contributes to some extent to leukocyte egress from the BM [132], we wondered whether 
an increased hematopoietic cell output from the bone marrow could contribute to the greater 
cellularity observed in the absence of CD69. For this, we quantified total leukocyte and NK cell 
numbers in bone marrow, spleen, blood and thymus of CD69-/- mice and CD69-/- Rag2-/- mice. Total cell 
counts were not altered or decreased in the bone marrow of CD69-/- mice and CD69-/- Rag2-/- mice, 
respectively, but were increased in secondary lymphoid organs and blood of CD69-/- mice compared 
to CD69+/+ counterparts in both backgrounds (Figure 9A-B). This was consistent with increased spleen 
weight in CD69-/- and CD69-/- Rag2-/- mice (data not shown). NK cells were decreased in the BM, and 
consistently with our recent publication, they tended to be or were significantly increased in the spleen 
of CD69-/- and CD69-/- Rag2-/- mice, respectively (Fig. 9C-D). This accumulation of leukocytes at 
peripheral sites and, in some strains, this relative depletion of BM leukocytes seen in CD69 knockout 
mice are consistent with a role of CD69 in leukocyte retention in the bone marrow.  
 
Targeting of mouse CD69 induces bone marrow mobilization of hematopoietic cells from 
primary lymphoid organs to the periphery. 
 
In view of the results explained above, we reasoned that compensatory mechanisms could be 
normalizing bone marrow (BM) cells numbers while still in the presence of an increased BM output, 
and that a role of CD69 in regulating cell egress from BM could be better appreciated when acutely  
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Figure 9. The absence of CD69 decreases the total cell number in bone marrow and increases in spleen and influences in NK 
cells number. A, Total cell number in Spleen, Bone Marrow, Thymus and Blood in Rag2+/+ mice. B, Total cell number in 
Spleen and Thymus and in Rag2-/- mice. C, NK cell number in Spleen, Bone Marrow, Thymus and Blood in Rag2+/+ mice 
and D, in Bone Marrow, Spleen and Thymus in and Rag2-/- mice. 
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affecting CD69 function with mAb targeting. Thus, we treated CD69+/+ mice with anti-mouse CD69 
MAb 2.2, and found that the treatment induces a 15% and 20% decrease of total leukocyte numbers 
in BM and thymus, respectively, and an increase of these numbers in the spleen and LN as soon as 24h 
after treatment, in comparison to PBS-injected controls (Fig. 10A). These findings are consistent with 
a decrease in thymus weight and an increase in spleen weight observed in anti-CD69 MAb-treated 
mice (data not shown). In control experiments, the treatment of CD69-/- mice with anti-mCD69 2.2 did 
not alter BM or spleen cell numbers, proving that the effect of the treatment was specific of mouse 
CD69 (data not shown). When analyzing the number of the main leukocyte subpopulations in the BM 
and the spleen we observed a sharp reduction in BM B cells and neutrophils, the most abundant cell 
types in this organ (Fig. 10B). In the spleen, the treatment induced a marked increase in B cell numbers, 
of about the same magnitude than the decrease observed in the BM (Fig. 10C). Splenic NK cell, CD8+ 
T cell, neutrophil and eosinophil numbers were also increased (Fig.10C). These results are consistent 
with anti-mCD69 2.2 treatment inducing mobilization of hematopoietic cells from primary lymphoid 
organs (bone marrow and thymus) and their accumulation in peripheral sites such as the spleen, being 
this effect evident in the most abundant leukocyte types in these organs (neutrophils in the BM and B 
cells in BM and spleen). 
 
Anti- human CD69 MAb treatment of huCD69 transgenic mice induces mobilization cells 
from Bone Marrow. 
 
With the aim of moving towards a more translational setting, we assessed the effect of anti-hCD69 2.8 
treatment in vivo, with the use of the huCD69 transgenic mice in CD69-/- background. When kept in 
hemizygosity, the diploid cells of these mice contain 3 copies of a human CD69 BAC. After 24h, the 
anti-hCD69 2.8 treatment had induced similar decreases and increases in total leukocyte counts in BM 
and spleen, respectively, in the same direction than those induced by anti-mCD69 2.2 targeting, but 
of greater magnitude (Fig. 11A). Mobilization is usually assessed by the increase in blood cell counts 
shortly after treatment with mobilizing agents. This increase is ephemeral, and it has usually 
disappeared 24h post-treatment [264]. However, we were still able to find slightly increased white 
blood cell counts at 24h after anti-hCD69 treatment. In this work we assess more durable changes in 
cell redistribution between primary and secondary lymphoid organs. The presented numbers of BM 
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cells are the sum of cells in the BM parenchyma and those that have already egressed and are in the 
sinusoids. Considering that white blood cell counts are still increased, we expect that if we quantified 
only cells in the BM parenchyma, we would find even greater differences. In control experiments, the 
treatment of CD69+/+ mice with anti-hCD69 2.8 did not alter BM or spleen cell numbers, proving that 
the effect was specific of human CD69 targeting. CD69 expression was measured in thymus cells, due 
to some T cells express CD69 as a constitutive form, and we observed that mice that had been treated 
with anti-human CD69 had inhibited the expression of human CD69 respect non treated mice (Fig. 
 
Figure 10. Treatment with anti-mCD69 2.2 
in B6 mice induced bone marrow leukocyte 
egress and accumulation in spleen. Mice 
were treated with 500ug of anti-mCD69 
2.2 or PBS i.v. and were analyzed one day 
later. A, Total cell number in Bone Marrow, 
Spleen, lymph nodes, thymus and blood. B-
C, Lymphoid and myeloid subpopulations 
in B, Bone Marrow and in C, Spleen. Pool of 
two experiments.  
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11B). When analyzing the main leukocyte subtypes, we observed a decrease in percentage of BM 
neutrophil and an increase in NK cells and dendritic cells (Supplementary Fig. 1A) whereas we found a 
decrease in BM neutrophils and B cell numbers (Fig. 11C). By the other hand, we observed a decrease 
in splenic percentage of CD8+ T, CD4+ T and dendritic cells and an increase in B cells and macrophages 
(Supplementary Fig. 1B) and we found an increase in splenic B cell, CD4+ T, CD8+ T cell, neutrophil, 
macrophage and eosinophil cell numbers (Fig. 11D). The fact that the treatment with anti-human CD69 
affects the distribution of more cell types and with a greater magnitude could be due to an increased 
expression level of CD69 in most leukocyte subtypes in the huCD69 mouse model than in WT mice 
(Fig. 11E). If so, this would make this one a suitable model for the detection of small effects of CD69 
targeting.  
In a time course experiment, the greatest decrease in BM cellularity was observed at the earliest time 
point analyzed (a 30% decrease 4h after anti-hCD69 2.8 injection) and the BM cells counts gradually 
recovered until reaching the basal levels 9 days after treatment (Fig. 11F). Spleen cells counts were 
slightly augmented 4h after injection and gradually increased until a maximum at 3 days post-
treatment, and had not reached basal levels by day 9 yet (Fig. 11G). 
Altogether, these results suggest that targeting of human CD69 promptly induces egress of 
hematopoietic cells from the bone marrow and their accumulation in peripheral sites such as the 
spleen that the cell numbers are largely restored after about a week and that then, the sensitivity to a 
second dose is the same as to the first dose. 
 
Anti-huCD69 treatment mobilizes B cells of various differentiation stages 
 
The BM is site of B cell differentiation, selection and maturation. The release of immature B cells from 
the BM has been shown to depend on surface S1P1 expression [163] [162], which is down-modulated 
by CD69 [108]. To explore whether the egress induced by anti-hCD69 targeting affected preferentially 
B cells in certain maturation stages, we characterized the percentages and numbers of the different B 
cell subsets in BM and spleen 24h after treatment. We found that the numbers of all the B cell 
differentiation stage subsets (ProB cells, PreB cells, PreB1cells, immature and mature B cells) were 
decreased in the BM, but the percentage of reduction was greater the more differentiated subset (Fig. 
12A) whereas percentages did not show changes except in B cell recirculating subpopulations  
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Figure 11. Targeting with anti-human CD69 2.8 in HuCD69 mice induced bone marrow leukocyte egress and accumulation in 
periphery. Mice were treated with 500ug of anti-huCD69 2.8 and were analyzed 1 day after treatment. A, Total cell number 
in Bone Marrow, Spleen and lymph nodes. B, CD69 expression in total thymocytes is shown. Staining of huCD69 (white) 
and anti-huCD69 treated mice (grey). C-D, Numbers of lymphoid and myeloid subpopulation cell in Bone Marrow. C, and in 
Spleen, D. E, Expression of CD69 in Lin+ cells in Spleen and Bone Marrow of CD69−/− and HuCD69+/- unmanipulated mice. 
F and G, Total cell number in F, Bone Marrow, and G, Spleen, where mice were sacrificed as indicated times. A and C-D, 
Pool of four experiments. B, One experiment representative of more than 10. E-G, One experiment. 
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where they were decreased (Supplementary Fig. 2A). This has been also reported in AMD3100- 
induced mobilization, and was related to a decreased motility of undifferentiated B cells [162]. 
In the spleen, we evaluated subsets of B cells according to CD23, CD21 and IgM  marker expression 
within B220+ cells [26] dividing B cells between transitional (T1 and T2), marginal zone and follicular B 
cells. 24h after MAb treatment, the percentages and numbers of all these subsets were roughly 
augmented, except for those of transitional 2 B cells, which remained unaltered (Fig. 12B and 
Supplementary Fig. 2B).  
Thus, CD69 targeting induces egress of all B cell subsets but preferentially of differentiated immature 
B cells from BM. However, this is not translated to a preferential accumulation of the recently 
recirculating, transitional B cell subsets in the periphery. Rather, the greatest increase is of follicular B 
cells, presumably naïve, suggesting a quick maturation of egressed B cells upon entering the spleen.  
 
Figure 12. Targeting of CD69 in HuCD69 mice induced egress of immature B cells from bone marrow. Mice were treated with 
500ug of anti-huCD69 2.8 and were sacrificed 1 day after treatment. A-B, Numbers of B cell subpopulations were measured 
in Bone Marrow in A and in spleen in B by flow cytrometry. Pool of three experiments. 
  
Bone Marrow Spleen
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CD69 surface expression is not detected on all BM leukocyte subtypes mobilized by the 
anti-CD69 targeting. 
 
In order to explore which cell types could be targeted by the antibody treatment, we analyzed CD69 
surface expression in CD69 WT mice and huCD69 transgenic mice by flow cytometry using a stained 
sample of CD69-/- mice as background control staining. In the CD69 WT BM, the eosinophils showed 
considerable levels of constitutive surface CD69, whilst the rest of differentiated leukocyte subtypes 
had very low (B cells, monocytes) to practically undetectable levels (including neutrophils) (Fig. 13). As 
described, BM B cells had low levels of CD69 expression [162]. Like in previous works of the laboratory, 
[104], in the CD69 WT spleen, low levels of CD69 constitutive expression were detected on NK cells, 
DC and on subsets of T and B cells (Fig. 13 and data not shown).  
In huCD69 transgenic mice, all the lymphocyte subtypes and dendritic cells of all the organs analyzed 
expressed surface CD69 at higher levels than WT mice (Fig. 13 and data not shown). Myeloid cells 
other than dendritic cells showed clearly detectable CD69 expression in the blood and LN (data not 
shown) but not in the BM and the spleen (Fig. 13). Thus, there is no direct correlation between the 
surface expression of CD69 and the extent of the effect on cell redistribution induced by anti-CD69 
MAb targeting on a given leukocyte subtype. This suggests that CD69 targeting can induce cell egress 
indirectly.  
 
CD69 targeting induces a mobilization of the same magnitude as AMD3100 and does not 
synergize with this drug. 
 
The CXCR4 antagonist AMD3100 induces rapid mobilization of cells from the BM into the blood [265]. 
We aimed at comparing the effects of AMD3100 with the ones of anti-CD69 2.8 treatment in huCD69 
mice, and also to analyze how they interacted upon co-administration. Importantly, anti-hCD69 2.8 
induced a similar decrease in total BM leukocyte numbers at 24h post-treatment (Fig. 14A), and similar 
or even slightly greater decreases in all leukocyte subtypes numbers than AMD3100, except for  
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Figure 13. Expression of CD69 by the main cell subtypes in Spleen and Bone Marrow of huCD69 unmanipulated mice.  
Leukocytes from CD69+/+, CD69−/−, HuCD69+/-, and HuCD69+/+ mice were stained for CD69. Characterization of CD69 
expression on CD4+ T cells (CD4+), CD8+ T cells (CD8+), B cells (CD19+,) NK cells (Nkp46+), DCs (CD11c  hi SSC -) myeloid cells 
(CD11b hi),  neutrophils (CD11b hi, GR1 hi SSC hi), monocytes (CD11b hi, GR1 lo SSC lo) and eosinophils  (CD11b hi, GR1 lo 
SSC hi) . Results are representative of one experiment. The FACS staining was performed with a pool of three mice. 
A. 
CD69 -/- 
CD69 +/+ 
HuCD69 Het 
HuCD69 Hom 
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DC, which were more affected by AMD3100 (Fig. 14B). The co-administration did not further decrease 
BM leukocyte numbers. Curiously, in eosinophils, the co-treatment inhibited the decrease in BM cells 
counts (Fig 14B). AMD3100 treatment achieved higher white blood cell numbers than anti-CD69 2.8 
treatment, and these were not additive when co-administered. In the spleen, though, the increase in 
cellularity was similar between the two treatments and, when co-administered, they achieved higher 
leukocyte numbers (Fig. 14A). These results show that, like AMD3100, anti-CD69 mAbs are potent and 
rapid BM leukocyte mobilizing agents. Taking into account that leukocyte numbers in the blood and 
spleen can be influenced by other processes, including homing into lymphoid organs and tissues and 
egress from lymphoid organs, we consider that the alteration in leukocyte numbers better reflecting 
leukocyte egress from bone marrow is the decrease observed in the bone marrow. Therefore, CD69 
targeting and AMD3100 do not have a neither a synergic effect nor a clear additive effect on BM 
mobilization.  This suggest that provided that the process is not saturated, the molecular mechanisms 
of mobilization are not independent, at least not their final steps. 
 
 
Figure 14. Combined treatment with anti-human CD69 and AMD3100 does not have a summative effect in the output of 
bone marrow cells. HuCD69 mice were treated with 500 µg of anti-hCD69 2.8 antibody one day before analysis or AMD3100 
(150 μg/mouse) one hour before analyzing as indicated. A, Total cell number in bone marrow, spleen and blood. B, Number 
of lymphoid and myeloid subpopulations in bone marrow. A, Pool of two experiments.  
A.
Bone Marrow
B.
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CD69 targeting increases bone marrow CXCR4 expression  
 
We further studied a possible implication of the CXCR4-CXCL12 axis. Petit et al. [3] describe that the 
mobilization induced by G-CSF is dependent on CXCL12 function and on elastase-mediated 
degradation of BM CXCL12. They show that CXCL12 BM levels rapidly but transiently increase 30-60 
min post-injection, and later on (by 24h) decrease. Treatment with AMD3100 is also mediated by 
CXCL12 and also transiently increases BM CXCL12 levels even more rapidly (in 10 min), but by 1 hour 
they are decreased, whilst the ones in plasma are increased [264] [4]. We quantified CXCL12 in plasma 
and in supernatant of BM, spleen and LN cell suspensions at 30 min and 24h after anti-CD69 2.8 
treatment. No differences were observed at 30 min (data not shown), but there was a tendency to 
increased CXCL12 levels in BM and decreased plasma, spleen and lymph nodes CXCL12 in treated mice 
at 24h (Fig.15A) and correspondingly RNA of CXCL12 in plasma was also observed decreased (Fig.15B). 
These results might be indicative of previous greater alterations.   
Petit et al. also show that G-CSF treatment induces mobilization depending on CXCR4 function, that 
BM cell CXCR4 expression is reduced shortly after treatment (30-60 min) but increased after 24 hours, 
progressively increasing with repetitive daily treatments [3]. We analyzed CXCR4 surface expression 
on BM and spleen leukocytes, and found it increased in anti-CD69 2.8-treated hCD69 mice 24h after 
treatment (Fig 15C). However, after 5 days of a second dose administered 1 week after the first 
injection, there were no differences in the BM, while increased CXCR4 expression was still visible in 
the spleen (Fig 15D).  Altogether, these results show that, like G-CSF, CD69 MAb targeting alters the 
expression of CXCR4-CXCL12 axis, at least the one of CXCR4, but suggest that it does it with a different 
kinetics. 
 
CD69 targeting-induced mobilization depends on S1P receptors function 
 
Nevertheless, S1P1 interacts with CD69 and they can mutually downregulate their surface expression 
[24]. We pursued to analyze the dependence on S1P receptors of the CD69-targeting induced 
mobilization by treating CD69 WT mice with anti-mCD69 2.2 with or without co-administration of 
FTY720. 24h after injection, the co-treatment with FTY720 almost completely inhibited the decrease 
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Figure 15. CXCL12 and CCXR4 expression in HuCD69 mice. A-C, HuCD69 were treated with 500 µg of anti-hCD69 2.8 antibody 
one day before analyzing .A-B, SDF-1 was measured by ELISA in A, in plasma, and supernatants of spleen, bone marrow 
and lymph nodes and in B, by RNA Primeflow in blood. C, Expression of CXCR4 in Bone Marrow and spleen 24 hours after 
treatment with anti-hCD69 2.8 was measured as percentage and geometric mean. D, Surface expression of CXCR4 and 
intranuclear expression of T-bet was measured after 5 days after second dose of 200 µg of anti-hCD69 2.8 antibody, both 
separated by a week. A, pool of two experiments. B, one experiment. C, Pool of three experiments. D, Pool of two 
experiments.  
 
in total BM leukocytes induced by the anti-mCD69 2.2, and it also reduced, albeit to a lesser extent, 
the increase in spleen leukocyte numbers (Fig. 16A). As expected [4], FTY720 treatment induced a 
decrease in white blood cells counts (Fig. 16A). Altogether these results strengthen the interpretation 
Negative control 
HuCD69 
HuCD69 +αCD69 
Positive control 
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that the decreased and increased cellularity in BM and spleen, respectively, observed upon anti-CD69 
treatment are predominantly due to an induction of leukocyte egress from the BM, and also show that 
CD69-targeting-induced mobilization of at least most BM leukocytes depends on S1P receptor 
function.  
Of interest, the in vivo treatment augmented S1P1 surface levels in total BM and blood leukocytes (Fig. 
16B-C). When analyzing S1P1 surface expression on the main lymphocyte subpopulations and DC, we 
found an increase of S1P1+ cells in bone marrow T and NK cells, but not B and DC (Fig. 16B). However, 
we found elevated S1P1 on spleen and blood B cells and spleen DC (Fig. 16C-D), opening the possibility 
that bone marrow B cells and DC that had upregulated S1P1 had trafficked from the bone marrow to 
the periphery. S1P1 surface levels were also elevated on blood T cells and spleen NK cells (Fig. 16C-D). 
Thus, anti-CD69 in vivo treatment increased S1P1 expression on leukocytes analyzed in bulk and on all 
the lymphocyte subsets and DC in at least one of the organs analyzed. We also incubated bone 
marrow, spleen and thymus cells from non-treated mice with anti-human CD69 2.8 in vitro (Fig. 16E), 
and measured S1P1 surface expression after two days. A significant increase in bone marrow and 
thymus but a decrease in spleen (Fig.16E) was observed after the culture, suggesting that CD69 
targeting upregulates surface S1P1 in cells from primary lymphoid organs but not spleen cells, and 
that the increase in S1P1+ NK and DC cells in the spleen might be due to incoming S1P1+ NK and DC. 
If CD69 targeting was blocking the interaction of CD69 with S1P1 and the downmodulation of surface 
S1P1, we would expect to find higher surface S1P1 levels on cells upon treatment, as we are finding. 
However, elevated S1P1 expression could also be due to other mechanisms, since, for example, G-CSF 
treatment also increases surface S1P1 levels. 
 
CD69 targeting induces mTOR signaling  
 
G-CSF induces increase of BM and plasma S1P levels and of BM cell surface S1P1 expression through 
mTOR signaling [4]. Since we found higher S1P1 expression upon anti-CD69 MAb treatment, we sought 
whether this could also be mediated by mTOR. This molecular complex signals through 4E-BP1 and 
phosphorylates it in Thr-37 and Thr-46 [131]. Thus, to assess mTOR activity we measured 4E-BP1 Thr-
37 and Thr-46 phosphorylation on bone marrow and spleen cells 24 hours after treatment with anti- 
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Figure 16. Treatment with FTY720 and anti-huCD69 impair bone marrow cell egress in HuCD69 mice. Mice were treated with 
500ug of anti-huCD69 2.8 i.v or FTY720 (1mg/kg) i.p or both as indicate 24 hours before analyzing. A, Total cell number in 
bone marrow and blood. B-D, Mice were treated with anti-huCD69 2.8 i.v. S1P1 expression was measured by flow 
cytometry in B, bone Marrow, in C, blood and in D, spleen cells in indicated cell population. E, Bone marrow, spleen and 
thymus cells from HuCD69 mice were cultured in vitro with anti-huCD69 for two days and S1P1 expression was analyzed 
by flow cytometry. A, Pool of two experiments. B-D, Pool of two experiments. G, One experiment. 
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human CD69 by intracellular staining and observed that it was increased in both sites (Fig 17). This 
data shows CD69 targeting induces mTOR signaling, and this could be the mechanism by which it 
upregulates S1P1. 
 
Anti-human CD69 increases VLA-4 expression in bone marrow 
 
The retention of bone marrow cells has been also related with the interaction between VCAM-1/VLA-
4. VLA-4 is an adhesion molecule expressed on HSPC and other bone marrow hematopoietic cells [266] 
[267] which binds, among other ligands,VCAM-1 expressed on bone marrow stroma. The disruption 
of this axis with VLA-4 inhibitors leads to HSC mobilization although the mobilization induced is less 
effective compared to G-CSF [268, 269]. Surface expression of VLA-4 has been reported to be 
downregulated upon G-CSF or AMD3100 treatment, and this decrease has been proposed to 
contribute to the loss of cell retention into the bone marrow [270] [271] [265]. To assess whether VLA-
4 expression decrease could also participate in anti-CD69 2.8-induced mobilization we analyzed 
surface VLA-4 on bone marrow subpopulations 24h after anti-human CD69 treatment. We observed 
an increase in the percentage of VLA-4+ NK cells, T cells and B cells, a decrease in VLA-4+ monocytes 
and eosinophils, and no changes in dendritic cells, macrophages and neutrophils (Fig.18A). In the 
spleen cells, VLA-4 expression was slightly decreased only on CD4+ T cells (Fig.18B) while it was 
unaltered on the rest of cell subtypes. However, the number of VLA-4 expressing cells was decreased 
in total cells, NK cells, macrophages, neutrophils and monocytes  (Fig.18A) whereas the number of 
Figure 17. mTOR regulates anti-huCD69 2.8 
mAb induced mobilization in Bone Marrow. A, 
Intracellular expression of mTOR was 
measured in mice treated with anti-huCD69 
2.8 mAb 24 hours before analyzing versus non 
treated mice. Geometric mean and 
percentages were analyzed by flow cytometry. 
One experiment.  
A.
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VLA-4 expressing cells in spleen was increased in total cells, NK cells, B cells, macrophages, monocytes 
and eosinophils (Fig.18B). Thus, anti-CD69 2.8 can induce bone marrow egress through VLA-4 
downregulation in some cell subtypes.  
 
Figure 18. The treatment with anti-human CD69 decreased VLA-4 cell number in bone marrow and increased in periphery in 
HuCD69 mice. A and B, Mice were treated with anti-huCD69 2.8 i.v. and were analyzed 1 day after treatment. Surface VLA4 
expression were measured by flow cytometric in lymphoid and myeloid subpopulations in Bone Marrow A, and Spleen B, 
as indicated in percentages (left) and numbers (right). One independent experiment.  
A.
B.
SpleenSpleen
Bone Marrow Bone Marrow
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Anti-huCD69 treatment induces proliferation and accumulation of primitive 
hematopoietic cell numbers in BM and spleen 
 
Mobilizing treatments are especially interesting to induce egress of hematopoietic stem and 
progenitor cells into the blood, where they can be collected and used for therapeutic interventions. 
To study whether anti-CD69 treatment could be used to mobilize this kind of cells, we analyzed the 
effects of anti-human CD69 2.8 treatment on their numbers in BM and spleen. Lin- cells were analyzed 
for Sca-1 and c-Kit expression to determine the number of KSL (Lin−Sca1+c-kit+). KSL cells were further 
divided into long term HSC (LT-HSC; KSL CD34neg FLT3neg), short term HSC (ST-HSC; KSL CD34+ FLT3neg) 
and multipotent progenitors (MPP; KSL CD34+ FLT3+) [27, 28]. 24 h after the injection, anti-hCD69 2.8 
treatment had induced a great increase in BM KSL cell numbers of all HSPC subtypes both in the spleen 
and the BM (Fig. 19A-B and supplementary Fig. 3A-B). Whilst such an accumulation of KSL in the spleen 
could be explained by an effect on mobilization, the increase in BM could not. When analyzing the 
effect on KSL cells, we observed that, 24h after injection, the administration of anti-CD69 to hCD69 
mice led to higher BM and spleen KSL, LT-HSC, ST-HSC and MPP cell numbers than those observed in 
AMD3100 treatment, and that the co-treatment tended to further increased those numbers (Fig.19C-
D). This could be due to the fact that AMD3100 tended to increase proliferation of BM KSL cells, and 
that this could be added to the effect on proliferation of CD69 targeting. 
We wondered whether these higher KSL numbers were related to an increase in the proliferation rate, 
and measured BrdU incorporation by BM and spleen KSL cells. As seen in Fig. 20, at 24h post-
treatment, the percentage of BrdU+ of all the KSL subtypes was much higher in anti-hCD69 2.8-treated 
hCD69 mice than in untreated controls, both in the BM and the spleen. 24h may seem a time too short 
for cell expansion. However, BM HSPC have been shown to proliferate in vivo in response to infection 
or treatment with adjuvants, and to be increased in number as soon as 24h post-challenge [272] [273]. 
Thus, the increase in BM HSPC number is likely due to an increase in their proliferation rate, while the 
increase in the spleen can be contributed by both HSPC mobilization and expansion. Actually, the 
quantity of BM and spleen HSPC tended to be even higher in anti-hCD69-treated mice than in 
AMD3100-treated mice both, and this was related to an induction of BrdU incorporation into HSPC by 
anti-hCD69 but not by AMD3100 treatment. Altogether, these results show that a single dose of anti-
hCD69 induces not only mobilization of HSPC but also their proliferation and expansion both in the BM 
and the periphery. 
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Figure 19. The treatment with anti-human CD69 increase HSC cells in Bone Marrow.  A-B, Mice were treated with anti-
human CD69 2.8 24 hours before scarifying. A and B, Lin- cells were stained by SCA+ and C-kit hi or C-kit int. Numbers in A, 
of KSL and CLP cells were measured in (left) Bone Marrow and (right) spleen. B, Cells CD34 and FLT3 were gated in Sca+, 
C-kit hi cells and numbers in B are shown in Bone Marrow. B, Cells CD34 and FLT3 were gated in Sca+, C-kit hi cells and 
numbers in B are shown in Bone Marrow. C-D, Mice were treated with anti-human CD69 2.8 i.v (24 hours), AMD3100 i.p 
(one hour), both treatments as indicated. Numbers in C, of KSL and CLP cells were measured in (left) Bone Marrow and 
(right) spleen. D, Number of LT-HSC, ST-HSC and MPP cells in Bone Marrow. A-B, Pool of three experiments. C-D, One 
experiment.  
Bone Marrow Spleen Bone MarrowA. B.
C. D.
Bone Marrow Spleen Bone Marrow
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Figure 20. Treatment with anti-hCD69 2.8 induced an increase proliferation rate in bone marrow primitive cells compared to 
AMD3100. Mice were treated with anti-mCD69 2.8 i.v or AMD3100 i.p. as indicated and were analyzed one day later. Mice 
received 1 mg of BrdU intraperitoneally and three hours later, mice were analyzed. Bone Marrow and Spleen cells were 
collected and cell proliferation rate was assessed by BrdU incorporation by flow cytometry in total cells and subpopulations 
of Lin- in Bone Marrow in A, and in spleen in B. One experiment.  
 
To assess whether anti-hCD69 2.8 could be influencing HSPC directly or indirectly, we analyzed CD69 
expression on the subpopulations of BM and spleen HSPC of HuCD69 mice, using CD69-/- mice as 
control for background staining (Fig.21A). We found clear CD69 expression on KSL cells in bone 
A.
B.
Bone Marrow
Spleen
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marrow. When KSL cells were divided in LT-HSC, ST-HSC and MPP, CD69 expression was detected on 
BM MPP cells. Of note, CD69 expression on human hematopoietic stem cells (CD34+) at steady state 
has been reported [274]. Thus, anti-hCD69 treatment also induces proliferation and expansion of HSPC 
subtypes with no detectable CD69 surface expression, suggesting that, at least on these subtypes, the 
antibody is acting indirectly.  
 
Figure 21. Expression of CD69 in hematopoietic stem cell in Spleen and Bone Marrow of unmanipulated mice.  Cells from 
bone marrow and spleen of CD69−/− C57Bl6 and HuCD69 mice were stained for specific markers of hematopoietic stem 
cell. Results are representative of one experiment. 
 
Targeting human CD69 increases proliferation rate of bone marrow mature leukocytes 
 
Since we observed proliferation induction of HSPC and since previous data of the laboratory showed 
that CD69 targeting induces non-cognate T cell proliferation through upregulation of the IL-2 and CD25 
CD69 -/- 
 
HuCD69 Het 
A. 
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[29], we wondered whether the antibody could also induce proliferation of mature leukocytes, which 
would help to explain the increase in spleen cellularity. Mice were treated with anti-human CD69 for 
24 hours, injected with BrdU and sacrificed 3 hours after. The frequencies of BrdU positive cells were 
increased in bulk bone marrow leukocytes as well as in the major leukocyte subpopulations, except 
for eosinophils (Fig.22A). The higher percentages of BrdU+ T cells in distinctive subpopulations of 
precursors cells are consistent with previous results. This proliferation also correspond with the 
observed augmented frequencies of CD25+ and IL-2+ cells in bone marrow, spleen and blood (Fig. 
23B).  
 
Figure 22. An increased proliferation rate in BM progenitor cells is observed in HuCD69 mice treated with antihuman-CD69 
in vivo. Mice were treated or not treated with anti-huCD69 2.8 24 hours before BrdU injection. Mice received 1 mg of BrdU 
intraperitoneally and three hours later, mice were analyzed. Bone Marrow were collected and cell proliferation rate was 
assessed by BrdU incorporation. A, BrdU was measured by flow cytometry in lymphoid and myeloid subpopulations in Bone 
Marrow. B, BrdU was measured in precursor cells in Bone Marrow. A- B, pool of two experiments. 
 
In previous works we have shown decreased spontaneous apoptosis of CD69-/- leukocytes [1] [275] 
associated with decreased TGFβ expression [1]. Thus, we also tested whether an increased immune 
cell survival could contribute to the higher spleen cellularity observed upon anti-CD69 2.8 treatment. 
Dead cells are quickly phagocytized in vivo. To circumvent this, we performed ex vivo cultures of spleen 
A.
Bone Marrow Bone Marrow
B.
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cells from anti-human CD69 treated mice and analyzed the spontaneous cell death by PI staining at 
different times of culture. Significant differences were found as soon as 2 days of culture and this 
difference was increased over time (Fig.24A). Moreover, we found a 50% decrease in TGF-b expression 
in bone marrow and spleen cells of treated mice, measured by real time RT-PCR. (Fig.23A). Thus, like 
CD69 deficiency, CD69 targeting also led to enhanced cell survival and low TGFβ expression. 
 
 
 
Figure 23. Targeting of human CD69 induce an increase IL-2 expression and reduce TGFβ. Mice were treated with 500ug of 
anti-huCD69 2.8 and were analyzed 1 day after treatment. A, mRNA of TGF-β was measured by Real Time PCR and was 
represented as relative fold change treated mice respect control mice B, Intracellular expression of IL-2 and CD25 surface 
expression was analyzed by flow cytometer in bone marrow, spleen and blood. A, One experiment of pool of samples from 
three independent experiments, each one of them with 4 animal for group. B, Pool of three experiments.  
 
Altogether these data point to that the leukocyte accumulation observed in the spleen, especially that 
observed at 3 and 6 days post-treatment, could be contributed by the lower spontaneous cell death 
and increased proliferation rate observed in CD69-targeted mice.  
A. B.
Spleen
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Figure 24. Attenuation of spontaneous cell death in targeting of human CD69. A, Survival was measured by PI staining of 
unfractionated splenic cells of uninfected HuCD69+ CD69+/+ mice in C57Bl/6 genetic background treated with anti-huCD69 
2.8 mAb or Isotype control.
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DISCUSSION 
 
Previous results have demonstrated the importance of mobilizing HSC as a treatment for people who 
have reduced cell counts as a result of diseases or due to chemotherapeutic agents that cause 
destruction of many cells [276]. Currently, G-CSF is one of the most used mobilizers. In the present 
work we describe for the first time the capacity of anti-CD69 MAbs to induce a rapid and massive 
egress of mature leukocytes as well as of HSPC from the bone marrow, both in wild type mice treated 
with anti-mCD69 as well as in transgenic hCD69 mice in CD69-/- background treated with anti-hCD69 
MAb. A single dose of anti-human CD69 decreased the number of total bone marrow leukocytes and 
increased those of the spleen and blood. The effects on cell redistribution were already apparent at 4 
hours after treatment and could be observed for at least 6 days. The fact that the decrease in BM 
cellularity was not observed when anti-CD69 mAbs were co-administered with FTY720 points to that 
the observed redistribution is due to leukocyte mobilization from the bone marrow, and that this is 
dependent on S1PR function. The treatment also upregulated S1P1 and CXCR4 surface levels and 
induced mTOR signaling. Importantly, the treatment led to the proliferation and expansion of HSCP.  
The mTOR pathway has been shown to have an essential role as mechanisms involved in the 
mobilization produced by G-CSF through activation of S1P. So in assays of inhibition of this route, the 
result is a defect in mobilization. We observed an increase of 4E-BP1 involved in mTOR signalling 
pathway, both in bone marrow and in spleen. In addition to the results already observed, in which the 
treatment with anti-human CD69 induces the mobilization of effector cells as well as hematopoietic 
stem cells. Finally, we required to compare the different mobilization between our treatment and 
AMD3100. Our data revealed that the mobilization induced by both treatments is similar in total cell 
counts but we observed a greater number of precursor cells in our treatment with anti-human CD69 
or when we combined both treatments, being more reduced in treatment with AMD3100. In addition, 
human CD69 targeting induced a significant increase in proliferation rate higher than induced by 
AMD3100 in total cells and precursor cells. 
Importantly, in humans, CD69 expression on human hematopoietic stem cells (CD34+) has already 
been described at steady state [274]. 
In the present results, CD69 targeting and CD69 deficiency affect bone marrow egress in the same 
sense but with different magnitude: CD69 deficiency has little or no effect on BM cellularity, depending 
on the mouse strain used, and a relatively small effect on cell counts of peripheral lymphoid organs 
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and blood. Instead, CD69 targeting induces massive mobilization from the BM. One possible 
explanation is that the effects of anti-CD69 targeting are not merely due to a blockade of CD69 
function but rather, that the antibody is inducing, directly or indirectly, signaling pathways, at least 
that of mTOR, and that these pathways lead to cytokine production, cell proliferation, increased 
survival and, in general, the emulation of a stress situation finally leading to massive leukocyte 
mobilization. Actually, early in vitro studies of CD69 function showed that Ab crosslinking of CD69 on 
pre-activated T cells, B cells, NK cells, monocytes, eosinophils and basophiles increased their activity 
[87, 103, 109, 134-139]. Another possibility is that a putative sudden loss of CD69 function upon anti-
CD69 treatment could activate signaling cascades leading to the observed effects, and that these were 
not detected in the constitutive deficiency of CD69 at steady state due to compensatory mechanisms.  
Like that of CD69, S1P1 deficiency also had a modest effect on egress from BM at steady state, as 
shown by the normal [4] or nearly normal numbers of blood [49] and peripheral S1P1 KO B cell counts 
[158] and the small increase in immature S1P1 KO B cells in the B parenchyma [162]. Thus, the effect 
of CD69 on BM cell egress at steady state could be due, to its interaction with S1P1. 
In contrast to the modest or absent effect of S1P1 deficiency on BM egress at steady state, this 
deficiency had more marked effects on G-CSF and AMD3100-induced mobilization [49][4]. This, 
together with the fact that treatment with FTY720 markedly reduced the egress induced by these 
agents, has led to the notion that S1P receptors mediate such mobilization. G-CSF and AMD3100 have 
been shown to increase plasma and BM levels of S1P through the induction of IgG-dependent 
complement cascade, which induces erythrocyte lysis and release of S1P [20, 45]. Like in these reports, 
we also observed inhibition of mobilization upon FTY720 co-treatment. FTY720 treatment desensitizes 
leukocytes to S1P-induced migration. Moreover, as well as S1P, it also increases endothelial barrier 
function by influencing actin and functional protein rearrangements [277]. Through either of the two 
functions, FTY720 could inhibit leukocyte translocation through the endothelium. 
Considering the fact that leukocyte and HSPC mobilization from BM partly depends on surface S1P1 
[49][4] and the fact that CD69 surface levels negatively regulate those of S1P1, one attractive 
explanation for this is that CD69 targeting is blocking its interaction with S1P1, allowing the 
accumulation of the latter on the cell surface and promoting its function in cell egress. Consistently 
with this possibility, anti-CD69 treatment leads to an increase of surface S1P1 levels. Of note, increase 
of S1P1 surface levels by transgenic overexpression in B cells was sufficient to increase B cell egress 
from the BM and B cell numbers in the periphery [162]. However, the fact that, for example, one of 
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the cell types undergoing higher mobilization, the neutrophils, does not express detectable surface 
CD69, not even in the huCD69 transgenic mouse, argues against that blockade of CD69 cis- interaction 
with S1P1 is, if anything, the main mobilizing force induced by CD69 targeting, at least not for all the 
cell subtypes, since that effect would be cell intrinsic. Nevertheless, a possible mechanism for a 
bystander effect of CD69 targeting could be that the egress CD69+ cells enhanced the egress of other 
CD69- cells. A similar phenomenon has been described for neutrophils, the first cells to be mobilized, 
whose egress paves the way for the mobilization of other cell types [278]. Since BM neutrophils are 
CD69-, the first mobilized cells in our case would be other cell types, likely B cells. Possibly related with 
this phenomenon, a positive feedback for cell mobilization can be envisaged from a recent publication 
showing that the increase in vascular permeability of the BM sinusoids induced by blockade of 
endothelial CXCR4 by AMD3100 enhances HSPC motility and egress through the influx into the 
parenchyma of ROS [279]. 
The fact that both anti-CD69- and G-CSF/AMD3100-induced mobilizations are inhibited by FTY720 
could be simply due to a common bottleneck last step consisting in a need for the function of S1P 
receptors-mediated for massive cell egress in stress-simulating situations. However, a more complex 
crosstalk has been reported between CXCR4/SDF-1 axis and S1PR roles in mobilization: apart from the 
fact that G-CSF and AMD3100 increase plasma and BM levels of S1P, S1P also induces release of SDF-
1 from stromal cells through ROS induced signaling [4][264]. SDF-1 can quickly diffuse from the BM 
towards blood and can promote chemotaxis and cell egress [264]. This crosstalk is compatible with 
the mentioned putative positive feedback mechanism by which an initial increased vascular 
permeability would promote diffusion of S1P from the plasma to the BM and of SDF-1 from the BM to 
plasma amplify mobilization. 
CXCR4-mediated mobilization with AMD3100 of B cells was reduced in B-cell conditional S1P1 KO mice, 
[280]. Like in our results using anti-huCD69 MAbs, the mobilization rate was higher in immature B cells 
than in B cells in earlier developmental stages. This was related to a decreased motility of the latter 
[162]. This observation suggested that other factors apart from CXCR4/SDF-1 determine cell motility 
and migration capacity.  
The effects of CD69 targeting and of AMD3100 in decreasing bone marrow cellularity were similar and 
were neither synergistic nor additive. If the process of bone marrow egress was not saturated, this 
would point to that the molecular mechanisms are not independent, that is, that at least the 
downstream molecular mediators are shared in both pathways. The synergy or additive effects 
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observed upon concomitant VLA-4 and CXCR4 blockades have been proposed as signs of independent 
molecular mechanisms of bone marrow mobilization [54] [56] [269]. However, a synergic effect of G-
CSF with AMD3100 was observed on the increase of blood colony-forming units counts at 1h post-
AMD3100 treatment, in spite of that G-CSF induces mobilization through CXCR4 and CXCL-12 [34]. In 
those experiments, G-CSF was administered 2-4 days before AMD3100 injection. It is possible, thus, 
that the G-CSF has had the time to induce bone marrow HSPC proliferation, and that these expanded 
HSPC are further mobilized by AMD3100 treatment, contributing to the synergic effect. In our 
experiments we administered anti-CD69 MAb and AMD3100 at the same time, and, in spite of the fact 
that anti-CD69 induces cell proliferation, we might not have allowed the time for significant leukocyte 
expansion and for such a synergic effect to be evident in total leukocyte.  
Even if the mobilization by agents disrupting the SDF-1/ CXCR4 axis is also dependent on S1P receptors 
function, a synergy was observed in the chemotactic effects induced by SDF-1 and S1P. However, this 
was observed in in vitro studies, in which the roles in S1P in processes other than chemotaxis and that 
may have a more prominent effect in vivo, like the decrease of endothelial permeability, may be 
missed.  
In spite of possible crosstalk at more upstream levels, a bottleneck effect of a common S1PR-
dependent last step of cell egress could still explain the non-synergic nor additive effects of AMD3100 
and anti-CD69 MAbs.  
If the effect of CD69 targeting was solely based on direct blockade of CD69 interaction with S1P1 and 
upregulation of the S1P1 surface levels, it would act at the level of this final step of S1P1-dependent 
cell egress. This mechanism could explain the upregulation of surface S1P1 levels but not that of CXCR4 
expression observed upon CD69 targeting. CD69 targeting-mediated S1P1 upregulation is not likely to 
be the cause of the increase of CXCR4 surface levels, since S1P1 deficiency in B cells had no effect on 
CXCR4 expression [280] and S1P1 overexpression even decreased CXCR4 expression on HSC [281]. 
Golan et al. report that S1P1 expression on LSK cells is upregulated by G-CSF and AMD3100 treatment, 
and that this is inhibited by co-treatment with FTY720. In the case of G-CSF, they show that S1P1 
upregulation is dependent on mTOR signaling. [4]. These reports, together with the fact that we 
observe S1P1 upregulation also on cell types with non-detectable CD69 surface expression, point to 
that this upregulation is not based on the interaction in cis between CD69-S1P1 but rather on anti-
CD69-induced mTOR signaling.  Moreover, the fact that we observe upregulation of CXCR4 and that 
this has also been described upon G-CSF treatment [3], strengthen the point that a possible crosstalk 
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between anti-CD69 mAbs and CXCR4/SDF-1-induced mechanisms of mobilization at upstream steps 
should not be disregarded. 
In conclusion, our data suggest that the treatment with anti-human CD69 could be used as a new 
mobilizer since it achieves a greater egress of bone marrow cells and a higher production of 
haematopoietic stem cells and this is mediated by S1P1, modulation of the axis SDF-1/CXCR4 and by 
the influence on mTOR. Furthermore, as previously described, it induces a significant increase 
proliferation rate than that induced by AMD3100. This results, attached with the benefit of not 
requiring a continuous dosage and due to the effects are seen at early times, makes it a good 
alternative to G-CSF. We propose the use of anti-human CD69 as a new mobilizer, alone or in 
combination with AMD3100 to support the mobilization of these cells and as an alternative to 
treatment with G-CSF.
  
  
 
 
 
 
 
 
 
 
 
 
CHAPTER III: 
CD69 TARGETING EFFECT IN 
VACCINIA VIRUS INFECTION.
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RESULTS 
 
CD69 targeting induces an increase and proliferation of all leukocyte subsets   
    
In this work, we aimed to know the effect of targeting of CD69 in VACV infection. For this, we have 
used the previously characterized mAb anti-CD69 2.2 that binds to mouse CD69 molecule and mAb 
anti-CD69 2.8 that binds to human CD69 molecule [172] (chapter II). Both were obtained from the 
same immunization in CD69 deficient mice, do not cross-react and not activate the complement 
system or Fc binding effector functions. We have reported that CD69 targeting induced cell 
mobilization affecting to all progenitors cells from bone marrow at 24 hours after treatment (chapter 
II). With the aim of ensuring that anti-CD69 treatment would be effective against a viral infection, we 
injected two doses of 200ug of anti-CD69 separated by a week and the cellularity of leukocyte subtypes 
were analyzed in BM and spleen 5 days after the second dose. Cellularity of main leukocyte subsets 
were observed decreased in BM and increased in SLO (Fig.25A-C). Similar pattern was found in total 
cell counts in bone marrow and spleen (Fig.25A) and the cell subsets profiles were largely similar to 
the ones seen 24 hours after the first treatment (chapter II), with the main difference in BM and spleen 
neutrophil and spleen macrophage numbers which were back to control levels (Fig.25B-C)  
To better characterize the action of CD69 targeting in spleen cell proliferation, we treated with anti-
CD69 2.8 mAb in transgenic mice that express human CD69, and analyzed BrdU incorporation in main 
spleen leukocytes subpopulations (Fig. 25D). As shown in figure 25, this treatment induced 
proliferation in almost all different subsets of splenic leukocytes. 
As CD69-/- mice had increased cellularity in SLO and an augmented anti-Vaccinia immune response 
mediated by increased number of NK cells and that CD69 targeting in uninfected mice led to a similar 
pattern of increased leukocytes in peripheral lymphoid organs (Chapter II), we studied whether anti-
CD69 treatment would increase the immune response against infection with VACV infection in WT 
mice.  
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Figure 25. HuCD69 mice treated with anti-human CD69 in vivo showed an increase proliferation in spleen and a similar effect 
with two doses compared to one dose treatment. A-C, Mice were treated with two doses of 200ug of anti-huCD69 2.8 
separated by a week and five days after second treatment, mice were analyzed. A, Total cell number in Bone Marrow, 
Spleen, thymus, lymph nodes and blood. B-C, Numbers of lymphoid and myeloid subpopulation cell in B, Bone Marrow and 
C, Spleen. D, Mice were treated or not treated with 500 ug of anti-huCD69 2.8 24 hours before BrdU injection. Mice 
received 1 mg of BrdU intraperitoneally and three hours later, mice were analyzed. Spleen cells were collected and cell 
proliferation rate was assessed by BrdU incorporation. BrdU was measured by flow cytometry in lymphoid and myeloid 
subpopulations. Pool of two experiments 
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Mouse CD69 targeting enhances immune response to VACV infection in Rag2-/- mice 
 
In order to assess the importance of the innate immunity response against VACV infection in anti-CD69 
treated mice, we infected Rag2-/- anti-mouse CD69 treated mice with 1x106 pfu of VACV in the  
schedule shown in figure 26A and it was performed the analysis at two days after infection, when the 
early immunity was developed (Fig26A). Interestingly, the mice treated with anti-mouse CD69 2.2 
exhibited less viral titers than control mice even in the absence of innate Tα/β and Tγ/δ cells (Fig. 26B). 
CD69 targeting induced a decreased and increased cell numbers in bone marrow and spleen 
respectively, compared to control mice (Fig. 26C). However, a significantly increase in total blood and 
thymus leukocyte counts was not detected. Bone marrow of anti-CD69 targeted mice had reduced 
numbers of all precursor cells as NK, DC and other myeloid cells and more primitive precursor cells as 
c-Kit+ cells compared to control mice (Fig. 26D and data not shown). Consistently, in spleen, CD69 
targeting induced an augmentation of NK cells, monocytes and neutrophils (Fig. 26E). Remarkably, we 
have found a lower number of bone marrow leukocytes in steady state and infection in Rag2-/- CD69-/- 
mice compared to WT mice (Fig 26F) These results are consistent with the data previously shown of 
the increased splenic leukocyte number after infection of Rag2-/- CD69-/- mice (Figure 5A in chapter I). 
These results demonstrated that in Rag-/- mice, anti-CD69 treatment increases control of viral 
elimination and is accompanied by augmented number of leukocyte. 
To assess whether activation was altered by CD69 targeting, we measured the production of effector 
cytokines such as IFNγ- and TNFα and the CD107a as marker of degranulation activity within NK cells. 
VACV infected mice treated with anti-CD69 2.2 had an increase of around 30  percentage of IFNγ- and 
TNFα-producing NK cells but CD107+ NK cells were increased although not significantly (Fig  27A).  
Since the number of NK cells were augmented in the CD69 targeted mice, the numbers of splenic IFNγ- 
and TNFα-producing NK cells reached more than double of the control  mice and CD107+ NK cells were 
significantly  increased (Fig. 27B).  
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Figure 26. mAb anti-mCD69 2.2 treatment in Rag2-/- CD69+/+ mice induced an increased accumulation of leukocytes. A, Mice 
were treated with anti-mCD69 2.2 or PBS with two doses separated by a week and 5 days after second treatment, mice 
were infected with 1x106 pfu i.p and two days after, mice were sacrificed. C-E, Cells were collected from treated and not 
treated mice, and subjected to flow analysis. B, Viral titers were analyzed in ovaries after two days of infection. C, Absolute 
cell numbers of spleen, thymus, bone marrow and blood in anti-mCD69 2.2 treated mice compared to untreated mice. D-
E, Lymphoid and myeloid subpopulations cell numbers were analyzed in D, Bone Marrow and E, spleen. Pool of three 
independent experiments. (At least n=9 in each condition). B, One experiment representative of two independent 
experiments. 
     Rag2-/- CD69+/+ 
      Rag2-/- CD69-/- 
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Figure 27. mAb anti-mCD69 2.2 treatment in Rag2-/- CD69+/+ mice promoted NK cell activity. Splenocytes were assayed for 
intracellular production of IFN-γ, TNFα and CD107a in NK cells. A, percentages and B, cell number. A and B, pool of three 
independent experiments.  
 
Together, these results showed that mouse CD69 targeting increases the innate immune response 
against VACV infection, increasing leukocyte counts, enhancing NK cell activity and increasing immune 
response to VACV infection.  In a similar VACV infection setting in the absence of CD69 (chapter I), we 
found that leukocyte numbers were increased, including NK cells, that led to an increased VACV 
elimination though NK cells activity was not changed. These data support the idea that the increased 
production of TNFα, IFNγ and cytolytic exocytosis of NK cells observed during CD69 targeting upon 
infection may be due to signaling derived of the anti-CD69 engagement.  
 
Mouse CD69 targeting enhances immune response to VACV infection in WT mice. 
 
Since in immunocompetent mice, T lymphocytes play a pivotal role in VACV infection response, we 
followed the scheme shown in figure 28A in order to observe the effect of CD69 targeting when 
adaptive response has been developed. Thus, mice were treated with anti-mouse CD69 2.2 and 
infected with 1x107 pfu and analyzed seven days after infection (Fig.28A). We have found that mice 
IF
N
TN
F
C
D
10
7a
%
 P
o
s
it
iv
e
 c
e
ll
A. B.
IF
N
TN
F
C
D
10
7a
0
2
4
6
8
*
*
***
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
144 
treated with anti-mouse CD69 2.2 were highly more efficient in removal Vaccinia virus infection than 
PBS-injected control mice (Fig.28B). The VACV infected CD69 targeted mice had decreased total 
leukocyte numbers in bone marrow and a strong increase of these numbers in the spleen, lymph node 
and blood compared to control mice (Fig.28C). When analyzing the main leukocyte subsets in the 
spleen, we observed a marked increase in cell numbers of all main subsets analyzed (Fig. 28D).  
Importantly, the number of TNFα and IFNγ cytokine producing cells were increased in splenic 
lymphocytes (Fig. 28E), specifically TNFα in T CD4 cells and IFNγ in CD4, NK and CD8 lymphocytes 
thought no major differences in the percentages of these subsets were observed (data not shown).  
Thus, the targeting of mouse CD69 and later VACV infection resulted in accumulation of leukocytes 
including effector lymphocytes in peripheral sites and increased the ability to clear VACV infection.  
Overall, these results showed that mouse CD69 targeting increases the innate and adaptive immune 
in response to VACV infection. 
 
Anti- human CD69 mAb treatment of huCD69 transgenic mice induces enhanced anti-
VACV response. 
 
To approach a clinical application of anti-CD69 treatment in VACV responses, we treated human CD69 
transgenic mice with anti-human CD69 2.8 mAb using the same schedule as before (Fig. 29A).  At two 
days after VACV infection, mAb CD69 2.8 treated mice were more efficient in clearing the virus (Fig. 
29B) and it was found an enhancement of total splenic cell number and blood (Fig. 29C). The number 
of all splenic subtypes analyzed was increased compared to control mice (Fig. 29D). When we analyzed 
the cytotoxic capacity of NK cells and CD8 and CD4 T lymphocytes at two days after infection, we 
observed that the treatment induced an increase in the number of TNFα-producing cells in all 
subpopulations and a significant increase in the number of IFNγ-producing cells in NK cells and CD4 
cells, and a trend in CD8 cells (Fig. 29E). These results revealed that the innate immune response to 
Vaccinia virus infection is increased in the targeting of human CD69.  
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Figure 28. mAb anti-mCD69 2.2 treatment in CD69+/+ mice also induced an increased accumulation of leukocytes in spleen. 
A, C57bl/6 mice were treated with PBS or 200ug of anti-mCD69 2.2 with two doses separated by a week and five days after 
second treatment, mice were infected with 1x107 pfu i.p and 7 days after mice were analyzed. Cells were collected from 
treated and not treated mice, and subjected to flow analysis. B, Ovaries were collected seven days after infection and viral 
titers were measured. C, Absolute cell numbers of spleen, thymus, bone marrow, lymph nodes and blood in anti-mCD69 
2.2 treated mice compared to untreated mice. D, Number of different lymphoid and myeloid subpopulations in spleen. E, 
Numbers of IFNγ and TNFα-producing cells in spleen.  
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
146 
 
Figure 29. Early anti-VACV response upon Targeting with anti-human CD69 2.8 mAb promoted a better virus clearance and 
a concomitant accumulation of leukocytes two days after infection. A, Mice were treated with 2 doses of 200ug of anti-
huCD69 2.8 or PBS i.v with a gap of 1 week and 5 days after second dose mice were infected with VACV and analyzed 2 
days after infection. B, Viral titles in ovaries. C, Absolute cell numbers of spleen, bone marrow, lymph nodes, thymus and 
blood. D, Numbers of leukocytes subpopulations in the spleen. E-F, Numbers of IFNγ and TNFα-producing cells in spleen. 
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When analyzing HuCD69 mice after 7 days of infection (Fig. 30A), we observed that anti-human CD69 
2.8 treatment cleared VACV infection more efficiently than control mice two days after infection (Fig. 
30B). These mice had induced similar decreases and increases in total leukocyte counts in BM and 
spleen, respectively, than those WT mice treated with anti-mCD69 targeting, and a small increase in 
lymph nodes and blood leukocyte counts (Fig. 30C). In control experiments, the treatment of CD69+/+ 
mice with anti-hCD69 2.8 did not alter BM or spleen cell numbers, proving that the effect was specific 
of human CD69 targeting (data not shown). In all main leukocyte subtypes, we observed a tendency 
to increased numbers whereas CD8 T cells, macrophages and eosinophils were increased significantly 
(Fig. 30D). The analysis of TNFα and IFNγ-producing cells showed an increase in both cytokines in CD4 
T cells (Fig. 30E). 
In summary, in vivo targeting of human CD69 mice with mAb 2.8 previous to VACV infection, increases 
viral elimination compared to non-treated mice both at early times, 2 and 7 days after infection and is 
accompanied by augmented cell number in peripheral lymphoid organs.  
 
The effect of anti-huCD69 2.8 on cytokine and chemokine production. 
 
To further investigate the mechanisms implicated in the increased anti-VACV response in treatment 
with mAb CD69.2.8, the expression of soluble immune mediators in splenic cells was evaluated. Q-
PCRs were performed on splenic cells obtained from huCD69 mice 1 day after treatment with mAb 
huCD69.2.8 mAb (Fig. 31). The results showed a highly significant increase in IL-1α, IL-1β, Lymphotoxin 
α and Lymphotoxin β, IFNγ, IL-17b and IL-17f mRNA expression (Fig. 31A), and a huge increase in CCL2 
and CCL12 in the mAb CD69.2.8–treated mice (Fig. 31B). Levels of IL-17a expression were unchanged 
(Fig. 31A). Because it is well documented that these cytokines and chemokines are important players 
in viral infection, these results are consistent with the augmented capacity of in vivo VACV elimination 
by mAb CD69.2.8. 
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Figure 30. HuCD69 mice treated with mAb anti-huCD69 2.8 exhibited a higher egress of Bone Marrow cells in Vaccinia virus 
infection. A, Mice were treated with PBS or 200ug of anti-huCD69 28 with two doses separated by a week and five days 
after second treatment, mice were infected with 1x107 pfu i.p and 7 days after, mice were analyzed. B, Measures of viral 
titres in ovaries. C, Absolute cell numbers in spleen, bone marrow, lymph nodes and blood. D, Number of different 
lymphoid and myeloid cells in spleen. E-F, Numbers of IFNγ and TNFα-producing cells in spleen Pool of two experiments. 
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Figure 31.  Increased induction of proinflammatory cytokines and 
chemokines production. Spleen cells were collected from anti-
human CD69 treated mice and control mice. Q-PCR analysis of 
proinflammatory cytokines and its receptors was assayed. A, 
Data from IL-17a, IL-17b, IL-17f, IL1-α, IL-1β, LTa, LTb and IFNγ. 
B, Data from CCL2 and CCL12. Data are represented in a graph 
as fold-induction to β-actin. 
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DISCUSSION 
 
Recent insights in CD69-/- mice have shown that CD69 molecule is a regulator of leukocyte egress from 
BM to periphery and is able to increase anti-VACV response (chapter I and chapter II). Both, anti-mouse 
CD69 named mAb 2.2 used in immunodeficient and WT mice and the novel anti-human CD69 named 
mAb 2.8 employed in transgenic mice expressing human-CD69, do not deplete CD69-expressing cells 
and have been associated with mobilization of bone marrow cells to peripheral lymphoid organs in 
steady state (Chapter II). Here we report that the murine anti-CD69 mAb 2.2 and the human anti-CD69 
mAb 2.8 display a potent host anti-VACV responses similar to CD69-/- mice. These anti-VACV responses 
are a consequence of a maintained increased cellularity in SLO and reduced in BM. Furthermore, 
treatment of healthy animals expressing human CD69 with mAb CD69.2.8 induces an increase in 
leukocytes rate proliferation of SLO and an increase of cytokines expression such as IL-1α, IL-1β 
Lymphotoxin α and Lymphotoxin β, IFNγ, IL-17b and IL-17f mRNA and chemokines such as CCL2 and 
CCL12 in the absence of VACV infection, unveiling a new role for mAb CD69.2.8 in triggering cytokines 
and chemokines expression. Importantly, this occurs with a significant decrease of TGF-β levels 
(chapter II, Fig. 23). Here, we significantly improve the knowledge of the effect of pretreatment with 
anti-CD69 in cytokine production in healthy animals since in previous works only it has been described 
an effect in increasing IFNγ production in NK cells and an increase in IL-17 production in splenocytes  
from healthy animals. However, treatment with anti-mouse CD69 2.2 studied in different mouse 
models diseases had already revealed a high variety of different cytokines and chemokines production 
[129, 145, 147, 172, 173]. Thus, during VACV infection the effect of mouse CD69 targeting in Rag2+/+ 
CD69+/+ mice, but not in CD69 deficiency mice, was the increase in NK cell activity through the 
induction of TNFα and IFNγ production supporting that anti-CD69 treatment augmented cytokine 
production. The mechanisms involved associating CD69 with Th17 differentiation have been described 
to be related to Jak3 and Stat5 signaling pathway [128]. However, the mechanisms which induce the 
increase of cytokines and chemokines production by anti-human CD69 treatment remain to be 
elucidated. The reduction of TGF-β may explain these results, since the inhibition of regulatory 
cytokines mediating the increase immune response was reported to occur through blockade of TGF-β 
signaling in T cells or diminishing TGF-β presence on antigen-presenting cells. Reduction of TGF-β 
production has been reported in almost all model of diseases described in CD69-/- mice and mAb -2.2 
treated mice [1, 126, 129, 141, 142, 172, 173].  In agreement with the increase in IL-2 production 
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reported in human CD69 targeting mice (chapter II) and the anti-CD69 induction of T cell proliferation 
through production of IL-2 by DC [104], the treatment with mAb CD69.2.8 induces leukocyte 
proliferation of all subset in SLO shown here and in BM (Chapter II).   
The data presented here in anti-CD69 mAb–treated mice resemble the results obtained in CD69-/- mice 
in almost all levels examined, including increased capacity to eliminate VACV infection, increased 
leukocyte subsets cellularity in SLO, increased proinflammatory cytokines and decreased TGF-β 
expression.  Importantly, we and other groups demonstrated that treatment with mAb CD69.2.2 
internalizes CD69 and that mAb CD69.2.2–treated mice showed these findings few hours after mAb 
CD69 treatment [131, 172].  
In conclusion, our observations indicate that mAb CD69.2.2 that reacts with mouse CD69 and mAb 
CD69 2.8 that reacts with human CD69 have similar effects, which are partially comparable to the 
absence of CD69. The properties of anti-CD69 mAb as adjuvant in immune response to infection may 
help in vaccination, since Vaccinia virus is widely used as viral vector, carrying heterologous antigens 
in most currently studies in vaccines clinical trials and is considered the best positioned candidate to 
be used in the priming phase when two different viral vector are used. 
 
 
 
  
 
 
 
 
 
 
 
CHAPTER IV: 
OVEREXPRESSION OF CD69 IN 
VACCINIA VIRUS INFECTION.
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RESULTS 
 
Altered leukocyte distribution by CD69 overexpression in mice. 
 
Though it has been widely studied the influence of the absence of CD69, an extensive study of the 
effect of the overexpression of CD69 has not been approached. To study the effect of CD69 
overexpression in the homeostasis and function of immune cells, we analyzed mice that carry 6 copies 
of BAC containing CD69 gene (herein after referred as Hi-CD69.BAC mice). As shown in figure 32 (and 
data not shown), all leukocyte subpopulations in bone marrow and lymphoid organs express CD69 at 
very high levels in Hi-CD69.BAC mice. Then, we analyzed at steady state the number of total leukocytes 
subsets in BM and lymphoid organs of Hi-CD69.BAC compared to WT mice (Figure 33A). Studying bone 
marrow, NK cell numbers were augmented but no significant differences were observed neither in 
total cell number nor in the number of any other subset analyzed (Figure 33A and B). NK cells were 
also increased in the thymus, although total cells were not altered by the overexpression of CD69 (Fig. 
33A and C). In addition, it was observed an important increase in SP CD4 and SP CD8 thymocytes, 
concomitant with a decrease of CD4 CD8 DP and CD4 CD8 DN thymocytes (Fig. 33C). These results 
supported the reported function of CD69 as regulator of S1P1 expression, controlling thymocytes 
egress [158, 282] and  are  in accordance with the previous reports that analyzed overexpression of 
CD69 in thymocytes [140, 161]. In the spleen of Hi-CD69.BAC mice, total spleen cell number was 
decreased and lymphocytes numbers were reduced eleven-fold in CD8 T cells, three-fold in CD4 T cells 
and almost two-fold in B cells compared to WT mice (Figure 33A and D). Consequently, number of NKs 
and myeloid cells were found increased (Fig. 33D). Similarly to spleen, in blood of CD69 overexpressing 
mice, it was observed a decrease in total cell number, due to a drastically decreased of T and B cells 
compared to WT mice (Fig. 33A and 33E). However in lymph nodes the decrease in total cells number 
of 45 percent, corresponded to the decrease in T lymphocytes cell number but not in the number of 
B cells (Fig. 33A and 33F). Together these results showed that CD69 controls the exit of mature SPCD4 
and SPCD8 cells in thymus and the release of B cells from the bone marrow [158, 163, 280, 283]. 
However, the increase in the NK cell numbers in bone marrow, thymus and spleen, cannot be 
explained by the possible interaction of CD69 and the known role described by S1PRs in these cells.      
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Figure 32. Hi-CD69.BAC mice overexpress CD69 in hematopoietic and immune cells. CD69 expression is shown in subsets of 
collected cells from thymus, spleen, bone marrow, and lymph nodes (brachial, axillary, maxillary, inguinal and popliteal) 
from Hi-CD69.BAC and control mice.  
 
Regulatory T cells in thymus in overexpressing CD69 mice. 
 
S1P1 has been described as an intrinsic negative regulator of thymic differentiation, peripheral 
maintenance and suppressive activity of Treg cells [284]. Because S1P1 is down-regulated by CD69 
overexpression, regulatory T cells in Hi-CD69.BAC were compared to WT mice. Accordingly with the 
function of CD69 in retention of T lymphocytes in thymus, we found an increase in the cell numbers 
of the major regulatory T cell subpopulations in thymus, being the most prominent increase in the  
  
 
 
A. 
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Figure 33.  Hi-CD69.BAC mice showed deregulated leukocytes homeostasis. Bone marrow, thymus, spleen, lymph nodes 
and blood cells were collected from WT and transgenic mice and absolute cell number were counted in A.  B-F, Numbers 
of lymphoid and myeloid subpopulations in B, bone marrow, in C, thymus, in D, spleen, in E, blood and in F, lymph nodes 
in WT mice compared to CD69+/+ BAC mCD69. One experiment representative of three. 
 
 
Thymus 
Bone Marrow 
Spleen 
Blood Lymph 
nodes 
A. B. 
C. D. 
E. F. 
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FOXP3+ CD25+CD4+ T cells of more than three-fold (Fig.34A). This increase is higher than the observed 
by SP CD4+ mature thymocytes that was about two-fold (Fig. 33C and 34A), agreeing with the role of 
CD69 as positive regulator of Treg differentiation. In spleen, a  decrease of about 70% were observed 
in FOXP3+CD25+CD4+ cells, a decrease proportional to the decreased observed in total CD4 T cells 
(Fig. 33D and 34C). On the contrary, in lymph node, the decrease of CD25+FOXP3+T cells is about 30% 
while the decrease of CD4 was more than 60% (Fig. 33F and 34B). These results point to a mechanism 
for selective retention of CD25+FOXP3+ Tregs in lymph nodes. Therefore, the high expression of CD69 
in Hi-CD69.BAC mice can affect differentially to regulatory and non-regulatory T cells.  
 
 
Figure 34. Influence of CD69 overexpression in Tregs distribution. Number of Tregs were analyzed in Hi-CD69.BAC mice and 
WT mice by flow cytometry according surface CD25 expression and Intranuclear FOXP3 expression in A, Thymus, B, spleen 
and C, Lymph nodes. 
 
Innate and adaptive immune response to Vaccinia virus infection in Hi-CD69.BAC mice  
 
To assess the implication of the overexpression of CD69 in the ability of the immune response, we 
analyzed the response to Vaccinia virus infection in Hi-CD69.BAC mice. Because in these mice the 
number of T and B lymphocytes were considerably diminished in peripheral lymphoid organs, we first 
evaluated this effect when the adaptive immune response has been developed. For this, we infected 
mice i.p. with 1x107 pfu and analyzed them 7 days after infection. Surprisingly, we found that the 
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infection was equally resolved by Hi-CD69.BAC and WT mice (Fig. 35A). The analysis of total cell 
number showed that the overexpression of CD69 limits the expansion of the immune response in the 
spleen, because while Hi-CD69.BAC mice only expanded 20%, the splenocytes number in WT mice 
increased more than two-fold (Fig. 35B). Thus, in WT mice compared to Hi-CD69.BAC mice, at 7 days 
after VACV infection, dendritic cells had an increase of more than ten-fold, NK cells four-fold, B 
lymphocytes almost two-fold, CD8 T cells three-fold whereas CD4 T lymphocytes were found similar 
(Fig. 35C). Besides,  the number of IFN-γ-producing (IFN-γ+) and TNF-α-producing (TNF-α+) cells within 
NK cells, CD8 cells and CD4 cells decreased in Hi-CD69.BAC mice compared to WT mice in similar 
proportion to NK, CD8 and CD4 cell number (Fig. 35D-E). Overall, these data discarded that Treg 
activity would be increased due the CD69 overexpression. Also, the analysis of the ratio of Treg to CD4 
T cells in Hi-CD69.BAC compared to WT mice showed a similar proportion before and after infection 
(Supplementary figure 1). Together, these data rejected the hypothesis that the diminished number 
of Treg cells in Hi-CD69.BAC mice would be responsible for the increased anti-viral response observed 
in this mice.    
Therefore, being the number of effector immune cells significantly decreased in infected Hi-CD69.BAC 
mice but the effectiveness of the adaptive immune response similar in Hi-CD69.BAC and WT mice, we 
reasoned that this could be due to an enhanced innate anti-VACV response supported by the increased 
NK cells and myeloid cell number found in the spleen at steady state. Accordingly, we infected Hi-
CD69.BAC mice and WT mice and we analyzed the response two days after infection and we found 
that Hi-CD69.BAC mice removed VACV infection more efficiently than WT mice (Fig.36A). When 
analyzing total cells counts, an expansion about 10% and 40% of splenic cells were observed in the Hi-
CD69.BAC mice and WT respectively (Fig.36B) that again point to the difficulties of CD69 
overexpressing mice to recruit or expand cells in the lymphoid organ. Analysis of the leukocyte 
subpopulations in Hi-CD69.BAC mice compared to WT mice revealed a decrease in the number of T 
and B cells in spleen similar to that observed at steady state whereas NK cell number were similar 
(Fig.36C).   
 
Detection of macrophages, neutrophils, B cells and T lymphocytes by histologic staining of lymphoid 
organs showed a similar results than that observed by FACS (Fig.37). In addition, histological staining 
of kidney and lung showed a low but equal level of infiltrating cells without any obvious differences 
between Hi-CD69.BAC and WT mice (data not shown) and therefore CD69 overexpression seemed 
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irrelevant for immune cell seeding of non-lymphoid organs. This data is consistent with the 
observation that TRM cells developed similarly in CD69-/- and WT mice [171].    
 
 
Figure 35. Reduced number of TNFα and IFNγ producing lymphocytes in SLO but similar VACV removal in Hi-CD69.BAC mice. 
Mice were infected with 1x107 pfu i.p and 7 days after infection, mice were sacrificed. Cells were collected from spleen 
and subjected to flow analysis. E, Ovaries were collected seven days after infection and viral titres were measured. B, 
Absolute cell numbers in spleen. C, Number of lymphoid subpopulations cells and dendritic cells in spleen. D-E, Number of 
TNF-α-producing cells in D and IFN-γ-producing cells in E, in spleen cells. 
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Figure 36. Reduced number of TNFα and IFNγ producing lymphocytes in SLO accompanied with an increased VACV 
elimination two days after infection in Hi-CD69.BAC mice. Mice were infected with 1x107 pfu i.p and 2 days after infection, 
mice were analyzed. A, Ovaries were collected two days after infection and viral titres were measured. B, Absolute cell 
numbers in spleen. C, Number of lymphoid subpopulations cells and dendritic cells in spleen. D-E, Number of TNF-α-
producing cells in C and IFN-γ-producing cells in D, in spleen cells. Pool of two experiments. 
 
Because, at steady stage, NK cells were augmented in Hi-CD69.BAC compared to WT mice in spleen, 
thymus and bone marrow and equal numbers in lymph node and blood, we speculated whether NK 
cells could be the responsible of the augmented anti-viral response. In fact, the augmented NK cells 
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Figure 37.  Immunohistochemichal analysis in Hi-CD69.BAC mice. Mice were infected intraperitoneally with 107 pfu of 
Vaccinia Virus and two days after infection, samples were collected from spleen, lymph nodes, kidney and lung and 
analyzed for macrophages, B lymphocytes, T lymphocytes and neutrophils staining. One experiment. The images are 
reprentive of three samples for group. 
 
numbers in spleen and blood before infection corresponded to an increase in the number of NK cells 
in the last stage of maturation analyzed by the expression of CD27and CD11b in Hi-CD69.BAC mice 
(Fig. 38A-B).  However, after VACV infection, a decrease in the TNF-α-producing (TNF-α+) cells and IFN-
γ-producing (IFN-γ+) cells were observed within NK cells as well as in T lymphocytes in spleen of Hi-
CD69.BAC mice when compared to WT mice (Fig.36D-E).  Hence, the increased innate viral resistance 
observed in Hi-CD69.BAC mice at two days after infection, could be induced by increased activity of 
NK cells, but not due to the production of TNF-α and IFN-γ by these cells.   
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Figure 38. Induced increased proportion of mature NK cells in Hi-CD69.BAC mice. A-B, Cells from spleen and blood were 
analyzed according to CD11b and CD27 expression within NK cells in four subpopulations in this order of maturation: 
CD27lo CD11blo, CD27hi CD11blo, CD27hi CD11bhi and CD27lo CD11bhi. Numbers of these subpopulations were analyzed 
in A, spleen and in B, blood. Pool of two experiments. 
 
Since CD69 have been described to be expressed in infiltrating leukocytes in many tissues including 
mucosa and skin regulating entrance and maintenance of T cell [171], we aimed to know whether the 
immunity in non-lymphoid organs, would be augmented against VACV in mice overexpressing CD69.  
Although the intraperitoneal pathway has been described as route of choice in Vaccinia virus infection 
with ovary as preferred site of virus replication where it remains for a long time, it has also described 
that the response could be evaluated in hematopoietic and non-lymphoid organs at short times upon 
intravenous injection. Therefore, we infected Hi-CD69.BAC and WT mice with Vaccinia virus 
intravenously and evaluated the viral titre in spleen, kidney, lung, lymph nodes and liver at 24 hours 
after infection (Fig.39). The results revealed a significantly better innate response to infection in 
spleen, kidney, lung and lymph nodes and the same tendency in the liver of Hi-CD69.BAC mice (Fig.39).  
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These results point to an increased immunity at day one after infection in non-lymphoid organs that 
might be mediated by infiltrating CD69 expressing immune cells. However, in the results shown in 
figure 36 and data not shown, the infiltration in lung and kidney after two days of infection was not 
different between CD69.BAC and WT mice.  NK cell numbers in bone marrow, thymus and spleen were 
increased and thus, overexpression of CD69 deregulated NK cells. Though, it have been described an 
increased in numbers of NK cell in peripheral organs at steady stage, how the NK cells reach and are 
maintained in different peripheral tissues has been poorly investigated.  
 
Besides, as in barrier tissues, most of the immune cells expressed CD69, we analyzed the local immune 
protection in the respiratory mucosal tissues by intranasal infection with 105 PFU of VACV in Hi-
CD69.BAC and WT mice. We approached to study the survival to the infection by examining over time 
the mice weight. The response was similar in both mouse strains until 7 day where Hi-CD69.BAC mice 
showed a greater capability in removal the intranasal infection of Vaccinia virus (Fig.40A). At this point, 
the animals were sacrificed and the virus titre was analyzed in lung, which constitutes the principal 
virus retention site in intranasal infection. Correspondingly with the increased survival observed, the 
viral titer was higher in WT mice than in transgenic mice (Fig.40B).  Therefore, also in mucosa, CD69 
overexpression leads to a higher immune protective capability, although the difference in survival of 
Figure 39. Improved efficiency in VACV 
elimination in lymphoid and non-lymphoid 
tissues in in Hi-CD69.BAC mice. Mice were 
infected intravenously with 107 pfu of 
Vaccinia virus infection and spleen, kidney, 
lymph nodes, lung and liver were collected 
and viral titres were measured at one day 
after infection. Pool of three experiments. 
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Hi-CD69.BAC mice compared to WT mice were not detected until 7 days post infection. In fact, 7 days 
are needed to produce specific effector and memory T cells which locally express CD69.    
Figure 40.  Increased survival in intranasal infection of Vaccinia virus in Hi-CD69.BAC mice. Mice were infected intranasally 
with 105 pfu of Vaccinia virus infection. A, Weight loss was evaluated over 7 days.  B, At 7 days after intranasal infection, 
lung were collected and analyzed for viral load. 
 
The effect of CD69 overexpression in cytokine and chemokine expression. 
 
To investigate the mechanism that induces the increase in anti-VACV response in CD69 overexpressing 
mice, the expression of soluble immune mediators in total and NK purified splenic cells were analyzed 
by Q- PCR (Fig. 41A-B and data not shown). We found that these mice showed an increased production 
of IL17a, IL17b and IL17f in total spleen cells and IL17a in NK cells (Fig. 41A and data not shown). An 
increase in the expression of IL-7, CCL2, CCL7 and CCL8 was also observed (Fig. 41A-B), which have 
been described its role on the development and homeostasis of NK cells and in other leukocytes 
subsets [285]. Surprisingly, overexpression of CD69 also increased expression of proinflammatory 
cytokines such as TNF and IFNγ production and IL-1α, IL-1β and IL-21 (Fig. 41A). Finally, CCL2 and CCL12 
expression were augmented in CD69 overexpressing mice whose role is associated with an increase in 
cell chemotaxis to the site of infection (Fig. 41B).  This increase in inflammatory humoral mediators 
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reveal an important role of CD69 in controlling the immune response mediated by cytokines and 
chemokines. Due to the overall increase in VACV elimination, together, these results suggest the 
influence of cytokines and chemokines in the better antiviral response in spite of the reduced number 
of T and B cells found in SLO. Also, this increase of humoral mediators may influence in the number of 
NK cells observed in thymus, bone marrow and spleen. In addition, CCL2 and its homolog CCL12 may 
contribute to recruit leukocytes to other tissues different of SLO.  
 
  
Chemokines 
A. 
B. 
Cytokines 
Figure 41.  Increased proinflammatory cytokines and 
chemokines production in Hi-CD69.BAC mice. Spleen 
cells from CD69 overexpressing mice and WT mice 
were collected. Q-PCR of the cytokines and 
chemokines shown in graph were assayed. A, Data 
from IL-17a, IL-17b, IL-17f, IL-7, IL1-α, IL-1β, IL21, 
IFNγ and TNF. B, Data from CCL2, CCL12, CCL7 and 
CCL8. Data are represented in a graph as fold-
induction to β-actin mRNA. 
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DISCUSSION 
 
In this study, we evaluated the implication of CD69 overexpression in leukocyte circulation and 
function. It was found an increased numbers of single positive T cells in thymus and a higher increase 
in regulatory T cells, leading to a high reduction in T lymphocytes including Treg cells in SLO. Likewise, 
B cells were moderately reduced in SLO, although an unexpected augmentation in NK cell numbers 
were found in bone marrow, thymus and spleen. Nevertheless, CD69 overexpressing mice showed a 
better control of VACV infection in spite of the reduction of T and B cells in SLO compared to WT mice. 
On the other hand, humoral mediators CCL2, CCL12, CCL7, CCL8, IL-17, IL-1, IL-7 and IL-21 was highly 
augmented and TNF and IFNγ moderately increased. 
In CD69 overexpressing mice, the increased number of SPCD4 and SPCD8 T cells in thymus, and the 
decreased T cells in SLO, is the result of  CD69 interfering with S1P1 function, since S1P1 regulates  
egress of mature thymocytes from thymus in response to a S1P gradient in plasma [286-288]. Similar 
results were reported in transgenic mice overexpressing CD69 in thymic cells driven by an Lck 
promoter [140, 161]. Our data also support the function described for S1P1 of negative regulation of 
development, function  and retention of Treg [284], since CD69 overexpression interfering with this 
function resulted in a stronger increased and decreased of Treg in the thymus and SLO respectively, 
compared to SP CD4 thymocytes.  In CD69 deficient mice, it has been reported a decrease in SPCD4 
thymocytes but a proportional decrease in CD4 CD25+FOXP3+ regulatory T thymocytes. Therefore, in 
CD69-/- mice, the differential function of S1P1 in the subset of Treg cells within the CD4 thymocytes 
was not appreciated [289]. B cell reduction in SLO of CD69 overexpressing mice is also in agreement 
with CD69 interfering with S1P1 function in B cell egress from bone marrow, although B cell 
progenitors in bone marrow were not altered [163, 280]. In agreement, similar altered distribution of 
B cells was appreciated in S1P1-/- mice [163] showing reduced numbers of B cells in spleen and blood 
and similar quantities in LNs. 
In CD69 overexpressing mice, the described function for CD69 in retention of mature T and B cells in 
lymph nodes [140, 161] is appreciated, since in these organs, T and B cell number are less decreased 
than in spleen of CD69 overexpressing mice compared to WT mice.  In NK cells, S1P1 facilitates egress 
from lymph node [290] reducing egress from BM  [291]. If CD69 could interfere with this function, it 
would be expected an increase in NK cell numbers in these organs, however, in CD69 overexpressing 
mice, the increase in NK cell number was found in bone marrow, thymus and spleen. NK cells egress 
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from bone marrow and lymph nodes is mediated by S1P5 which does not interact with CD69 [166]. 
Therefore, the increased development of NK cells in CD69 overexpression mice is induced, at least 
partially, by a non-S1P related mechanism. The increased number of NK cells in bone marrow, thymus 
and spleen may be justified by the increased expression of CCL7, CCL8, IL7 and IL21 expression 
important for NK cell survival, development and homeostasis [292]. These huge increase of soluble 
activation and attractant factors might attract almost all types of leukocytes but since NK and myeloid 
cells are less strongly controlled by CD69 than T and B lymphocytes, they will be less retained than 
these cells in primary lymphoid organs, allowing a greater output to SLO [132]. 
To assess whether overexpression of CD69 could be involved in a differential immune response, we 
analyzed the impact of Vaccinia virus infection in this transgenic mice model. The study of innate and 
adaptive immune response in SLO of CD69 overexpressing mice during Vaccinia virus infection 
revealed that the number of leukocytes and their pattern of distribution were similar to that observed 
at steady state which may be explained by a limited recruitment of cells into SLO organs. 
Vaccinia virus is characterized for its wide tropism, being capable of infecting any cell type. Despite of 
a reducing number of IFNγ producing cells found in VACV infected CD69 overexpressing mice, we 
found a better response to Vaccinia virus infection both analyzed in ovaries after intraperitoneal 
infection, in lung after intranasal infection and in spleen, lymph nodes, kidney, lung and liver after 24 
hours of intravenously infection. Therefore, the overexpression of CD69 leads to a better immune 
response to removal Vaccinia virus infection by all routes analyzed, except the similar adaptive 
immune response observed between Hi-CD69.BAC mice and WT mice in response to intraperitoneal 
Vaccinia Virus infection. These data suggest that these mice have an increased response when the 
peripheral non-lymphoid or mucosa tissue are involved by any implicated route of entrance and a 
better adaptive immune response when a mucosa is involved as virus entrance. Since we did not 
observed by histological studies differences in the number of infiltrating cells in non-lymphoid organs 
of CD69 overexpressing compared to WT mice (figure 34 and data not shown), and most of infiltrating 
leucocytes expressed CD69, we suggested that overexpression of CD69 may help to retain myeloid 
and NK cells in these locations. In addition, it is well documented the function of CD69 in retention of 
T effector cells and memory local formation [171]. We reasoned that in the CD69 overexpressing mice 
during the immune response to intranasal VACV infection, the better innate response developed in 
the lung of these mice, seen during i.v. infection, would support the improved adaptive immune 
response observed in this mice mediated by the CD69 retention of T cells. The increased expression 
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of IL17a, IL17b and IL17f, IL-1 and IL-21 production in CD69 overexpressing mice between 10 and 100-
fold compared to WT mice and 5-fold in TNF and IFNγ expression are agree with the increased 
resistance to Vaccinia virus infection in this mice. Also, TNF and IFNγ play a key role in the best 
response to Vaccinia virus infection. IL17 deficient mice showed to be more sensitive to VACV infection 
than WT mice [241]. The blockage of IL-1βR in Vaccinia virus led to an increase of IL-1β expression in 
murine and human antigen-presenting cells being responsible of an enhanced T CD8 memory T cells 
and resistance to VACV infection [293]. Recent studies have shown that IL-21 is required to sustain an 
antiviral function of T CD8, B and NK cells preventing disease progression and is considered as a good 
candidate for use as a Vaccinia adjuvant [294-297]. Thus, the increased expression of IL-17 and the 
proinflammatory cytokines TNF and IFNγ accompanied by the augmented number of NK cells probably 
resulted of the increase of CCL7, CCL8, IL-21 and IL-7 expression may be promoting the higher immune 
response found in CD69 overexpressing mice leading to a better control of VACV infection.  In spite of 
the reduced number of T lymphocytes in SLO is compensated by the vast increased production of 
humoral mediators.
  
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION
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The results presented in this thesis show the importance of CD69 in cell distribution and in Vaccinia 
virus infection in the absence, targeting or overexpression of CD69. In the presented work, it has been 
found that the absence of CD69 displayed a better control of Vaccinia virus infection through an 
enhanced cellularity in spleen, TNFα and IFNγ-producing NK cell, NK cell number and a reduced 
spontaneous cell death. The targeting of mouse and human CD69 induced a decrease of bone marrow 
cells and an increase of spleen cells and this effect was maintained for 6 days. Anti-human CD69 
showed a similar mobilization than AMD3100 and was non-summative in combined treatment. CXCR4 
expression was augmented in bone marrow and spleen cells whereas CXCL12 expression was found 
increased in bone marrow and decreased in spleen, lymph nodes and plasma. FTY720 treatment 
inhibited bone marrow cell mobilization in anti-CD69 treated mice and an increase of S1P1 expression 
in the main leukocyte subtypes in bone marrow and blood was observed in targeted mice pointing to 
S1P1 increase as a mechanism of mobilization of bone marrow cells. Accordingly, anti-human CD69 
also induced an increase of mTOR signaling. Besides, anti-human CD69 induced proliferation of 
progenitor and stem cells that was more a homeostatic proliferation since was higher than the 
observed after AMD3100 treatment. In agreement, the targeting of mouse and human CD69 resulted 
in an improved immune response against Vaccinia virus infection in immunodeficient and 
immunocompetent mice. Treatment with anti-human CD69 2.8 induced a significant increased 
expression of different cytokines and chemokines in HuCD69 mice. Moreover, overexpression of CD69 
induced T cell and Treg cell retention in thymus, being more affected Treg cells, and a proportionally 
reduced output of these cell to periphery. B cell numbers were also diminished in SLO in less 
proportion whereas a significant increase of NK cell number was established in bone marrow, thymus 
and spleen. Also, IL17a, IL17b, IL17f, IL-1α, IL-1β, IL-7 and IL-21 were augmented between 10 and 100-
fold, TNF and IFNγ around 5-fold and CCL2, CCL12, CCL7 and CCL8 between 40 and 140-fold compared 
to WT mice. The vast majority of these cytokines and chemokines were also augmented in CD69 
human treated mice. Thus, this great augment of proinflammatory cytokines and chemokines, seems 
to overpass the effect of the reduced number of T and B lymphocytes found in the CD69-
overexpressing mice since anti-Vaccinia immune response was found augmented in intraperitoneal, 
intravenous and intranasal infection. 
The absence of CD69 enhances the host response to Vaccinia virus infection in immunocompetent and 
immunodeficient mice in both innate immune response and adaptive immune response. This is 
accompanied by an increased leukocyte number including NK cells and TNFα and IFNγ-producing NK 
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cells in the spleen and NK cell depleted mice exhibited a similar response in CD69-/- mice than WT mice 
but a significantly worse response in Rag2-/-CD69-/- mice compared to Rag2-/-CD69+/+, pointing to NK 
cell numbers as the responsible of the best antiviral response. The increase of spleen cellularity 
observed in these mice after infection had already been detected in uninfected mice. Similarly, 
increased cell number were previously reported in CD69 deficient mice in a different genetic 
background at steady state and spleen and peritoneum in an anti-tumor response [1]. In previous 
works, CD69 knockout mice have been associated with an increase of IFNγ production and a reduced 
TGF-β expression [1]. In the presented work, the reduction of TGF-β has been also linked with an 
increased cell survival, which has been observed augmented in Rag2-/- CD69 knockout mice whereas 
no differences in proliferation rate were observed. Thus, the increase in spleen cell number may be, 
at least in part, the result of a reduced cellular apoptosis. 
The role of CD69 has been studied in numerous models of autoimmune [131, 142, 144, 147-149, 153] 
and antitumor diseases [1], acting as negative regulator of the immune response. However, the 
influence of CD69 on anti-infectious immune response has been only described in the infection of 
Listeria monocytogenes [141] but not in antiviral immune response. The absence of CD69 in mice 
infected with Listeria monocytogenes led to an increased in lymphocyte numbers with an increased 
production of IFN type I and II. As it is described, an augmented interferon together with listeriolysin 
from the bacterial infection leads to an increase of cellular apoptosis and poorer infection control. 
However, in Vaccinia virus infection, similar to the results observed in the antitumor response, the 
increase of NK cells and other cell type number contribute to the best antiviral response observed.  
In addition to the increased number of spleen cells in CD69-/- mice at steady state, we found a 
decreased cell number in BM. To analyze whether the absence of CD69 induced an augmented NK cell 
egress from BM, we assayed BM chimeras of CD69-/- and CD69+/+ in CD69+/+ recipient mice and found 
a higher proportions of CD69−/− NK cells than CD69+/+ NK cells in spleen among total donor-derived NK 
cells. Also, previous works showed that CD69 targeting mice resemble the phenotype of CD69-/- mice 
[147, 172, 173], and then we used anti-CD69 antibodies to check if these mice had a similar phenotype 
in steady and infection setting than knockout mice and to know the mechanism involved. Targeting of 
CD69 mouse showed a greater cellular recruitment in periphery and decreased bone marrow cell 
count. We studied the effect of anti-human CD69 antibodies in a mouse model that expresses human 
CD69 to analyze the possible use of this treatment as mobilizer of hematopoietic bone marrow cells 
in humans. Human CD69 targeting decreased the number of the major cell populations of bone 
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marrow, and an increase of many spleen cell subtypes. CD69 targeting induced bone marrow cell 
mobilization similar than AMD3100 and both treatments did not have a summative effect. Besides an 
increase of CXCR4 expression in bone marrow and spleen and a reduction of CXCL12 expression in 
blood, spleen and lymph nodes and an increase in bone marrow was found in treated mice. Both 
CXCL12 and CXCR4 are potent chemoattractants and constitute one of main mechanism of HSC 
mobilization [18], but changes in the expression of these chemokines depended on the time analyzed 
[3]. Lapidot et al. demonstrated that CXCL12 expression increases in bone marrow after G-CSF-induced 
mobilization but decreases over time [3]. Anti-CD69 treatment acts on CXCL12/CXCR4 axis but we have 
not studied its expression dynamics. Importantly, it has been described that CD69 and S1P1 are 
mutually regulated [108] and that the involvement of S1P/S1P1 axis as one the main mechanism of 
hematopoietic cell mobilization [22]. In fact, an increased S1P1 expression is detected in CD69 
knockout mice. In the presented work, CD69 treatment increased S1P1 expression in the major cell 
types of bone marrow and blood and treatment with anti-CD69 together with FTY720, an inhibitor of 
S1P1 expression, prevented the mobilization induced by anti-CD69 treatment implicating S1P1/S1P 
axis in CD69 targeting induced. On the other hand, we found an implication of mTOR cell signaling 
pathway in both spleen and bone marrow from CD69 treated mice measured as phosphorylation of 
4E-BP1 and it has been also described that this pathway was implicated in CD69 signaling [131] and in 
bone marrow cell mobilization induced by G-CSF [4]. The importance of mobilizers lies in its use for 
hematopoietic stem cells mobilization, which were shown to be increased in bone marrow and spleen 
after treatment with human anti-CD69. This increase has been also related to a significant increase in 
proliferation rate of hematopoietic stem cells being significantly higher than AMD3100 treatment. 
Proliferation could be also mediated by the increase in IL2 and CD25 (IL2rα) production found in bone 
marrow, spleen and blood of CD69 treated mice and this corresponds with previous data of our lab 
where was described that anti-mouse CD69 treatment induces proliferation of IL2-mediated memory 
phenotype T cells and was inhibited by treatment with anti-CD25 antibodies [104]. As described above, 
CD69 knockout mice had been previously characterized by a reduction of TGFβ, which was also 
observed in CD69 treated mice reproducing CD69 knockout mouse phenotype [1]. Thus, anti-human 
CD69 can induce mobilization of mature and precursor cells through changes in CXCR4/CXCL12 axis 
and increasing S1P1 expression, mTOR signaling and proliferation rate. 
Currently, G-CSF constitutes the main mobilizer of bone marrow progenitor cells and is combined in 
research studies with other treatments to improve mobilization efficiency [30]. More studies are 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
176 
needed to approach the possible use of anti-CD69 antibodies together with G-CSF to improve current 
results.  
Since we have seen an increased leucocyte cells numbers in peripheral organs in CD69-targeted mice 
similar to CD69-/- mice and we observed an augmented anti-VAV response in CD69-/- mice, the study 
of anti-VACV response in this mice was approached. To evaluate the response, we designed a 
treatment to keep reduced CD69 expression over time and similar results were found. Mice treated 
with anti-mouse CD69 resulted in a cellular mobilization in both Rag2-/-CD69+/+ mice and human CD69 
mice. The treatment with anti-mouse CD69 in Rag2-/-CD69+/+ mice demonstrated increased viral 
clearance capacity two days after infection accompanied with an increase of leucocytes numbers and 
increased proportion and number of TNFα and IFNγ-producing NK cell. Similar results were found in 
human CD69 mice model two days after infection whereas a better response to Vaccinia virus infection 
was also found in mice treated with anti-human CD69 at seven days after infection but no changes 
were found in the NK cell activity. In addition, anti-human CD69 treated mice showed an enhanced 
production of proinflammatory cytokines such as IL17, IL1, IFNγ and Lymphotoxin and chemokines 
such as CCL2 and CCL12. Therefore, CD69 targeting reveals the possibility of targeting CD69 to 
manipulate the immune response against Vaccinia virus infection and its use for the treatment of this 
infection.  
The effect of CD69 targeting has been linked to the NK cell-dependent antitumor model [172], to a 
collagen-induced arthritis model [173]and to an ovalbumin-induced asthma model [147]. To date, its 
role in an antiviral model was unknown.  
Therefore, the absence and targeting of CD69 induced a higher cell numbers in spleen in uninfected 
mice and promoted a better antiviral immune response.  
Finally, the transgenic mouse model that  overexpressed CD69 expressed CD69 at basal conditions in 
all cell populations analyzed, demonstrating the influence of CD69 on cellular distribution, inducing 
retention of mature T lymphocytes, T CD4 SP and T CD8 SP, in thymus and a reduction in the numbers 
of these cells in SLO and peripheral blood. Also, overexpression of CD69 interferes to a greater extent 
in regulatory T cell subpopulation, inducing retention of FOXP3+ CD25+ CD4+ cells in thymus and a 
proportional reduction in the number of regulatory T cells in spleen and to a lesser extent in lymph 
nodes. This cell distribution is justified by the relation between CD69 and S1P1, whose interaction has 
been described for lymphocytes [108, 163, 171]. The absence of S1P1 impairs exit of T lymphocytes to 
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the periphery being incapable of leaving thymus and although we can find lymphocytes B in peripheral 
lymphoid organs, they are severely reduced in blood and lymph [158]. Number of B cells in CD69 
overexpressing mice were also diminished in SLO although less than T lymphocytes. Overexpression 
of CD69 influences in NK cells numbers being increased in thymus, bone marrow and spleen. The 
significant increase of IL-21, CCL7, CCL8 and IL-7 in CD69 overexpressing mice, which can influence in 
NK cell homeostasis, could be responsible of the increased NK cell number observed in this mice. 
Because the immune response of CD69 overexpression in Vaccinia virus infection induced an increased 
innate immunity measured in ovaries after intraperitoneal infection and in spleen, lymph nodes, 
kidney, lung and liver after intravenous inoculation, despite of the small number of TNFα and IFNγ 
producing cells and augmented adaptive immune response measured in lungs after intranasal 
infection. The study of proinflammatory cytokines revealed a very significant increase in IL17a, IL17b 
and IL17f, IL-1α and IL-1β production in these mice and an increase of TNF and IFNγ expression. 
Increased TNF and IFNγ production may justify the best response found in mice overexpressing CD69 
since both cytokines have been shown to play a key role in the best response to Vaccinia virus 
infection. On the other hand, the increase of IL17 could be related to an increase in differentiation to 
Th17 which establishes a balance with regulatory T cells. The increase of IL17 in transgenic mice could 
be justified by the reduction of regulatory T cells observed in SLO. The importance of CD69 in Th17 
has been studied in an in vitro model of T CD4 lymphocytes differentiation to Th17 in CD69 knockout 
mouse, which showed increased levels of IL17 [128]. IL17 deficiency mice or treatment with anti-IL17 
mAb resulted to be more sensitive to Vaccinia virus infection than control mice [241]. Thus, the best 
response of the CD69 overexpressing mice may be a result of the increase of IL-17 and the 
proinflammatory cytokines TNF and IFNγ. 
In summary, our data reveal that the absence and targeting of CD69 show increased spleen cell 
recruitment due to an increased mobilization of bone marrow cells whereas CD69 overexpressing mice 
have a similar number of bone marrow cells, probably due to the reduced expression of S1P1, and a 
lower cellularity in SLO. And on the other hand, the absence, targeting and overexpression of CD69 
showed a better response to Vaccinia virus infection.
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CONCLUSION 
 
In the immune response to Vaccinia Virus infection in CD69 knockout mice: 
1. CD69-/- and Rag2-/- CD69-/- mice show an enhanced in vivo anti-Vaccinia activity mediated by NK 
cells.  
2. Infected CD69-/- and Rag2-/- CD69-/- mice show an increased accumulation of splenocytes at early 
response in VACV. 
3. The increased antiviral response in these mice is mediated by similar NK cell reactivity but 
increased NK cell number and similar NK cell proliferation rate. 
4. In uninfected mice, Rag2-/- CD69-/- mice exhibit increased NK cells numbers and a reduced 
spontaneous cell death rate. 
5. CD69-/- mice show decreased bone marrow cellularity and increased leukocyte counts in the 
periphery. 
 
Influence of human CD69 targeting in mobilization of progenitor cell: 
6. Targeting of mouse and human CD69 induce bone marrow mobilization of hematopoietic cell from 
primary lymphoid organs and accumulation in periphery. 
7. Anti-human CD69 treatment mobilizes immature B cells from bone marrow. 
8. The effect on mobilization of CD69 targeting is similar and non-additive to the one of AMD3100 
(inhibitor of CXCR4). 
9. Targeting of CD69 alters CXCR4/CXCL12 axis, increasing CXCR4 expression in bone marrow and 
spleen. 
10. Treatment with FTY720 (inhibitor of S1P1) and anti-CD69 impairs bone marrow cell egress, 
demonstrating the role of S1P receptors in CD69 targeting-induced bone marrow mobilization. 
11. CD69 targeting induces mTOR signaling and this mechanism links to the upregulation of S1P1. 
12. Anti-CD69 treatment induces accumulation of primitive hematopoietic cell number in bone 
marrow and spleen. 
13. Treatment with CD69 increases proliferation rate in mature and primitive hematopoietic cell in 
bone marrow and spleen and this proliferating rate is higher than AMD3100 treatment. 
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14. CD69 targeting induces an increase in IL2 and IL2-R expression and a decrease in TGF-β in bone 
marrow and spleen. 
15. Targeting of CD69 with two doses induces an increase in number of leukocyte subsets in periphery 
and increase proliferation rate and humoral proinflammatory mediators in spleen. 
 
In CD69 targeting effect in Vaccinia virus in Ra2-/- CD69+/+, CD69+/+ and human CD69 mice: 
16. In these mice targeting of CD69 promotes better virus clearance and a concomitant accumulation 
of leukocytes in periphery and a decrease in bone marrow cell number. 
17. During the innate immune response to Vaccinia virus infection analyzed in Ra2-/- CD69+/+ mice, anti-
CD69 treatment induces an enhanced activity of NK cells, increasing percentages of IFN-γ and 
TNFα-producing cells. 
 
In overexpression of CD69 in Vaccinia virus infection: 
18. Overexpression of CD69 alters leukocyte homeostasis resulting in a decrease of the main subsets 
in SLO and an increase in thymus of SP CD4 T cells, SP CD8 T being Tregs cells more affected. 
However, NK cell numbers were increased in bone marrow, thymus and spleen.  
19. CD69 overexpressing mice induces a high increase of proinflammatory cytokines and chemokines. 
20. In these mice, innate immune response was increased in different inoculation settings. Viral titres 
were found diminished in ovary by intraperitoneal infection and spleen, lymph nodes, liver, lung 
and kidney in intravenous inoculation. 
21. In intranasal infection, removal of Vaccinia virus in lungs and survival were increased in 
overexpressing mice compared to WT mice. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY
 
 
  
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
185 
1. Esplugues E, Sancho D, Vega-Ramos J, Martinez C, Syrbe U, Hamann A, Engel P, Sanchez-Madrid F, 
Lauzurica P: Enhanced antitumor immunity in mice deficient in CD69. The Journal of experimental 
medicine 2003, 197(9):1093-1106. 
2. Eaves CJ: Hematopoietic stem cells: concepts, definitions, and the new reality. Blood 2015, 
125(17):2605-2613. 
3. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, 
Arenzana-Seisdedos F, Fujii N et al: G-CSF induces stem cell mobilization by decreasing bone 
marrow SDF-1 and up-regulating CXCR4. Nature immunology 2002, 3(7):687-694. 
4. Golan K, Vagima Y, Ludin A, Itkin T, Cohen-Gur S, Kalinkovich A, Kollet O, Kim C, Schajnovitz A, 
Ovadya Y et al: S1P promotes murine progenitor cell egress and mobilization via S1P1-mediated 
ROS signaling and SDF-1 release. Blood 2012, 119(11):2478-2488. 
5. Merchant A, Joseph G, Wang Q, Brennan S, Matsui W: Gli1 regulates the proliferation and 
differentiation of HSCs and myeloid progenitors. Blood 2010, 115(12):2391-2396. 
6. Spangrude GJ, Heimfeld S, Weissman IL: Purification and characterization of mouse hematopoietic 
stem cells. Science 1988, 241(4861):58-62. 
7. Ikuta K, Weissman IL: Evidence that hematopoietic stem cells express mouse c-kit but do not 
depend on steel factor for their generation. Proceedings of the National Academy of Sciences of the 
United States of America 1992, 89(4):1502-1506. 
8. Li CL, Johnson GR: Murine hematopoietic stem and progenitor cells: I. Enrichment and biologic 
characterization. Blood 1995, 85(6):1472-1479. 
9. Challen GA, Boles N, Lin KK, Goodell MA: Mouse hematopoietic stem cell identification and 
analysis. Cytometry Part A : the journal of the International Society for Analytical Cytology 2009, 
75(1):14-24. 
10. Ema H, Morita Y, Nakauchi H, Matsuzaki Y: Isolation of murine hematopoietic stem cells and 
progenitor cells. Current protocols in immunology 2005, Chapter 22:Unit 22B 21. 
11. Bonnet D: Haematopoietic stem cells. The Journal of pathology 2002, 197(4):430-440. 
12. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ et al: Identification 
of the haematopoietic stem cell niche and control of the niche size. Nature 2003, 425(6960):836-
841. 
13. Wilson A, Trumpp A: Bone-marrow haematopoietic-stem-cell niches. Nature reviews Immunology 
2006, 6(2):93-106. 
14. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ: SLAM family receptors 
distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. 
Cell 2005, 121(7):1109-1121. 
15. Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, Sandbank J, Arenzana-Seisdedos F, Magerus 
A, Caruz A, Fujii N et al: Induction of the chemokine stromal-derived factor-1 following DNA 
damage improves human stem cell function. The Journal of clinical investigation 2000, 
106(11):1331-1339. 
16. Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh JH, Hackett NR, Quitoriano MS, Crystal RG, 
Rafii S et al: Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and 
immature hematopoietic progenitor and stem cells. Blood 2001, 97(11):3354-3360. 
17. Tzeng YS, Li H, Kang YL, Chen WC, Cheng WC, Lai DM: Loss of Cxcl12/Sdf-1 in adult mice decreases 
the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of 
hematopoietic regeneration after myelosuppression. Blood 2011, 117(2):429-439. 
18. Nie Y, Han YC, Zou YR: CXCR4 is required for the quiescence of primitive hematopoietic cells. The 
Journal of experimental medicine 2008, 205(4):777-783. 
19. Massberg S, Schaerli P, Knezevic-Maramica I, Kollnberger M, Tubo N, Moseman EA, Huff IV, Junt T, 
Wagers AJ, Mazo IB et al: Immunosurveillance by hematopoietic progenitor cells trafficking 
through blood, lymph, and peripheral tissues. Cell 2007, 131(5):994-1008. 
20. Ratajczak MZ, Lee H, Wysoczynski M, Wan W, Marlicz W, Laughlin MJ, Kucia M, Janowska-Wieczorek 
A, Ratajczak J: Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
186 
chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone 
marrow and its level in peripheral blood increases during mobilization due to activation of 
complement cascade/membrane attack complex. Leukemia 2010, 24(5):976-985. 
21. Bendall LJ, Basnett J: Role of sphingosine 1-phosphate in trafficking and mobilization of 
hematopoietic stem cells. Current opinion in hematology 2013, 20(4):281-288. 
22. Golan K, Kollet O, Lapidot T: Dynamic Cross Talk between S1P and CXCL12 Regulates Hematopoietic 
Stem Cells Migration, Development and Bone Remodeling. Pharmaceuticals 2013, 6(9):1145-1169. 
23. Broudy VC: Stem cell factor and hematopoiesis. Blood 1997, 90(4):1345-1364. 
24. Ashman LK: The biology of stem cell factor and its receptor C-kit. The international journal of 
biochemistry & cell biology 1999, 31(10):1037-1051. 
25. Nervi B, Link DC, DiPersio JF: Cytokines and hematopoietic stem cell mobilization. Journal of cellular 
biochemistry 2006, 99(3):690-705. 
26. Masumoto A, Hemler ME: Multiple activation states of VLA-4. Mechanistic differences between 
adhesion to CS1/fibronectin and to vascular cell adhesion molecule-1. The Journal of biological 
chemistry 1993, 268(1):228-234. 
27. Yednock TA, Cannon C, Vandevert C, Goldbach EG, Shaw G, Ellis DK, Liaw C, Fritz LC, Tanner LI: Alpha 
4 beta 1 integrin-dependent cell adhesion is regulated by a low affinity receptor pool that is 
conformationally responsive to ligand. The Journal of biological chemistry 1995, 270(48):28740-
28750. 
28. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon 
T, Ifrah N et al: A prospective, randomized trial of autologous bone marrow transplantation and 
chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. The New England journal 
of medicine 1996, 335(2):91-97. 
29. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, Medical 
Research Council Adult Leukaemia Working P: High-dose chemotherapy with hematopoietic stem-
cell rescue for multiple myeloma. The New England journal of medicine 2003, 348(19):1875-1883. 
30. Hopman RK, DiPersio JF: Advances in stem cell mobilization. Blood reviews 2014, 28(1):31-40. 
31. Motabi IH, DiPersio JF: Advances in stem cell mobilization. Blood reviews 2012, 26(6):267-278. 
32. Kim SN, Moon JH, Kim JG, Chae YS, Cho YY, Lee SJ, Kim YJ, Lee YJ, Suh JS, Lee KS et al: Mobilization 
effects of G-CSF, GM-CSF, and darbepoetin-alpha for allogeneic peripheral blood stem cell 
transplantation. Journal of clinical apheresis 2009, 24(5):173-179. 
33. Cashen AF, Nervi B, DiPersio J: AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. 
Future oncology 2007, 3(1):19-27. 
34. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, Liles WC, Li X, Graham-Evans 
B, Campbell TB et al: Rapid mobilization of murine and human hematopoietic stem and progenitor 
cells with AMD3100, a CXCR4 antagonist. The Journal of experimental medicine 2005, 201(8):1307-
1318. 
35. Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson 
D, Gleason C et al: Effectiveness and cost analysis of "just-in-time" salvage plerixafor 
administration in autologous transplant patients with poor stem cell mobilization kinetics. 
Transfusion 2011, 51(10):2175-2182. 
36. Vishnu P, Roy V, Paulsen A, Zubair AC: Efficacy and cost-benefit analysis of risk-adaptive use of 
plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012, 52(1):55-
62. 
37. Carlos TM, Harlan JM: Leukocyte-endothelial adhesion molecules. Blood 1994, 84(7):2068-2101. 
38. Herbert KE, Morgan S, Prince HM, Westerman DA, Wolf MM, Carney DA, Yuen K, di Iulio J, Seymour 
JF: Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood 
stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated 
with fludarabine: results of a Phase II study with an historical comparator. Leukemia 2009, 
23(2):305-312. 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
187 
39. Prosper F, Sola C, Hornedo J, Arbona C, Menendez P, Orfao A, Lluch A, Cortes-Funes H, Lopez JJ, 
Garcia-Conde J: Mobilization of peripheral blood progenitor cells with a combination of 
cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated 
with chemotherapy. Leukemia 2003, 17(2):437-441. 
40. Stiff P, Gingrich R, Luger S, Wyres MR, Brown RA, LeMaistre CF, Perry J, Schenkein DP, List A, Mason 
JR et al: A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in 
heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone marrow 
transplantation 2000, 26(5):471-481. 
41. To LB, Bashford J, Durrant S, MacMillan J, Schwarer AP, Prince HM, Gibson J, Lewis I, Swart B, Marty J 
et al: Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell 
factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-
stimulating factor) alone or with chemotherapy plus filgrastim. Bone marrow transplantation 2003, 
31(5):371-378. 
42. Tong J, Gordon MS, Srour EF, Cooper RJ, Orazi A, McNiece I, Hoffman R: In vivo administration of 
recombinant methionyl human stem cell factor expands the number of human marrow 
hematopoietic stem cells. Blood 1993, 82(3):784-791. 
43. Hanel P, Andreani P, Graler MH: Erythrocytes store and release sphingosine 1-phosphate in blood. 
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 
2007, 21(4):1202-1209. 
44. Ohkawa R, Nakamura K, Okubo S, Hosogaya S, Ozaki Y, Tozuka M, Osima N, Yokota H, Ikeda H, 
Yatomi Y: Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation 
with red blood cell parameters. Annals of clinical biochemistry 2008, 45(Pt 4):356-363. 
45. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, 
Cyster JG et al: Promotion of lymphocyte egress into blood and lymph by distinct sources of 
sphingosine-1-phosphate. Science 2007, 316(5822):295-298. 
46. Fukuhara S, Simmons S, Kawamura S, Inoue A, Orba Y, Tokudome T, Sunden Y, Arai Y, Moriwaki K, 
Ishida J et al: The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells 
regulates lymphocyte trafficking in mice. The Journal of clinical investigation 2012, 122(4):1416-
1426. 
47. Hisano Y, Kobayashi N, Yamaguchi A, Nishi T: Mouse SPNS2 functions as a sphingosine-1-phosphate 
transporter in vascular endothelial cells. PloS one 2012, 7(6):e38941. 
48. Venkataraman K, Thangada S, Michaud J, Oo ML, Ai Y, Lee YM, Wu M, Parikh NS, Khan F, Proia RL et 
al: Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. The 
Biochemical journal 2006, 397(3):461-471. 
49. Juarez JG, Harun N, Thien M, Welschinger R, Baraz R, Pena AD, Pitson SM, Rettig M, DiPersio JF, 
Bradstock KF et al: Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and 
their mobilization by CXCR4 antagonists in mice. Blood 2012, 119(3):707-716. 
50. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR: VCAM-1 on activated 
endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-
4/fibronectin binding site. Cell 1990, 60(4):577-584. 
51. Cao B, Zhang Z, Grassinger J, Williams B, Heazlewood CK, Churches QI, James SA, Li S, 
Papayannopoulou T, Nilsson SK: Therapeutic targeting and rapid mobilization of endosteal HSC 
using a small molecule integrin antagonist. Nature communications 2016, 7:11007. 
52. Papayannopoulou T, Nakamoto B: Peripheralization of hemopoietic progenitors in primates treated 
with anti-VLA4 integrin. Proceedings of the National Academy of Sciences of the United States of 
America 1993, 90(20):9374-9378. 
53. Vermeulen M, Le Pesteur F, Gagnerault MC, Mary JY, Sainteny F, Lepault F: Role of adhesion 
molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells. 
Blood 1998, 92(3):894-900. 
54. Bonig H, Watts KL, Chang KH, Kiem HP, Papayannopoulou T: Concurrent blockade of alpha4-integrin 
and CXCR4 in hematopoietic stem/progenitor cell mobilization. Stem cells 2009, 27(4):836-837. 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
188 
55. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R: The monoclonal anti-VLA-4 
antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008, 
111(7):3893-3895. 
56. Ramirez P, Rettig MP, Uy GL, Deych E, Holt MS, Ritchey JK, DiPersio JF: BIO5192, a small molecule 
inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009, 114(7):1340-
1343. 
57. Ohishi M, Schipani E: PTH and stem cells. Journal of endocrinological investigation 2011, 34(7):552-
556. 
58. Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, Dey BR, Attar E, McAfee S, 
Konopleva M et al: Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biology 
of blood and marrow transplantation : journal of the American Society for Blood and Marrow 
Transplantation 2007, 13(7):838-843. 
59. Brunner S, Theiss HD, Murr A, Negele T, Franz WM: Primary hyperparathyroidism is associated with 
increased circulating bone marrow-derived progenitor cells. American journal of physiology 
Endocrinology and metabolism 2007, 293(6):E1670-1675. 
60. Brunner S, Zaruba MM, Huber B, David R, Vallaster M, Assmann G, Mueller-Hoecker J, Franz WM: 
Parathyroid hormone effectively induces mobilization of progenitor cells without depletion of 
bone marrow. Experimental hematology 2008, 36(9):1157-1166. 
61. Niesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M, Stern J, Christos PJ, Mathews L, 
Shore TB et al: Overcoming the response plateau in multiple myeloma: a novel bortezomib-based 
strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clinical cancer 
research : an official journal of the American Association for Cancer Research 2013, 19(6):1534-1546. 
62. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Van Waes C: 
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, 
tumor growth, and angiogenesis in squamous cell carcinoma. Clinical cancer research : an official 
journal of the American Association for Cancer Research 2001, 7(5):1419-1428. 
63. Haskill S, Peace A, Morris J, Sporn SA, Anisowicz A, Lee SW, Smith T, Martin G, Ralph P, Sager R: 
Identification of three related human GRO genes encoding cytokine functions. Proceedings of the 
National Academy of Sciences of the United States of America 1990, 87(19):7732-7736. 
64. King AG, Horowitz D, Dillon SB, Levin R, Farese AM, MacVittie TJ, Pelus LM: Rapid mobilization of 
murine hematopoietic stem cells with enhanced engraftment properties and evaluation of 
hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a 
specific truncated form of the human CXC chemokine GRObeta. Blood 2001, 97(6):1534-1542. 
65. Pelus LM: Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand. 
Current opinion in hematology 2008, 15(4):285-292. 
66. Pelus LM, Fukuda S: Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly 
mobilizes hematopoietic stem cells with enhanced engraftment properties. Experimental 
hematology 2006, 34(8):1010-1020. 
67. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD: Distribution of hematopoietic stem cells in 
the bone marrow according to regional hypoxia. Proceedings of the National Academy of Sciences 
of the United States of America 2007, 104(13):5431-5436. 
68. Winkler IG, Barbier V, Wadley R, Zannettino AC, Williams S, Levesque JP: Positioning of bone 
marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting 
hematopoietic stem cells reside in distinct nonperfused niches. Blood 2010, 116(3):375-385. 
69. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, 
Bondesson M: Hypoxia requires notch signaling to maintain the undifferentiated cell state. 
Developmental cell 2005, 9(5):617-628. 
70. Danet GH, Pan Y, Luongo JL, Bonnet DA, Simon MC: Expansion of human SCID-repopulating cells 
under hypoxic conditions. The Journal of clinical investigation 2003, 112(1):126-135. 
71. Levesque JP, Winkler IG, Hendy J, Williams B, Helwani F, Barbier V, Nowlan B, Nilsson SK: 
Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
189 
transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow. Stem cells 
2007, 25(8):1954-1965. 
72. Forristal CE, Nowlan B, Jacobsen RN, Barbier V, Walkinshaw G, Walkley CR, Winkler IG, Levesque JP: 
HIF-1alpha is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors 
enhance mobilization by stabilizing HIF-1alpha. Leukemia 2015, 29(6):1366-1378. 
73. Suresh M, Gao X, Fischer C, Miller NE, Tewari K: Dissection of antiviral and immune regulatory 
functions of tumor necrosis factor receptors in a chronic lymphocytic choriomeningitis virus 
infection. Journal of virology 2004, 78(8):3906-3918. 
74. Durbin JE, Fernandez-Sesma A, Lee CK, Rao TD, Frey AB, Moran TM, Vukmanovic S, Garcia-Sastre A, 
Levy DE: Type I IFN modulates innate and specific antiviral immunity. Journal of immunology 2000, 
164(8):4220-4228. 
75. Jacoby RO, Bhatt PN, Brownstein DG: Evidence that NK cells and interferon are required for genetic 
resistance to lethal infection with ectromelia virus. Archives of virology 1989, 108(1-2):49-58. 
76. Gherardi MM, Ramirez JC, Esteban M: IL-12 and IL-18 act in synergy to clear vaccinia virus infection: 
involvement of innate and adaptive components of the immune system. The Journal of general 
virology 2003, 84(Pt 8):1961-1972. 
77. Pien GC, Satoskar AR, Takeda K, Akira S, Biron CA: Cutting edge: selective IL-18 requirements for 
induction of compartmental IFN-gamma responses during viral infection. Journal of immunology 
2000, 165(9):4787-4791. 
78. Klose CS, Artis D: Innate lymphoid cells as regulators of immunity, inflammation and tissue 
homeostasis. Nature immunology 2016, 17(7):765-774. 
79. Liu KD, Gaffen SL, Goldsmith MA: JAK/STAT signaling by cytokine receptors. Current opinion in 
immunology 1998, 10(3):271-278. 
80. O'Garra A, Vieira P: Regulatory T cells and mechanisms of immune system control. Nature medicine 
2004, 10(8):801-805. 
81. Shevach EM: CD4+ CD25+ suppressor T cells: more questions than answers. Nature reviews 
Immunology 2002, 2(6):389-400. 
82. Shinoda K, Tokoyoda K, Hanazawa A, Hayashizaki K, Zehentmeier S, Hosokawa H, Iwamura C, Koseki 
H, Tumes DJ, Radbruch A et al: Type II membrane protein CD69 regulates the formation of resting 
T-helper memory. Proceedings of the National Academy of Sciences of the United States of America 
2012, 109(19):7409-7414. 
83. Bromley SK, Yan S, Tomura M, Kanagawa O, Luster AD: Recirculating memory T cells are a unique 
subset of CD4+ T cells with a distinct phenotype and migratory pattern. Journal of immunology 
2013, 190(3):970-976. 
84. Ziegler SF, Ramsdell F, Hjerrild KA, Armitage RJ, Grabstein KH, Hennen KB, Farrah T, Fanslow WC, 
Shevach EM, Alderson MR: Molecular characterization of the early activation antigen CD69: a type 
II membrane glycoprotein related to a family of natural killer cell activation antigens. European 
journal of immunology 1993, 23(7):1643-1648. 
85. Hamann J, Fiebig H, Strauss M: Expression cloning of the early activation antigen CD69, a type II 
integral membrane protein with a C-type lectin domain. Journal of immunology 1993, 
150(11):4920-4927. 
86. Lopez-Cabrera M, Santis AG, Fernandez-Ruiz E, Blacher R, Esch F, Sanchez-Mateos P, Sanchez-Madrid 
F: Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte 
activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-
transmitting receptors. The Journal of experimental medicine 1993, 178(2):537-547. 
87. Hara T, Jung LK, Bjorndahl JM, Fu SM: Human T cell activation. III. Rapid induction of a 
phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl 
phorbol-13-acetate, mitogens, and antigens. The Journal of experimental medicine 1986, 
164(6):1988-2005. 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
190 
88. Cosulich ME, Rubartelli A, Risso A, Cozzolino F, Bargellesi A: Functional characterization of an 
antigen involved in an early step of T-cell activation. Proceedings of the National Academy of 
Sciences of the United States of America 1987, 84(12):4205-4209. 
89. Gerosa F, Scardoni M, Tommasi M, Benati C, Snelli L, Gandini G, Libonati M, Tridente G, Carra G: 
Interferon alpha induces expression of the CD69 activation antigen in human resting NK cells, 
while interferon gamma and tumor necrosis factor alpha are ineffective. International journal of 
cancer 1991, 48(3):473-475. 
90. Sanchez-Mateos P, Sanchez-Madrid F: Structure-function relationship and immunochemical 
mapping of external and intracellular antigenic sites on the lymphocyte activation inducer 
molecule, AIM/CD69. European journal of immunology 1991, 21(10):2317-2325. 
91. Testi R, D'Ambrosio D, De Maria R, Santoni A: The CD69 receptor: a multipurpose cell-surface 
trigger for hematopoietic cells. Immunology today 1994, 15(10):479-483. 
92. Lopez-Cabrera M, Munoz E, Blazquez MV, Ursa MA, Santis AG, Sanchez-Madrid F: Transcriptional 
regulation of the gene encoding the human C-type lectin leukocyte receptor AIM/CD69 and 
functional characterization of its tumor necrosis factor-alpha-responsive elements. The Journal of 
biological chemistry 1995, 270(37):21545-21551. 
93. Ziegler SF, Levin SD, Johnson L, Copeland NG, Gilbert DJ, Jenkins NA, Baker E, Sutherland GR, 
Feldhaus AL, Ramsdell F: The mouse CD69 gene. Structure, expression, and mapping to the NK 
gene complex. Journal of immunology 1994, 152(3):1228-1236. 
94. Cebrian M, Redondo JM, Lopez-Rivas A, Rodriguez-Tarduchy G, De Landazuri MO, Sanchez-Madrid F: 
Expression and function of AIM, an activation inducer molecule of human lymphocytes, is 
dependent on the activation of protein kinase C. European journal of immunology 1989, 19(5):809-
815. 
95. Santis AG, Lopez-Cabrera M, Sanchez-Madrid F, Proudfoot N: Expression of the early lymphocyte 
activation antigen CD69, a C-type lectin, is regulated by mRNA degradation associated with AU-
rich sequence motifs. European journal of immunology 1995, 25(8):2142-2146. 
96. Vazquez BN, Laguna T, Carabana J, Krangel MS, Lauzurica P: CD69 gene is differentially regulated in 
T and B cells by evolutionarily conserved promoter-distal elements. Journal of immunology 2009, 
183(10):6513-6521. 
97. Castellanos MC, Munoz C, Montoya MC, Lara-Pezzi E, Lopez-Cabrera M, de Landazuri MO: 
Expression of the leukocyte early activation antigen CD69 is regulated by the transcription factor 
AP-1. Journal of immunology 1997, 159(11):5463-5473. 
98. Castellanos Mdel C, Lopez-Giral S, Lopez-Cabrera M, de Landazuri MO: Multiple cis-acting elements 
regulate the expression of the early T cell activation antigen CD69. European journal of 
immunology 2002, 32(11):3108-3117. 
99. Vazquez BN, Laguna T, Notario L, Lauzurica P: Evidence for an intronic cis-regulatory element within 
CD69 gene. Genes and immunity 2012, 13(4):356-362. 
100. Sancho D, Gomez M, Sanchez-Madrid F: CD69 is an immunoregulatory molecule induced following 
activation. Trends in immunology 2005, 26(3):136-140. 
101. De Maria R, Cifone MG, Trotta R, Rippo MR, Festuccia C, Santoni A, Testi R: Triggering of human 
monocyte activation through CD69, a member of the natural killer cell gene complex family of 
signal transducing receptors. The Journal of experimental medicine 1994, 180(5):1999-2004. 
102. Gao Y, Majchrzak-Kita B, Fish EN, Gommerman JL: Dynamic accumulation of plasmacytoid dendritic 
cells in lymph nodes is regulated by interferon-beta. Blood 2009, 114(13):2623-2631. 
103. Testi R, Pulcinelli F, Frati L, Gazzaniga PP, Santoni A: CD69 is expressed on platelets and mediates 
platelet activation and aggregation. The Journal of experimental medicine 1990, 172(3):701-707. 
104. Alari-Pahissa E, Vega-Ramos J, Zhang JG, Castano AR, Turley SJ, Villadangos JA, Lauzurica P: 
Differential effect of CD69 targeting on bystander and antigen-specific T cell proliferation. Journal 
of leukocyte biology 2012, 92(1):145-158. 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
191 
105. Lauzurica P, Sancho D, Torres M, Albella B, Marazuela M, Merino T, Bueren JA, Martinez AC, 
Sanchez-Madrid F: Phenotypic and functional characteristics of hematopoietic cell lineages in 
CD69-deficient mice. Blood 2000, 95(7):2312-2320. 
106. Mackay LK, Minnich M, Kragten NA, Liao Y, Nota B, Seillet C, Zaid A, Man K, Preston S, Freestone D et 
al: Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in 
lymphocytes. Science 2016, 352(6284):459-463. 
107. Marzio R, Jirillo E, Ransijn A, Mauel J, Corradin SB: Expression and function of the early activation 
antigen CD69 in murine macrophages. Journal of leukocyte biology 1997, 62(3):349-355. 
108. Shiow LR, Rosen DB, Brdickova N, Xu Y, An J, Lanier LL, Cyster JG, Matloubian M: CD69 acts 
downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid 
organs. Nature 2006, 440(7083):540-544. 
109. Testi R, Phillips JH, Lanier LL: T cell activation via Leu-23 (CD69). Journal of immunology 1989, 
143(4):1123-1128. 
110. Hartnell A, Robinson DS, Kay AB, Wardlaw AJ: CD69 is expressed by human eosinophils activated in 
vivo in asthma and in vitro by cytokines. Immunology 1993, 80(2):281-286. 
111. Laffon A, Garcia-Vicuna R, Humbria A, Postigo AA, Corbi AL, de Landazuri MO, Sanchez-Madrid F: 
Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in 
rheumatoid arthritis. The Journal of clinical investigation 1991, 88(2):546-552. 
112. Garcia-Monzon C, Moreno-Otero R, Pajares JM, Garcia-Sanchez A, Lopez-Botet M, de Landazuri MO, 
Sanchez-Madrid F: Expression of a novel activation antigen on intrahepatic CD8+ T lymphocytes in 
viral chronic active hepatitis. Gastroenterology 1990, 98(4):1029-1035. 
113. Van den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorevits L, Van Damme B, Ceuppens JL: 
Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T 
lymphocytes in human renal cell carcinoma. Clinical and experimental immunology 1997, 
109(3):501-509. 
114. D'Arena G, Musto P, Nunziata G, Cascavilla N, Savino L, Pistolese G: CD69 expression in B-cell 
chronic lymphocytic leukemia: a new prognostic marker ? Haematologica 2001, 86(9):995-996. 
115. Villalba M, Hernandez J, Deckert M, Tanaka Y, Altman A: Vav modulation of the Ras/MEK/ERK 
signaling pathway plays a role in NFAT activation and CD69 up-regulation. European journal of 
immunology 2000, 30(6):1587-1596. 
116. Bjorndahl JM, Nakamura S, Hara T, Jung LK, Fu SM: The 28-kDa/32-kDa activation antigen EA 1. 
Further characterization and signal requirements for its expression. Journal of immunology 1988, 
141(12):4094-4100. 
117. Imboden JB, Shoback DM, Pattison G, Stobo JD: Cholera toxin inhibits the T-cell antigen receptor-
mediated increases in inositol trisphosphate and cytoplasmic free calcium. Proceedings of the 
National Academy of Sciences of the United States of America 1986, 83(15):5673-5677. 
118. Aussel C, Mary D, Peyron JF, Pelassy C, Ferrua B, Fehlmann M: Inhibition and activation of 
interleukin 2 synthesis by direct modification of guanosine triphosphate-binding proteins. Journal 
of immunology 1988, 140(1):215-220. 
119. D'Ambrosio D, Cantrell DA, Frati L, Santoni A, Testi R: Involvement of p21ras activation in T cell 
CD69 expression. European journal of immunology 1994, 24(3):616-620. 
120. Tugores A, Alonso MA, Sanchez-Madrid F, de Landazuri MO: Human T cell activation through the 
activation-inducer molecule/CD69 enhances the activity of transcription factor AP-1. Journal of 
immunology 1992, 148(7):2300-2306. 
121. Seger R, Krebs EG: The MAPK signaling cascade. FASEB journal : official publication of the Federation 
of American Societies for Experimental Biology 1995, 9(9):726-735. 
122. Milella M, Gismondi A, Roncaioli P, Bisogno L, Palmieri G, Frati L, Cifone MG, Santoni A: CD16 cross-
linking induces both secretory and extracellular signal-regulated kinase (ERK)-dependent cytosolic 
phospholipase A2 (PLA2) activity in human natural killer cells: involvement of ERK, but not PLA2, 
in CD16-triggered granule exocytosis. Journal of immunology 1997, 158(7):3148-3154. 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
192 
123. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ: cPLA2 is phosphorylated and activated by 
MAP kinase. Cell 1993, 72(2):269-278. 
124. Santini F, Beaven MA: Tyrosine phosphorylation of a mitogen-activated protein kinase-like protein 
occurs at a late step in exocytosis. Studies with tyrosine phosphatase inhibitors and various 
secretagogues in rat RBL-2H3 cells. The Journal of biological chemistry 1993, 268(30):22716-22722. 
125. Offermanns S, Jones SV, Bombien E, Schultz G: Stimulation of mitogen-activated protein kinase 
activity by different secretory stimuli in rat basophilic leukemia cells. Journal of immunology 1994, 
152(1):250-261. 
126. Han Y, Guo Q, Zhang M, Chen Z, Cao X: CD69+ CD4+ CD25- T cells, a new subset of regulatory T 
cells, suppress T cell proliferation through membrane-bound TGF-beta 1. Journal of immunology 
2009, 182(1):111-120. 
127. Pisegna S, Zingoni A, Pirozzi G, Cinque B, Cifone MG, Morrone S, Piccoli M, Frati L, Palmieri G, 
Santoni A: Src-dependent Syk activation controls CD69-mediated signaling and function on human 
NK cells. Journal of immunology 2002, 169(1):68-74. 
128. Martin P, Gomez M, Lamana A, Cruz-Adalia A, Ramirez-Huesca M, Ursa MA, Yanez-Mo M, Sanchez-
Madrid F: CD69 association with Jak3/Stat5 proteins regulates Th17 cell differentiation. Molecular 
and cellular biology 2010, 30(20):4877-4889. 
129. Cortes JR, Sanchez-Diaz R, Bovolenta ER, Barreiro O, Lasarte S, Matesanz-Marin A, Toribio ML, 
Sanchez-Madrid F, Martin P: Maintenance of immune tolerance by Foxp3+ regulatory T cells 
requires CD69 expression. Journal of autoimmunity 2014, 55:51-62. 
130. Sanchez-Diaz R, Blanco-Dominguez R, Lasarte S, Tsilingiri K, Martin-Gayo E, Linillos-Pradillo B, de la 
Fuente H, Sanchez-Madrid F, Nakagawa R, Toribio ML et al: Thymus-derived Treg cell development 
is regulated by C-type-lectin-mediated BIC/miRNA155 expression. Molecular and cellular biology 
2017. 
131. Cibrian D, Saiz ML, de la Fuente H, Sanchez-Diaz R, Moreno-Gonzalo O, Jorge I, Ferrarini A, Vazquez J, 
Punzon C, Fresno M et al: CD69 controls the uptake of L-tryptophan through LAT1-CD98 and AhR-
dependent secretion of IL-22 in psoriasis. Nature immunology 2016, 17(8):985-996. 
132. Cyster JG, Schwab SR: Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. 
Annu Rev Immunol 2012, 30:69-94. 
133. Santis AG, Campanero MR, Alonso JL, Tugores A, Alonso MA, Yague E, Pivel JP, Sanchez-Madrid F: 
Tumor necrosis factor-alpha production induced in T lymphocytes through the AIM/CD69 
activation pathway. European journal of immunology 1992, 22(5):1253-1259. 
134. Conde M, Montano R, Moreno-Aurioles VR, Ramirez R, Sanchez-Mateos P, Sanchez-Madrid F, 
Sobrino F: Anti-CD69 antibodies enhance phorbol-dependent glucose metabolism and Ca2+ levels 
in human thymocytes. Antagonist effect of cyclosporin A. Journal of leukocyte biology 1996, 
60(2):278-284. 
135. Sancho D, Santis AG, Alonso-Lebrero JL, Viedma F, Tejedor R, Sanchez-Madrid F: Functional analysis 
of ligand-binding and signal transduction domains of CD69 and CD23 C-type lectin leukocyte 
receptors. Journal of immunology 2000, 165(7):3868-3875. 
136. Cebrian M, Yague E, Rincon M, Lopez-Botet M, de Landazuri MO, Sanchez-Madrid F: Triggering of T 
cell proliferation through AIM, an activation inducer molecule expressed on activated human 
lymphocytes. The Journal of experimental medicine 1988, 168(5):1621-1637. 
137. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY: Interleukin-15 mediates T cell-dependent 
regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nature medicine 
1997, 3(2):189-195. 
138. Ramirez R, Carracedo J, Castedo M, Zamzami N, Kroemer G: CD69-induced monocyte apoptosis 
involves multiple nonredundant signaling pathways. Cellular immunology 1996, 172(2):192-199. 
139. Walsh GM, Williamson ML, Symon FA, Willars GB, Wardlaw AJ: Ligation of CD69 induces apoptosis 
and cell death in human eosinophils cultured with granulocyte-macrophage colony-stimulating 
factor. Blood 1996, 87(7):2815-2821. 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
193 
140. Nakayama T, Kasprowicz DJ, Yamashita M, Schubert LA, Gillard G, Kimura M, Didierlaurent A, Koseki 
H, Ziegler SF: The generation of mature, single-positive thymocytes in vivo is dysregulated by CD69 
blockade or overexpression. Journal of immunology 2002, 168(1):87-94. 
141. Vega-Ramos J, Alari-Pahissa E, Valle JD, Carrasco-Marin E, Esplugues E, Borras M, Martinez AC, 
Lauzurica P: CD69 limits early inflammatory diseases associated with immune response to Listeria 
monocytogenes infection. Immunol Cell Biol 2010, 88(7):707-715. 
142. Sancho D, Gomez M, Viedma F, Esplugues E, Gordon-Alonso M, Garcia-Lopez MA, de la Fuente H, 
Martinez AC, Lauzurica P, Sanchez-Madrid F: CD69 downregulates autoimmune reactivity through 
active transforming growth factor-beta production in collagen-induced arthritis. The Journal of 
clinical investigation 2003, 112(6):872-882. 
143. Lamana A, Sancho D, Cruz-Adalia A, del Hoyo GM, Herrera AM, Feria M, Diaz-Gonzalez F, Gomez M, 
Sanchez-Madrid F: The role of CD69 in acute neutrophil-mediated inflammation. European journal 
of immunology 2006, 36(10):2632-2638. 
144. Murata K, Inami M, Hasegawa A, Kubo S, Kimura M, Yamashita M, Hosokawa H, Nagao T, Suzuki K, 
Hashimoto K et al: CD69-null mice protected from arthritis induced with anti-type II collagen 
antibodies. International immunology 2003, 15(8):987-992. 
145. Gomez M, Sanz-Gonzalez SM, Abu Nabah YN, Lamana A, Sanchez-Madrid F, Andres V: 
Atherosclerosis development in apolipoprotein E-null mice deficient for CD69. Cardiovascular 
research 2009, 81(1):197-205. 
146. Martin P, Sanchez-Madrid F: CD69: an unexpected regulator of TH17 cell-driven inflammatory 
responses. Science signaling 2011, 4(165):pe14. 
147. Martin P, Gomez M, Lamana A, Matesanz Marin A, Cortes JR, Ramirez-Huesca M, Barreiro O, Lopez-
Romero P, Gutierrez-Vazquez C, de la Fuente H et al: The leukocyte activation antigen CD69 limits 
allergic asthma and skin contact hypersensitivity. The Journal of allergy and clinical immunology 
2010, 126(2):355-365, 365 e351-353. 
148. Miki-Hosokawa T, Hasegawa A, Iwamura C, Shinoda K, Tofukuji S, Watanabe Y, Hosokawa H, 
Motohashi S, Hashimoto K, Shirai M et al: CD69 controls the pathogenesis of allergic airway 
inflammation. Journal of immunology 2009, 183(12):8203-8215. 
149. Cruz-Adalia A, Jimenez-Borreguero LJ, Ramirez-Huesca M, Chico-Calero I, Barreiro O, Lopez-Conesa 
E, Fresno M, Sanchez-Madrid F, Martin P: CD69 limits the severity of cardiomyopathy after 
autoimmune myocarditis. Circulation 2010, 122(14):1396-1404. 
150. Lamana A, Martin P, de la Fuente H, Martinez-Munoz L, Cruz-Adalia A, Ramirez-Huesca M, Escribano 
C, Gollmer K, Mellado M, Stein JV et al: CD69 modulates sphingosine-1-phosphate-induced 
migration of skin dendritic cells. The Journal of investigative dermatology 2011, 131(7):1503-1512. 
151. Liappas G, Gonzalez-Mateo GT, Sanchez-Diaz R, Lazcano JJ, Lasarte S, Matesanz-Marin A, Zur R, 
Ferrantelli E, Ramirez LG, Aguilera A et al: Immune-Regulatory Molecule CD69 Controls Peritoneal 
Fibrosis. Journal of the American Society of Nephrology : JASN 2016, 27(12):3561-3576. 
152. Hasegawa A, Iwamura C, Kitajima M, Hashimoto K, Otsuyama K, Ogino H, Nakayama T, Shirai M: 
Crucial role for CD69 in the pathogenesis of dextran sulphate sodium-induced colitis. PloS one 
2013, 8(6):e65494. 
153. Radulovic K, Manta C, Rossini V, Holzmann K, Kestler HA, Wegenka UM, Nakayama T, Niess JH: CD69 
regulates type I IFN-induced tolerogenic signals to mucosal CD4 T cells that attenuate their 
colitogenic potential. Journal of immunology 2012, 188(4):2001-2013. 
154. Zhao Q, Kuang DM, Wu Y, Xiao X, Li XF, Li TJ, Zheng L: Activated CD69+ T cells foster immune 
privilege by regulating IDO expression in tumor-associated macrophages. Journal of immunology 
2012, 188(3):1117-1124. 
155. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K: Persistent signaling induced by 
FTY720-phosphate is mediated by internalized S1P1 receptors. Nature chemical biology 2009, 
5(6):428-434. 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
194 
156. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, 
Keohane C et al: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor 
agonists. Science 2002, 296(5566):346-349. 
157. Bankovich AJ, Shiow LR, Cyster JG: CD69 suppresses sphingosine 1-phosophate receptor-1 (S1P1) 
function through interaction with membrane helix 4. The Journal of biological chemistry 2010, 
285(29):22328-22337. 
158. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG: 
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. 
Nature 2004, 427(6972):355-360. 
159. Allende ML, Zhou D, Kalkofen DN, Benhamed S, Tuymetova G, Borowski C, Bendelac A, Proia RL: 
S1P1 receptor expression regulates emergence of NKT cells in peripheral tissues. FASEB journal : 
official publication of the Federation of American Societies for Experimental Biology 2008, 22(1):307-
315. 
160. Cinamon G, Matloubian M, Lesneski MJ, Xu Y, Low C, Lu T, Proia RL, Cyster JG: Sphingosine 1-
phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nature immunology 
2004, 5(7):713-720. 
161. Feng C, Woodside KJ, Vance BA, El-Khoury D, Canelles M, Lee J, Gress R, Fowlkes BJ, Shores EW, Love 
PE: A potential role for CD69 in thymocyte emigration. International immunology 2002, 14(6):535-
544. 
162. Pereira JP, Xu Y, Cyster JG: A role for S1P and S1P1 in immature-B cell egress from mouse bone 
marrow. PloS one 2010, 5(2):e9277. 
163. Allende ML, Tuymetova G, Lee BG, Bonifacino E, Wu YP, Proia RL: S1P1 receptor directs the release 
of immature B cells from bone marrow into blood. The Journal of experimental medicine 2010, 
207(5):1113-1124. 
164. Kabashima K, Haynes NM, Xu Y, Nutt SL, Allende ML, Proia RL, Cyster JG: Plasma cell S1P1 
expression determines secondary lymphoid organ retention versus bone marrow tropism. The 
Journal of experimental medicine 2006, 203(12):2683-2690. 
165. Liu G, Burns S, Huang G, Boyd K, Proia RL, Flavell RA, Chi H: The receptor S1P1 overrides regulatory T 
cell-mediated immune suppression through Akt-mTOR. Nature immunology 2009, 10(7):769-777. 
166. Jenne CN, Enders A, Rivera R, Watson SR, Bankovich AJ, Pereira JP, Xu Y, Roots CM, Beilke JN, 
Banerjee A et al: T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes 
and bone marrow. The Journal of experimental medicine 2009, 206(11):2469-2481. 
167. Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon ML, Vega-Ramos J, Lauzurica P, Mueller 
SN, Stefanovic T et al: The developmental pathway for CD103(+)CD8+ tissue-resident memory T 
cells of skin. Nature immunology 2013, 14(12):1294-1301. 
168. Takamura S, Yagi H, Hakata Y, Motozono C, McMaster SR, Masumoto T, Fujisawa M, Chikaishi T, 
Komeda J, Itoh J et al: Specific niches for lung-resident memory CD8+ T cells at the site of tissue 
regeneration enable CD69-independent maintenance. The Journal of experimental medicine 2016, 
213(13):3057-3073. 
169. Park SL, Mackay LK, Gebhardt T: Distinct recirculation potential of CD69+CD103- and CD103+ 
thymic memory CD8+ T cells. Immunology and cell biology 2016, 94(10):975-980. 
170. Masopust D, Vezys V, Wherry EJ, Barber DL, Ahmed R: Cutting edge: gut microenvironment 
promotes differentiation of a unique memory CD8 T cell population. Journal of immunology 2006, 
176(4):2079-2083. 
171. Mackay LK, Braun A, Macleod BL, Collins N, Tebartz C, Bedoui S, Carbone FR, Gebhardt T: Cutting 
edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T 
cell retention. Journal of immunology 2015, 194(5):2059-2063. 
172. Esplugues E, Vega-Ramos J, Cartoixa D, Vazquez BN, Salaet I, Engel P, Lauzurica P: Induction of 
tumor NK-cell immunity by anti-CD69 antibody therapy. Blood 2005, 105(11):4399-4406. 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
195 
173. Sancho D, Gomez M, Martinez Del Hoyo G, Lamana A, Esplugues E, Lauzurica P, Martinez AC, 
Sanchez-Madrid F: CD69 targeting differentially affects the course of collagen-induced arthritis. 
Journal of leukocyte biology 2006, 80(6):1233-1241. 
174. Wang HY, Shen HH, Lee JJ, Lee NA: CD69 expression on airway eosinophils and airway 
inflammation in a murine model of asthma. Chinese medical journal 2006, 119(23):1983-1990. 
175. de la Fuente H, Cruz-Adalia A, Martinez Del Hoyo G, Cibrian-Vera D, Bonay P, Perez-Hernandez D, 
Vazquez J, Navarro P, Gutierrez-Gallego R, Ramirez-Huesca M et al: The leukocyte activation 
receptor CD69 controls T cell differentiation through its interaction with galectin-1. Molecular and 
cellular biology 2014, 34(13):2479-2487. 
176. Rabinovich GA, Toscano MA, Jackson SS, Vasta GR: Functions of cell surface galectin-glycoprotein 
lattices. Current opinion in structural biology 2007, 17(5):513-520. 
177. Shan M, Gentile M, Yeiser JR, Walland AC, Bornstein VU, Chen K, He B, Cassis L, Bigas A, Cols M et al: 
Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. 
Science 2013, 342(6157):447-453. 
178. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, 
Hughes C, Kasai K et al: Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994, 
76(4):597-598. 
179. Lanier LL, Buck DW, Rhodes L, Ding A, Evans E, Barney C, Phillips JH: Interleukin 2 activation of 
natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation 
antigen. The Journal of experimental medicine 1988, 167(5):1572-1585. 
180. Battig P, Saudan P, Gunde T, Bachmann MF: Enhanced apoptotic activity of a structurally optimized 
form of galectin-1. Molecular immunology 2004, 41(1):9-18. 
181. Lin CR, Wei TY, Tsai HY, Wu YT, Wu PY, Chen ST: Glycosylation-dependent interaction between 
CD69 and S100A8/S100A9 complex is required for regulatory T-cell differentiation. FASEB journal : 
official publication of the Federation of American Societies for Experimental Biology 2015, 
29(12):5006-5017. 
182. Grigorova IL, Schwab SR, Phan TG, Pham TH, Okada T, Cyster JG: Cortical sinus probing, S1P1-
dependent entry and flow-based capture of egressing T cells. Nature immunology 2009, 10(1):58-
65. 
183. Bezouska K, Nepovim A, Horvath O, Pospisil M, Hamann J, Feizi T: CD 69 antigen of human 
lymphocytes is a calcium-dependent carbohydrate-binding protein. Biochemical and biophysical 
research communications 1995, 208(1):68-74. 
184. Vance BA, Harley PH, Backlund PS, Ward Y, Phelps TL, Gress RE: Human CD69 associates with an N-
terminal fragment of calreticulin at the cell surface. Archives of biochemistry and biophysics 2005, 
438(1):11-20. 
185. Moss B: Regulation of vaccinia virus transcription. Annual review of biochemistry 1990, 59:661-688. 
186. Moss B: Poxvirus DNA replication. Cold Spring Harbor perspectives in biology 2013, 5(9). 
187. Hruby DE, Guarino LA, Kates JR: Vaccinia virus replication. I. Requirement for the host-cell nucleus. 
Journal of virology 1979, 29(2):705-715. 
188. Burshtyn DN: NK cells and poxvirus infection. Frontiers in immunology 2013, 4:7. 
189. Xu R, Johnson AJ, Liggitt D, Bevan MJ: Cellular and humoral immunity against vaccinia virus 
infection of mice. Journal of immunology 2004, 172(10):6265-6271. 
190. Payne LG: Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of 
vaccinia. The Journal of general virology 1980, 50(1):89-100. 
191. Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL: Extracellular enveloped vaccinia 
virus is resistant to complement because of incorporation of host complement control proteins 
into its envelope. Proceedings of the National Academy of Sciences of the United States of America 
1998, 95(13):7544-7549. 
192. Appleyard G, Hapel AJ, Boulter EA: An antigenic difference between intracellular and extracellular 
rabbitpox virus. The Journal of general virology 1971, 13(1):9-17. 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
196 
193. Ichihashi Y, Matsumoto S, Dales S: Biogenesis of poxviruses: role of A-type inclusions and host cell 
membranes in virus dissemination. Virology 1971, 46(3):507-532. 
194. Vanderplasschen A, Hollinshead M, Smith GL: Antibodies against vaccinia virus do not neutralize 
extracellular enveloped virus but prevent virus release from infected cells and comet formation. 
The Journal of general virology 1997, 78 ( Pt 8):2041-2048. 
195. Ichihashi Y: Extracellular enveloped vaccinia virus escapes neutralization. Virology 1996, 
217(2):478-485. 
196. Mackett M, Smith GL, Moss B: Vaccinia virus: a selectable eukaryotic cloning and expression vector. 
Proceedings of the National Academy of Sciences of the United States of America 1982, 79(23):7415-
7419. 
197. Panicali D, Paoletti E: Construction of poxviruses as cloning vectors: insertion of the thymidine 
kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proceedings of the 
National Academy of Sciences of the United States of America 1982, 79(16):4927-4931. 
198. Franke CA, Hruby DE: Expression of recombinant vaccinia virus-derived alphavirus proteins in 
mosquito cells. The Journal of general virology 1985, 66 ( Pt 12):2761-2765. 
199. Good MF, Maloy WL, Lunde MN, Margalit H, Cornette JL, Smith GL, Moss B, Miller LH, Berzofsky JA: 
Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite 
protein. Science 1987, 235(4792):1059-1062. 
200. Jones L, Ristow S, Yilma T, Moss B: Accidental human vaccination with vaccinia virus expressing 
nucleoprotein gene. Nature 1986, 319(6054):543. 
201. Mackett M, Yilma T, Rose JK, Moss B: Vaccinia virus recombinants: expression of VSV genes and 
protective immunization of mice and cattle. Science 1985, 227(4685):433-435. 
202. Garcia F, Bernaldo de Quiros JC, Gomez CE, Perdiguero B, Najera JL, Jimenez V, Garcia-Arriaza J, 
Guardo AC, Perez I, Diaz-Brito V et al: Safety and immunogenicity of a modified pox vector-based 
HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) 
in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine 2011, 
29(46):8309-8316. 
203. Cavenaugh JS, Awi D, Mendy M, Hill AV, Whittle H, McConkey SJ: Partially randomized, non-blinded 
trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic 
HBV infection. PloS one 2011, 6(2):e14626. 
204. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, 
Fletcher HA et al: Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic 
influenza A vaccine, MVA-NP+M1. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America 2011, 52(1):1-7. 
205. Langford CJ, Edwards SJ, Smith GL, Mitchell GF, Moss B, Kemp DJ, Anders RF: Anchoring a secreted 
plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its 
immunogenicity. Molecular and cellular biology 1986, 6(9):3191-3199. 
206. Bejon P, Ogada E, Mwangi T, Milligan P, Lang T, Fegan G, Gilbert SC, Peshu N, Marsh K, Hill AV: 
Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 
ME-TRAP and MVA ME-TRAP among children in Kenya. PloS one 2007, 2(8):e707. 
207. Wakamiya N, Wang YL, Imai H, Gu HX, Ueda S, Kato S: Feasibility of UV-inactivated vaccinia virus in 
the modification of tumor cells for augmentation of their immunogenicity. Cancer immunology, 
immunotherapy : CII 1986, 23(2):125-129. 
208. Moulton EA, Atkinson JP, Buller RM: Surviving mousepox infection requires the complement 
system. PLoS pathogens 2008, 4(12):e1000249. 
209. Rivera R, Hutchens M, Luker KE, Sonstein J, Curtis JL, Luker GD: Murine alveolar macrophages limit 
replication of vaccinia virus. Virology 2007, 363(1):48-58. 
210. Moraes TJ, Zurawska JH, Downey GP: Neutrophil granule contents in the pathogenesis of lung 
injury. Current opinion in hematology 2006, 13(1):21-27. 
211. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. 
Nature reviews Immunology 2009, 9(3):162-174. 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
197 
212. Fortin C, Huang X, Yang Y: NK cell response to vaccinia virus is regulated by myeloid-derived 
suppressor cells. Journal of immunology 2012, 189(4):1843-1849. 
213. Shen X, Wong SB, Buck CB, Zhang J, Siliciano RF: Direct priming and cross-priming contribute 
differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. 
Journal of immunology 2002, 169(8):4222-4229. 
214. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A: Vaccinia virus immune evasion. 
Immunological reviews 1997, 159:137-154. 
215. Haig D, McInnes C, Deane D, Lear A, Myatt N, Reid H, Rothel J, Seow HF, Wood P, Lyttle D et al: 
Cytokines and their inhibitors in orf virus infection. Veterinary immunology and immunopathology 
1996, 54(1-4):261-267. 
216. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J: Type I IFNs enhance the terminal 
differentiation of dendritic cells. Journal of immunology 1998, 161(4):1947-1953. 
217. Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N: A monocyte conditioned medium is more 
effective than defined cytokines in mediating the terminal maturation of human dendritic cells. 
Blood 1997, 90(9):3640-3646. 
218. Winzler C, Rovere P, Rescigno M, Granucci F, Penna G, Adorini L, Zimmermann VS, Davoust J, 
Ricciardi-Castagnoli P: Maturation stages of mouse dendritic cells in growth factor-dependent long-
term cultures. The Journal of experimental medicine 1997, 185(2):317-328. 
219. Martinez J, Huang X, Yang Y: Direct action of type I IFN on NK cells is required for their activation in 
response to vaccinia viral infection in vivo. Journal of immunology 2008, 180(3):1592-1597. 
220. Lanier LL: NK cell recognition. Annual review of immunology 2005, 23:225-274. 
221. Martinez J, Huang X, Yang Y: Direct TLR2 signaling is critical for NK cell activation and function in 
response to vaccinia viral infection. PLoS pathogens 2010, 6(3):e1000811. 
222. Zhu J, Martinez J, Huang X, Yang Y: Innate immunity against vaccinia virus is mediated by TLR2 and 
requires TLR-independent production of IFN-beta. Blood 2007, 109(2):619-625. 
223. Fortin C, Huang X, Yang Y: Both NK cell-intrinsic and -extrinsic STAT1 signaling are required for NK 
cell response against vaccinia virus. Journal of immunology 2013, 191(1):363-368. 
224. Parker AK, Parker S, Yokoyama WM, Corbett JA, Buller RM: Induction of natural killer cell responses 
by ectromelia virus controls infection. Journal of virology 2007, 81(8):4070-4079. 
225. Kohonen-Corish MR, King NJ, Woodhams CE, Ramshaw IA: Immunodeficient mice recover from 
infection with vaccinia virus expressing interferon-gamma. European journal of immunology 1990, 
20(1):157-161. 
226. van den Broek MF, Muller U, Huang S, Aguet M, Zinkernagel RM: Antiviral defense in mice lacking 
both alpha/beta and gamma interferon receptors. Journal of virology 1995, 69(8):4792-4796. 
227. Bartlett NW, Buttigieg K, Kotenko SV, Smith GL: Murine interferon lambdas (type III interferons) 
exhibit potent antiviral activity in vivo in a poxvirus infection model. The Journal of general virology 
2005, 86(Pt 6):1589-1596. 
228. Farrar MA, Schreiber RD: The molecular cell biology of interferon-gamma and its receptor. Annual 
review of immunology 1993, 11:571-611. 
229. Chang HW, Watson JC, Jacobs BL: The E3L gene of vaccinia virus encodes an inhibitor of the 
interferon-induced, double-stranded RNA-dependent protein kinase. Proceedings of the National 
Academy of Sciences of the United States of America 1992, 89(11):4825-4829. 
230. Goulding J, Abboud G, Tahiliani V, Desai P, Hutchinson TE, Salek-Ardakani S: CD8 T cells use IFN-
gamma to protect against the lethal effects of a respiratory poxvirus infection. Journal of 
immunology 2014, 192(11):5415-5425. 
231. Nie S, Cornberg M, Selin LK: Resistance to vaccinia virus is less dependent on TNF under conditions 
of heterologous immunity. Journal of immunology 2009, 183(10):6554-6560. 
232. Gracie JA, Robertson SE, McInnes IB: Interleukin-18. Journal of leukocyte biology 2003, 73(2):213-
224. 
233. Tanaka-Kataoka M, Kunikata T, Takayama S, Iwaki K, Ohashi K, Ikeda M, Kurimoto M: In vivo antiviral 
effect of interleukin 18 in a mouse model of vaccinia virus infection. Cytokine 1999, 11(8):593-599. 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
198 
234. Alcami A: Viral mimicry of cytokines, chemokines and their receptors. Nature reviews Immunology 
2003, 3(1):36-50. 
235. Dao T, Mehal WZ, Crispe IN: IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. 
Journal of immunology 1998, 161(5):2217-2222. 
236. French AR, Holroyd EB, Yang L, Kim S, Yokoyama WM: IL-18 acts synergistically with IL-15 in 
stimulating natural killer cell proliferation. Cytokine 2006, 35(5-6):229-234. 
237. Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, Okamura H, Nakanishi K, Akira 
S: Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998, 8(3):383-390. 
238. Bachmann MF, Schorle H, Kuhn R, Muller W, Hengartner H, Zinkernagel RM, Horak I: Antiviral 
immune responses in mice deficient for both interleukin-2 and interleukin-4. Journal of virology 
1995, 69(8):4842-4846. 
239. Kundig TM, Schorle H, Bachmann MF, Hengartner H, Zinkernagel RM, Horak I: Immune responses in 
interleukin-2-deficient mice. Science 1993, 262(5136):1059-1061. 
240. Villacres MC, Bergmann CC: Enhanced cytotoxic T cell activity in IL-4-deficient mice. Journal of 
immunology 1999, 162(5):2663-2670. 
241. Kohyama S, Ohno S, Isoda A, Moriya O, Belladonna ML, Hayashi H, Iwakura Y, Yoshimoto T, Akatsuka 
T, Matsui M: IL-23 enhances host defense against vaccinia virus infection via a mechanism partly 
involving IL-17. Journal of immunology 2007, 179(6):3917-3925. 
242. Charo IF, Ransohoff RM: The many roles of chemokines and chemokine receptors in inflammation. 
The New England journal of medicine 2006, 354(6):610-621. 
243. Rot A, von Andrian UH: Chemokines in innate and adaptive host defense: basic chemokinese 
grammar for immune cells. Annual review of immunology 2004, 22:891-928. 
244. Howard OM, Ben-Baruch A, Oppenheim JJ: Chemokines: progress toward identifying molecular 
targets for therapeutic agents. Trends in biotechnology 1996, 14(2):46-51. 
245. Lehmann MH, Torres-Dominguez LE, Price PJ, Brandmuller C, Kirschning CJ, Sutter G: CCL2 
expression is mediated by type I IFN receptor and recruits NK and T cells to the lung during MVA 
infection. Journal of leukocyte biology 2016, 99(6):1057-1064. 
246. Munier CM, van Bockel D, Bailey M, Ip S, Xu Y, Alcantara S, Liu SM, Denyer G, Kaplan W, group PS et 
al: The primary immune response to Vaccinia virus vaccination includes cells with a distinct 
cytotoxic effector CD4 T-cell phenotype. Vaccine 2016, 34(44):5251-5261. 
247. Zaunders JJ, Dyer WB, Wang B, Munier ML, Miranda-Saksena M, Newton R, Moore J, Mackay CR, 
Cooper DA, Saksena NK et al: Identification of circulating antigen-specific CD4+ T lymphocytes with 
a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood 
2004, 103(6):2238-2247. 
248. Zaunders JJ, Ip S, Munier ML, Kaufmann DE, Suzuki K, Brereton C, Sasson SC, Seddiki N, Koelsch K, 
Landay A et al: Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of 
CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency 
virus type 1 infection. Journal of virology 2006, 80(20):10162-10172. 
249. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME: Cytotoxicity-
dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) 
with the receptor. The EMBO journal 1995, 14(22):5579-5588. 
250. von Herrath MG, Yokoyama M, Dockter J, Oldstone MB, Whitton JL: CD4-deficient mice have 
reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished 
resistance to subsequent virus challenge. Journal of virology 1996, 70(2):1072-1079. 
251. Wyatt LS, Earl PL, Eller LA, Moss B: Highly attenuated smallpox vaccine protects mice with and 
without immune deficiencies against pathogenic vaccinia virus challenge. Proceedings of the 
National Academy of Sciences of the United States of America 2004, 101(13):4590-4595. 
252. Ruby J, Ramshaw I: The antiviral activity of immune CD8+ T cells is dependent on interferon-
gamma. Lymphokine and cytokine research 1991, 10(5):353-358. 
253. Spriggs MK, Koller BH, Sato T, Morrissey PJ, Fanslow WC, Smithies O, Voice RF, Widmer MB, 
Maliszewski CR: Beta 2-microglobulin-, CD8+ T-cell-deficient mice survive inoculation with high 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
199 
doses of vaccinia virus and exhibit altered IgG responses. Proceedings of the National Academy of 
Sciences of the United States of America 1992, 89(13):6070-6074. 
254. Kempe CH, Bowles C, Meiklejohn G, Berge TO, St Vincent L, Babu BV, Govindarajan S, Ratnakannan 
NR, Downie AW, Murthy VR: The use of vaccinia hyperimmune gamma-globulin in the prophylaxis 
of smallpox. Bulletin of the World Health Organization 1961, 25:41-48. 
255. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, 
Moss B et al: Shared modes of protection against poxvirus infection by attenuated and 
conventional smallpox vaccine viruses. Proceedings of the National Academy of Sciences of the 
United States of America 2003, 100(16):9458-9463. 
256. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R: Cutting edge: long-term B cell 
memory in humans after smallpox vaccination. Journal of immunology 2003, 171(10):4969-4973. 
257. Edwards LE, Haluszczak C, Kedl RM: Phenotype and function of protective, CD4-independent CD8 T 
cell memory. Immunologic research 2013, 55(1-3):135-145. 
258. Smith GL, Benfield CT, Maluquer de Motes C, Mazzon M, Ember SW, Ferguson BJ, Sumner RP: 
Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. The Journal of general 
virology 2013, 94(Pt 11):2367-2392. 
259. Rosado MM, Scarsella M, Cascioli S, Giorda E, Carsetti R: Evaluating B-cells: from bone marrow 
precursors to antibody-producing cells. Methods in molecular biology 2013, 1032:45-57. 
260. Bukowski JF, Woda BA, Habu S, Okumura K, Welsh RM: Natural killer cell depletion enhances virus 
synthesis and virus-induced hepatitis in vivo. Journal of immunology 1983, 131(3):1531-1538. 
261. Zhao Y, Adams YF, Croft M: Preferential replication of vaccinia virus in the ovaries is independent 
of immune regulation through IL-10 and TGF-beta. Viral immunology 2011, 24(5):387-396. 
262. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton 
D et al: Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25(2):331-
342. 
263. Narni-Mancinelli E, Ugolini S, Vivier E: Tuning the threshold of natural killer cell responses. Curr 
Opin Immunol 2013, 25(1):53-58. 
264. Dar A, Schajnovitz A, Lapid K, Kalinkovich A, Itkin T, Ludin A, Kao WM, Battista M, Tesio M, Kollet O et 
al: Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated 
by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia 2011, 25(8):1286-
1296. 
265. Bonig H, Chudziak D, Priestley G, Papayannopoulou T: Insights into the biology of mobilized 
hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 
antagonist AMD3100. Experimental hematology 2009, 37(3):402-415 e401. 
266. Soligo D, Schiro R, Luksch R, Manara G, Quirici N, Parravicini C, Lambertenghi Deliliers G: Expression 
of integrins in human bone marrow. British journal of haematology 1990, 76(3):323-332. 
267. Lund-Johansen F, Terstappen LW: Differential surface expression of cell adhesion molecules during 
granulocyte maturation. Journal of leukocyte biology 1993, 54(1):47-55. 
268. Bendall LJ, Bradstock KF: G-CSF: From granulopoietic stimulant to bone marrow stem cell 
mobilizing agent. Cytokine & growth factor reviews 2014, 25(4):355-367. 
269. Bonig H, Papayannopoulou T: Mobilization of hematopoietic stem/progenitor cells: general 
principles and molecular mechanisms. Methods in molecular biology 2012, 904:1-14. 
270. Yamaguchi M, Ikebuchi K, Hirayama F, Sato N, Mogi Y, Ohkawara J, Yoshikawa Y, Sawada K, Koike T, 
Sekiguchi S: Different adhesive characteristics and VLA-4 expression of CD34(+) progenitors in 
G0/G1 versus S+G2/M phases of the cell cycle. Blood 1998, 92(3):842-848. 
271. Prosper F, Stroncek D, McCarthy JB, Verfaillie CM: Mobilization and homing of peripheral blood 
progenitors is related to reversible downregulation of alpha4 beta1 integrin expression and 
function. The Journal of clinical investigation 1998, 101(11):2456-2467. 
272. Zhang P, Nelson S, Bagby GJ, Siggins R, 2nd, Shellito JE, Welsh DA: The lineage-c-Kit+Sca-1+ cell 
response to Escherichia coli bacteremia in Balb/c mice. Stem cells 2008, 26(7):1778-1786. 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
200 
273. Ueda Y, Cain DW, Kuraoka M, Kondo M, Kelsoe G: IL-1R type I-dependent hemopoietic stem cell 
proliferation is necessary for inflammatory granulopoiesis and reactive neutrophilia. Journal of 
immunology 2009, 182(10):6477-6484. 
274. Tassone P, Turco MC, Tuccillo F, Bonelli P, Morrone G, Cecco L, Cerra M, Bond H, Di Nicola M, Gianni 
AM et al: CD69 expression on primitive progenitor cells and hematopoietic malignancies. Tissue 
antigens 1996, 48(1):65-68. 
275. Notario L, Alari-Pahissa E, de Molina A, Lauzurica P: CD69 Deficiency Enhances the Host Response to 
Vaccinia Virus Infection through Altered NK Cell Homeostasis. Journal of virology 2016, 
90(14):6464-6474. 
276. Korbling M, Holle R, Haas R, Knauf W, Dorken B, Ho AD, Kuse R, Pralle H, Fliedner TM, Hunstein W: 
Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior 
radiation to the pelvic site. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology 1990, 8(6):978-985. 
277. Belvitch P, Dudek SM: Role of FAK in S1P-regulated endothelial permeability. Microvascular 
research 2012, 83(1):22-30. 
278. Singh P, Hu P, Hoggatt J, Moh A, Pelus LM: Expansion of bone marrow neutrophils following G-CSF 
administration in mice results in osteolineage cell apoptosis and mobilization of hematopoietic 
stem and progenitor cells. Leukemia 2012, 26(11):2375-2383. 
279. Itkin T, Gur-Cohen S, Spencer JA, Schajnovitz A, Ramasamy SK, Kusumbe AP, Ledergor G, Jung Y, Milo 
I, Poulos MG et al: Distinct bone marrow blood vessels differentially regulate haematopoiesis. 
Nature 2016, 532(7599):323-328. 
280. Pereira JP, Cyster JG, Xu Y: A Role for S1P and S1P1 in Immature-B Cell Egress from Mouse Bone 
Marrow. PLoS ONE 2010, 5(2):e9277. 
281. Ryser MF, Ugarte F, Lehmann R, Bornhauser M, Brenner S: S1P(1) overexpression stimulates S1P-
dependent chemotaxis of human CD34+ hematopoietic progenitor cells but strongly inhibits SDF-
1/CXCR4-dependent migration and in vivo homing. Molecular immunology 2008, 46(1):166-171. 
282. Blaho VA, Hla T: An update on the biology of sphingosine 1-phosphate receptors. Journal of lipid 
research 2014, 55(8):1596-1608. 
283. Schwab SR, Cyster JG: Finding a way out: lymphocyte egress from lymphoid organs. Nature 
immunology 2007, 8(12):1295-1301. 
284. Liu G, Burns S, Huang G, Boyd K, Proia RL, Flavell RA, Chi H: The receptor S1P1 overrides regulatory T 
cell-mediated immune suppression through Akt-mTOR. Nat Immunol 2009, 10(7):769-777. 
285. Michaud A, Dardari R, Charrier E, Cordeiro P, Herblot S, Duval M: IL-7 enhances survival of human 
CD56bright NK cells. Journal of immunotherapy 2010, 33(4):382-390. 
286. Alfonso C, McHeyzer-Williams MG, Rosen H: CD69 down-modulation and inhibition of thymic 
egress by short- and long-term selective chemical agonism of sphingosine 1-phosphate receptors. 
European journal of immunology 2006, 36(1):149-159. 
287. Rosen H, Alfonso C, Surh CD, McHeyzer-Williams MG: Rapid induction of medullary thymocyte 
phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor 
agonist. Proceedings of the National Academy of Sciences of the United States of America 2003, 
100(19):10907-10912. 
288. Zachariah MA, Cyster JG: Neural crest-derived pericytes promote egress of mature thymocytes at 
the corticomedullary junction. Science 2010, 328(5982):1129-1135. 
289. Martin-Gayo E, Sierra-Filardi E, Corbi AL, Toribio ML: Plasmacytoid dendritic cells resident in human 
thymus drive natural Treg cell development. Blood 2010, 115(26):5366-5375. 
290. Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, Jacques Y, Baratin M, Tomasello 
E, Vivier E: Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate 
receptor. Nature immunology 2007, 8(12):1337-1344. 
291. Jenne CN, Enders A, Rivera R, Watson SR, Bankovich AJ, Pereira JP, Xu Y, Roots CM, Beilke JN, 
Banerjee A et al: T-bet–dependent S1P5 expression in NK cells promotes egress from lymph nodes 
and bone marrow. The Journal of experimental medicine 2009, 206(11):2469-2481. 
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
201 
292. Marcais A, Viel S, Grau M, Henry T, Marvel J, Walzer T: Regulation of mouse NK cell development 
and function by cytokines. Frontiers in immunology 2013, 4:450. 
293. !!! INVALID CITATION !!! 
294. Elsaesser H, Sauer K, Brooks DG: IL-21 is required to control chronic viral infection. Science 2009, 
324(5934):1569-1572. 
295. Frohlich A, Kisielow J, Schmitz I, Freigang S, Shamshiev AT, Weber J, Marsland BJ, Oxenius A, Kopf M: 
IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 
2009, 324(5934):1576-1580. 
296. Leonard WJ, Wan CK: IL-21 Signaling in Immunity. F1000Research 2016, 5. 
297. Xin G, Schauder DM, Lainez B, Weinstein JS, Dai Z, Chen Y, Esplugues E, Wen R, Wang D, Parish IA et 
al: A Critical Role of IL-21-Induced BATF in Sustaining CD8-T-Cell-Mediated Chronic Viral Control. 
Cell reports 2015, 13(6):1118-1124. 
298. Kean LS, Sen S, Onabajo O, Singh K, Robertson J, Stempora L, Bonifacino AC, Metzger ME, Promislow 
DE, Mattapallil JJ et al: Significant mobilization of both conventional and regulatory T cells with 
AMD3100. Blood 2011, 118(25):6580-6590. 
299. Condomines M, Quittet P, Lu ZY, Nadal L, Latry P, Lopez E, Baudard M, Requirand G, Duperray C, 
Schved JF et al: Functional regulatory T cells are collected in stem cell autografts by mobilization 
with high-dose cyclophosphamide and granulocyte colony-stimulating factor. Journal of 
immunology 2006, 176(11):6631-6639. 
  
  
 
 
 
 
 
 
 
 
 
 
ANNEX
   
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
205 
ANNEX CHAPTER I:  
 
The increased viral control in Rag-/-CD69-/- mice is dependent on IFNγ.  
 
IFNγ-secretion by NK cells and possibly professional APCs is likely to be important in early host defense 
against infection, whereas T lymphocytes become the major source of IFNγ in the adaptive immune 
response. As the anti-VACV response in CD69-/- mice is augmented at day one after infection, to 
investigate the involvement of IFNγ in the control of anti-VACV response in CD69-/- mice, the interferon 
activity was blocked before VACV infection by treatment with anti- IFNγ blocking mAb. Injection with 
either control diluent or anti-IFNγ was performed in Rag2-/- CD69-/- and Rag2-/- CD69+/+ mice, 6 hours 
before infection and spleen cell subpopulation and ovary viral load was analyzed after 2 days. IFNγ 
blockaded in Rag2-/-CD69-/- mice lost efficiency in eliminating VACV reaching even  lower competence 
than IFNγ blockaded in Rag2-/-CD69+/+ mice, reversing the phenotype observed in untreated mice 
(Figure 1B). The analysis of splenic cell subpopulations showed that the anti-IFNγ treatment  reduced 
in  Rag2-/-CD69-/- mice the accumulation in spleen of macrophages and dendritic cells reaching similar 
numbers than in Rag2-/-CD69+/+ mice,  however IFNγ blockade  did not affect accumulation of NK 
lymphocytes that remained increased compared to Rag2-/-CD69+/+ mice as in NK-non-IFNγ blockade 
mice (Figure 1A and C). Therefore in IFNγ blockade in Rag2-/-CD69-/- mice, the increased number of NK 
lymphocytes are not efficient in VACV elimination and thus IFNγ but no other mediators produced by 
NK cells account for viral elimination in Rag2-/-CD69-/- mice.  Accordingly with the effect that IFNγ has 
in leukocyte trafficking and viral elimination and to understand the role of IFNγ in other subpopulations 
of cells, IFNγ was blocked using CD69-/- and CD69+/+ mice. The same treatment as Rag2-/- mice was 
carried out in and CD69+/+ mice. The blockade of IFNγ in both mice leads to approx. 50% decrease in 
cell accumulation in the spleen (Figure 1D) and a significant viral load increase in of both infected mice 
(Figure 1E). However, an augmented accumulation of leukocytes (Figure 1F) and increase efficiency in 
viral elimination are observed in CD69-/- mice compared to WT mice. Since, as shown above, in anti-
IFNγ treated in Rag2-/- CD69-/- and Rag2-/- CD69+/+ mice there are no difference in viral elimination or 
accumulation of myeloid cells, then, in these  mice, mediators different  of IFNγ produced by cells not 
present in Rag mice, lymphocytes T and/or B, are responsible for the differences in cell accumulation 
and efficient viral elimination observed. Together the presented results point to a crucial role of IFNγ 
in the increased immune response against VACV seen in Rag2-/- CD69-/- mice, but other factors 
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produced by rearranged antigen based lymphocytes, seems to be relevant in the augmented early 
anti-viral response found in the CD69-/- mice.  
 
 
Figure 1. The increased viral control of Rag2-/-CD69-/- NK cells is dependent on IFNγ whereas is not required to improve the 
antiviral response in immunocompetent mice. Mice were treated with 250 ug of Anti mouse IFN γ (clone XMG 1.2) 4 
hours before infection with of VV i.p in immunodeficient mice and 1 × 107 pfu in immunocompetent mice. Two days after 
infection mice were analyzed. A and D, Total cell number of spleen. B and E, Ovaries viral load. C and F, number of splenic 
lymphoid and myeloid cell subpopulations. Pool of two experiments. 
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CD69 promotes M1 polarization in response to LPS. 
Activation of macrophages is related to the immune response to viruses. M1 macrophages are mainly 
induced by IFNγ or upon stimulation with bacterial products such as LPS. To investigate whether CD69 
contributes to the polarization to M1, we examined the levels of classical inflammatory mediators such 
as NOS-2, COX-2 and TNFα. Peritoneal macrophages from WT and CD69−/− mice were stimulated with 
LPS or not stimulated. As expected, the stimulation of WT macrophages with LPS generated high NOX-
2, COX-2 and TNFα levels, whereas a deficient response was observed in the absence of CD69 
measured by both real time PCR (Figure 2A) and western blot (Figure 2B). 
  
Figure 2. Impairment of inflammatory response in CD69-deficient macrophages. (A) Peritoneal macrophages from WT and 
CD69-deficient mice were activated for 6 hours with LPS (200 ng/ml) and expression of NOS-2, COX-2 and TNF- was 
evaluated by quantitative PCR. Results were obtained from three independent experiments carried out by duplicate. 
Data indicate Standard Deviation (S.D.). (B) Protein levels of NOS-2 and COX-2 were evaluated by Western blot after 
stimulation of peritoneal macrophages with LPS (200 ng/ml) for 24 hours. Western blots are a representative experiment 
out of three. Band intensity of Western blots was analyzed by densitometry, normalized to actin levels and represented 
as the mean S.D. of the fold change from LPS condition (n=3). 
A. 
B. 
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ANNEX CHAPTER II:  
 
Mobilization of regulatory T regs with anti-human CD69 
 
In addition, once observed that our treatment leads to significantly more mobilization of both mature 
and precursor cells, we decided to analyze the effect on regulatory T CD4 cells since previously had 
been demonstrated that AMD3100 produce an increase of mobilization of Tregs immediately after 
treatment [298] and this effect has also been shown with G-CSF [299]. Therefore, after inducing 
mobilization with anti-human CD69, we collect spleen, thymus and lymph nodes cells and analyzed 
the expression of FOXP3 and CD25 within CD4 cells. The classic Tregs CD4 CD25+FOXP3+ were 
augmented in percentage in spleen (Fig.1A) in both treatments whereas in lymph nodes and thymus 
(Fig.1B-C) no changes were observed in one dose treatment and an increase was detected  in two 
doses treatment in lymph nodes and a decrease in thymus. Then we analyzed the number of Treg cells 
and observed that the spleen displayed a greater number of regulatory cells in treated mice (Fig.1A), 
the lymph nodes showed a trend at 24 hours but the differences were significant in the long treatment 
(Fig.1B) while in thymus the tendency was the opposite, there was a clear reduction at 24 hours 
whereas when we treated with two doses that decrease was not significant (Fig.1C). We also found 
changes in the number of other populations in spleen, such as CD4 CD25+, including FOXP3+ and 
FOXP3-, and CD4 FOXP3+, including CD25 + and CD25- (Fig.1A). Lymph nodes showed no changes 
when mice were treated at 24 hours except the CD4+ CD25+ FOXP3- population which was increased, 
whereas when the mouse was treated with two doses of anti-human CD69, all regulatory populations 
were increased. And lastly in the thymus, the numbers of regulatory cells do not present differences 
between treated and control mice when they received two doses of treatment, whereas at 24 hours 
we found a decrease of CD4 CD25+ (Fig.1C). Together, these results suggest that treatment with anti-
human CD69 induces egress of regulatory T cells from thymus which were observed in spleen and 
lymph nodes to produce a compensatory effect that regulates cell mobilization and prevents the 
complete emptying of the bone marrow. 
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A. Spleen: Percentage: 1 dose
Spleen: Percentage: 2 dose
Spleen: Number: 1 dose
Spleen: Number: 2 dose
B. LN: Percentage: 1 dose LN : Number: 1 dose
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LN : Percentage: 2 doses LN : Number: 2 doses
C.
Thymus: Percentage: 1 dose
Thymus : Percentage: 2 dose
Thymus : Number: 1 dose
Thymus : Number: 2 dose
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Figure 1. Targeting of human CD69 induce peripheral CD4+ Treg cells. Mice were treated with 2 doses of 200ug of anti-
huCD69 2.8 or PBS i.v with a gap of 1 week and 5 days after second dose mice were analyzed or with 1 dose of 500ug of 
anti-huCD69 2.8 or PBS i.v and one day after mice were analyzed. Tregs were analyzed by flow cytometry according surface 
CD25 expression and Intranuclear FOXP3 expression in A, spleen, B, Lymph nodes and C, Thymus left t in percentages and 
right in numbers within CD4 T cells. Pool of two experiments.  
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ANNEX CHAPTER III:  
 
CD69 expression in Rag2-/- at steady-state. 
 
To assess CD69 expression levels at steady-state in the different bone marrow, spleen, thymus blood 
and lymph nodes cell subtypes, we stained samples from Rag2-/- CD69+/+ and Rag2-/-  CD69−/−mice for 
different cell subsets (Figure 1). NK cells showed a constitutive CD69 expression in spleen, thymus, 
blood and lymph nodes while NK cells from bone marrow not changes were observed. Similar result 
was observed in CD69 expression in dendritic cells. CD11b+ cells also presented a constitutive 
expression in spleen, thymus and lymph nodes. Macrophages, MSDC, granulocytes and B cells did not 
show CD69 expression in samples analyzed except granulocytes from lymph nodes that also expressed 
CD69 as a constitutive form.  Thus, most cell subtypes show a certain expression of CD69 at steady-
state, but this is especially remarkable for NK and dendritic cells. 
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Figure 1. CD69 expression in different cell subpopulations in Rag2-/- CD69-/- mice. Mice were treated with poly i:c or PBS 
and Spleen, Bone Marrow, Thymus, Blood and lymph nodes were collected and CD69 expression was measured in the 
indicated subpopulations. Red lines correspond to Rag2-/-CD69-/- mice, Blue lines in Rag2-/-CD69+/+ mice, green line in Rag2-
/-CD69-/- mice treated with poly i:c and brown lines in Rag2-/-CD69+/+ mice treated with poly i:c. One experiment. 
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ANNEX CHAPTER IV:  
 
Overexpression CD69 also influenced in NK cell distribution. 
 
As we mentioned in the corresponding chapter, CD69 influences in cell distribution through its 
interaction with S1P1. Here, we examine the influence of CD69 overexpression on the proportion of 
different lymphoid and myeloid populations. Accordingly, we observed that the percentage of single-
positive CD4 and CD8 were significantly augmented in thymus (data not shown) and a reduction was 
observed in the percentage of these cells in spleen, blood and lymph nodes (Fig. 1A-C). However, we 
found that the overexpression of CD69 not only influenced in proportion of T cells, but also affected 
the distribution of NK cells and myeloid cells being found augmented in spleen, blood and lymph 
nodes. This increase in the proportion of NKs but also of myeloid populations may be related to the 
increase production of humoral mediators modulating the immune response of transgenic mice to 
Vaccinia virus infection.  
Figure 1.  Overexpression of CD69 increase NK cell 
number. A-C, Percentages  of lymphoid and myeloid 
subpopulations in A, spleen, in B, blood, and in C, 
lymph nodes in WT mice compared to CD69+/+ BAC 
mCD69. One experiment representative of two. 
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SUPPLEMENTARY CHAPTER II:  
 
 
 
Supplementary Figure 1. Targeting of CD69 in HuCD69 mice induced changes in bone marrow and spleen leukocyte 
distribution.  Mice were treated with 500ug of anti-huCD69 2.8 and were analyzed 1 day after treatment. A, Percentages 
in of lymphoid and myeloid subpopulation cell in A, Bone Marrow and B, spleen. A-B, Pool of four experiments.  
  
Bone Marrow SpleenA. B.
Tesis Doctoral Laura Notario Muñoz: Function of CD69 in hematopoietic progenitor cells and in Vaccinia virus infection. 
 
 
 
220 
 
 
Supplementary Figure 2. Targeting of CD69 in HuCD69 mice induced egress of immature B cells from bone marrow. Mice 
were treated with 500ug of anti-huCD69 2.8 and were sacrificed 1 day after treatment. A-B, Percentages of B cell 
subpopulations were measured in Bone Marrow in A and in spleen in B, by flow cytrometry. Pool of three experiments. 
Bone Marrow Spleen
A. B.
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Supplementary Figure 3. The treatment with anti-human CD69 increase HSC cells in Bone Marrow.  A-B, Mice were treated 
with anti-human CD69 2.8 24 hours before analyzing. Cells from Bone Marrow and Spleen were analyzed by flow 
cytometry. A and B, Lin- cells were stained by SCA+ and C-kit hi or C-kit int. Percentages in A, of KSL and CLP cells were 
measured in (left) Bone Marrow and (right) spleen. B, Cells CD34 and FLT3 were gated in Sca+, C-kit hi cells and numbers 
of LT-HSC, ST-HSC and MPP are shown in Bone Marrow. A-B, Pool of three experiments. 
Bone Marrow Spleen Bone Marrow
A. B.
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SUPPLEMENTARY CHAPTER IV:  
 
 
 
Supplementary Figure 1. Overexpression of CD69 also retains regulatory T cells in thymus after 7 days of VACV unfection. 
Mice were infected with 1x107 pfu i.p and 7 days after infection, mice were sacrificed. Number of Tregs were analyzed by 
flow cytometry according surface CD25 expression and Intranuclear FOXP3 expression in A, spleen, B, Thymus and C, 
Lymph nodes. 
B.A. C.

